Modification of splicing with antisense oligonucleotides in the Insulin receptor exon 11 and Apolipoprotein B exon 26. by Srirangalingam, Umasuthan
Modification of splicing with antisense oligonucleotides in the Insulin







The copyright of this thesis rests with the author and no quotation from it or information
derived from it may be published without the prior written consent of the author
 
 





Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For




Modification of splicing with antisense oligonucleotides 
in the Insulin receptor exon 11 and Apolipoprotein B 















A thesis submitted to the University of London for the 




Centre for Endocrinology, 
St Bartholomew’s Hospital, 







I declare that the work presented in this thesis is original work carried out by 
Umasuthan Srirangalingam in the Centre for Endocrinology, St Bartholomew’s 
Hospital and Queen Mary, University of London. 
 
     






















Background - The alternatively spliced insulin receptor (IR) exon 11 (36 
nucleotides) and the constitutively spliced Apolipoprotein B (APOB) exon 26 (7572 
nucleotides) are examples of the shortest and longest exons in the genome.  
 
Aim - The aim of this study was to investigate the regulation of splicing of these 2 
exons in cell culture using 2′-O-methyl RNA antisense oligonucleotides (ASOs) and 
peptide nucleic acid (PNA)-peptide hybrid ASOs.  
 
Methods - ASOs were designed to target key sequences involved in the splicing of 
the IR exon 11 and exonic splicing silencer sequences (ESS) in APOB exon 26. 
HepG2 cells were reverse-transfected with the ASOs for 48 hours, mRNA 
harvested and RT-PCR was performed to amplify the IR isoform and APOB cDNAs 
which were separated by PAGE and quantified. 
 
Results    
Insulin receptor exon 11 - 2′-O-methyl RNA ASOs targeted to two intronic sites, 
the 3′ half of exon 11 and spanning the entire exon caused significant exon 
skipping.  
PNA-peptide hybrids predicted to increase exon 11 splicing, paradoxically caused 
exon skipping. PNA-peptide hybrids with 3′ tails caused exon 11 skipping more 
effectively than hybrids with 5′ tails. 
 
Apolipoprotein B exon 26 - Only combinations of 2′-O-methyl RNA ASOs 
targeting multiple ESSs in APOB exon 26 caused a small proportion of aberrant 
 
4 
splicing. This consisted of complete exon 26 skipping and the selection of a 
downstream cryptic 3′ splice site in preference to the native 3′ splice site. 
 
Discussion - Exclusion of the IR exon 11 can be induced by targeting a 
combination of intronic or exonic sequences. PNA-peptide hybrid ASOs were 
unable to increase exon 11 splicing. The aberrant splicing of large constitutive 
exons such as APOB exon 26 can be induced by targeting multiple ESS sites along 
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1.1  Introduction. 
 
The elucidation of the human genome has had a significant impact on 
endocrinology. The realisation that the number of human genes is more limited 
than initially predicted has emphasised the key role of molecular mechanisms that 
lead to phenotypic diversity, of which RNA splicing is one. Identification of the 
nucleotide sequences of endocrine genes has allowed an understanding and 
modulation of their functions. Antisense strategies have developed directly from this 
knowledge.  
This work focuses on understanding gene expression in two key genes in the 
endocrine system: the Insulin Receptor (IR) and Apolipoprotein B (APOB) genes. 
Both are involved in key metabolic pathways. This thesis attempts to understand 
the regulation of the splicing of these two genes to modulate gene expression for 
possible future therapeutic manoeuvres. This work reports the modification of the 
splicing process using antisense oligonucleotides (ASOs) in these two contrasting 





1.2.1 The ‘Central Dogma’ of Molecular Biology. 
 
The generation of protein from DNA involves the process of transcription (DNA into 
RNA) and translation (RNA into protein). DNA is initially transcribed by RNA 
polymerases (RNA Pol II) into pre-messenger RNA (pre-mRNA), which contains 
both coding exons and non-coding introns. The pre-mRNA is processed at both 
ends of the transcript with 5’ capping as it emerges from RNA Pol II and 3’ 
polyadenylation. Pre-mRNA is spliced (section 1.2.2) to generate the mature 
messenger RNA (mRNA). The mRNA is exported out of the nucleus into the 
cytoplasm as part of a messenger ribonucleoprotein (mRNP) and then translat2ed 
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into an amino acid sequence by the cytoplasmic ribosomes in association with 
tRNA, to synthesise proteins. The transcript remains under surveillance throughout 
the process and incomplete or miscopied transcripts are identified and targeted for 
degradation.  
 
1.2.2 Splicing and alternative splicing.  
Splicing is the process by which introns are removed and exons ligated from pre-
mRNA sequences to form a translatable message, messenger RNA (mRNA). 
Alternative splicing is the process by which multiple protein isoforms are generated 
from one pre-mRNA due to inclusion of alternative exons. Alternative splicing 
events include exon skipping, intron retention, the use of mutually exclusive exons 
and alternative 5’ and 3’ splice sites. The splicing mechanism is reliant on the co-
ordinated interaction of both cis (sequences within the pre-mRNA) and trans-acting 
(molecules and complexes separate from the pre-mRNA) elements.  
 
1.2.3 The need for genetic diversity. 
The Human genome consists of 3 billion nucleotide base-pairs making up 
approximately 22,000 genes, though only 1.2% of this constitutes exonic coding 
sequence (International Human Genome Sequencing Consortium 2004). The 
number of genes in the human genome is only twice the number found in a simple 
organism such as the fruit fly (~14,000 genes) despite the vast difference in 
organism complexity (Halligan et al. 2006).  Mechanisms to account for the 
diversity of the resultant proteome include the regulation of transcription, splicing, 
polyadenylation and translation. 
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Alternative splicing provides a major mechanism for generating phenotypic diversity 
from such a limited number of genes. Alternative splicing occurs in 95% of human 
genes in comparison to significantly lower rates in simple organisms and the 
number of splice variants per gene correlates with the complexity of the organism 
suggesting an evolutionary drive to efficiently code for complexity within the 
genome (Wang et al. 2008; Pan et al. 2008; Kim et al. 2004). Comparative genomic 
studies reinforce this assertion finding that alternatively spliced exons tend not to 
be conserved between species, suggesting they are a more recent evolutionary 
development (Modrek et al. 2003).  
Alternative transcription includes alternative transcription initiation (ATI) in which an 
alternative promoter in the 5’ untranslated region (UTR) is utilised and alternative 
transcription termination (ATT) in which an alternative termination site is used. 
Transcriptome analysis using next generation RNA sequencing (RNA seq) has 
made it feasible to compare alternative transcriptional to alternative splicing events.  
A study of the transcriptome of 15 human tissues showed that alternative splicing 
events predominated over alternative transcriptional events (ATI and ATT) (Wang 
et al. 2008). However more recent analyses of the transcriptome suggests that 
alternative transcriptional events predominated over splicing events overall, to 
account for transcriptome diversity (Pal et al. 2011; Shabalina et al. 2010; 
Gonzalez-Porta et al. 2012). Possible explanations for this discrepancy include the 
different species studied (human and mouse), the improved definition of 5’ and 3’ 
splice sites and the variable use of multiple genome databases. 
The relative frequency of alternative transcription and splicing events varies 
depending on the location within a transcript, thus alternative splicing is the 
predominant alternative event in the coding region of the transcript but ATI and ATT 
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appear to more important overall and specifically at the 5’UTR and 3’UTR 
respectively (Shabalina et al. 2010).  
 
Alternative translation occurs when translation is initiated by the ribosome at an 
alternative start codon and can increase genetic diversity by generating different 
truncated proteins (Kochetov 2008). Recent estimates that up to 10% of human 
genes have alternative translational initiation sites (Zhang et al. 2007) suggests that 
this mechanism plays a less prominent role than alternative splicing or 
transcription. 
 
Gene duplication during DNA replication in mitosis or meiosis is a mechanism that 
has been postulated to play an important role in contributing to genetic diversity. A 
study comparing the genomes of nine eukaryotic species concluded that duplicate 
genes arise at a high rate of 0.01 of a gene per million years (Lynch et al. 2000). 
Mutations and natural selection may then generate new functional gene products 
(neofunctionalisation). However the majority of gene duplications do not lead to the 
generation of new functional proteins. Most will degenerate and be silenced 
(nonfunctionalisation) with others dividing functions between the duplicated genes 
(subfunctionalisation). If gene duplication were a dominant mechanism, complex 
organism may be expected to contain proportionately more genes than simple 
organisms but this is not the case. Thus while gene duplication remains an 
important mechanism for generating genetic diversity for species over vast spans of 
time it plays a negligible role in the variability of gene expression for the individual 
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1.2.4 The splicing mechanism. 
1.2.4.1 Cis-acting sites involved in splicing.  
Splicing is determined by the identification of degenerate RNA sequences defining 
intron/exon boundaries which include the 3′ splice site and 5′ splice site (figure 
1.2.4.A). These sequences are recognised, in the majority of cases, by the intronic 
residues GU at the 5′ splice site and AG at the 3′ splice site in the predominant 
canonical form of splicing. Non-canonical splicing via the minor spliceosome 
recognises other sequences at the 5′ and 3′ end of the intron e.g. AT-AC 
respectively for U12 type introns.  
The inherent strength of the 5’ splice site has been estimated based on the 
sequence of 9 nucleotides at positions -3 to +6 (position 0 defined as the exon-
intron boundary) with further studies demonstrating the additional utility of including 
nucleotides in position 7+ and 8+ (Seraphin et al. 1988; Freund et al. 2003). 
Bioinformatic tools which identify splice site sequences may do so by assessing the 
nucleotides in isolation, with respect to the adjacent nucleotide or non-adjacent 
nucleotides. The position-specific weight matrix of Shapiro and Senapathy gives a 
score for the strength of a splice site assuming independence between adjacent 
nucleotide sites (Shapiro et al. 1987). Burge and Karlin produced a predictive tool, 
GENSCAN, which identifies potential splice sites based on the interdependencies 
between nucleotides both adjacent and at a distance from one another (Burge et al. 
1997). 
Other key intronic sites upstream of the 3′ splice site include the polypyrimidine 
tract (PPT), a sequence rich in the pyrimidines uracil and cytosine. It functions as 
the site of binding for the splicing factor U2AF65 (Zamore et al. 1989). The BPS is 
situated further upstream and contains a conserved adenine residue within the 
consensus sequence YNCUGAC (where N is any nucleotide and Y is a pyrimidine) 
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(Reed et al. 1988). The BPS binds Splicing factor 1 (SF1) during the formation of 
the E complex and is necessary for ligation of the intron to form the lariat during 
splicing (Berglund et al. 1997). 
 




1.2.4.2 The spliceosome.  
The major spliceosome is a nuclear complex which includes both RNA and protein 
elements in the form of five small nuclear ribonucleoproteins (snRNPs), designated 
U1, U2, U4, U5 and U6 and many non-snRNPs (Jurica et al. 2003). Over 300 
proteins have been shown to co-purify with the splicing complex (Rappsilber et al. 
2002). The minor spliceosome is a separate ribonucleoprotein complex involved in 
the removal of the less common U12 type introns. Both the major and minor 
spliceosome reside and function within the nucleus of the cell (Pessa et al. 2008). 
They co-ordinate the identification of intron/exon boundaries within the pre-mRNA 
and interactions between splicing factors and the pre-mRNA in the subsequent 
Figure 1.2.4.A  Cis-acting splicing elements. Figure shows section of pre-mRNA. 
Introns are bound by the 5′ splice site and the 3′ splice site. Further key intronic sites 
involved in the process of splicing include the polypyrimidine tract (PPT) and the branch 
point sequence (BPS). Regulatory elements in the intron include intronic splicing 
enhancers (ISE) and intronic splicing silencers (ISS). Exonic regulatory elements include 
exonic splicing enhancers (ESE) and exonic splicing silencers (ESS). 
Figure 1.2.4.A 
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splicing process. SnRNPs, via their RNA and protein components, are able to 
mediate RNA-RNA interactions (Watson and Crick base-pairing), RNA-protein and 
protein-protein interactions within the spliceosome. Proteomic analysis of the 
spliceosome has identified a significant number of proteins that have known roles in 
processes other than splicing, emphasising the coupling of these different aspects 
of gene expression (Zhou et al. 2002). 
 
Detailed analysis of the crystalline structure of U1 snRNP provides further insights 
to the composition and structure of snRNPs. The U1 snRNP is composed of the 4 
stem loops of U1 small nuclear RNA (snRNA) and 7 Sm proteins (Sm-B, Sm-D1, 
Sm-D2, SmD3, Sm-E, Sm-F and Sm-G) that form a surrounding ring core domain. 
A further 3 U1-specific proteins, U1-70K, U1-A and U1-C bind via stem loop 1 and 
2 of U1 snRNA. U1-C binding to the U1 snRNA is facilitated via the N terminus of 
U1-70K and the C terminus of Sm-D3 (Pomeranz Krummel et al. 2009). 
 
The SnRNPs, U1, U2, U4 and U5 all traverse the cytoplasm for processing prior to 
re-entry into the nucleus (Will et al. 2001). The minor spliceosomal components 
U11, U12 and U4atac are also thought to be processed via the cytoplasm. 
Following transcription and capping within the nucleus the snRNA precursors bind 
an export complex to traverse into the cytoplasm. The export complex dissociates 
allowing the Sm proteins to bind and form the snRNP core, mediated by the 
survival of motor neurone (SMN) complex (Massenet et al. 2002). Following cap 
hypermethylation and 3’ end trimming the snRNP core is transported back into the 
nucleus via an import complex. Once in the nucleus other snRNP associated 
proteins then attach e.g. U1-70K, U1-A and U1-C in the case of U1 snRNP. Final 
modification, processing and association between snRNPs e.g. formation of the tri-
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snRNP U4/U6.U5 occurs within the nucleus in the Cajal bodies (Novotny et al. 
2011). U6 is the exception in that it is transcribed by RNA Pol III and acquires its 
LSm (Sm-like proteins) ring whilst remaining in the nucleus	   (Mayes et al. 1999; 
Listerman et al. 2007). U6atac generation and processing occurs along similar 
lines.   
Kinetic analysis of spliceosome assembly on a single pre-mRNA within yeast 
(Saccharomyces cerevisiae) whole cell extract has been achieved via co-
localisation single-molecule spectroscopy (CoSMoS) (Hoskins et al. 2011). 
Spliceosomal components (U1, U2, U4/U6.U5 and the Prp19-complex) were 
protein tagged at the C terminus to allow different fluorophores to be attached, 
which could then be detected simultaneously by CoSMoS. These studies confirmed 
both the order and kinetics of complex binding and subsequent disassembly in the 
order U1, U2, U4/U6.U5 and finally Prp19. Commitment to splicing appears to 
increase as assembly proceeds but there was evidence that complexes may bind 
and dissociated multiple times prior to a commitment to splicing (Hoskins et al. 
2011).  
 
1.2.4.3 The splicing reaction 
The pre-mRNA is generated following transcription and is converted to mRNA 
through the process of splicing. A recent study measured the half-life of pre-mRNA 
from over 2000 genes in mouse dendritic cells in response to lipopolysaccharide 
and predicted the half-life (for 95% of genes) to be between 1 to 30 minutes, with a 
peak of 5 minutes. The wide distribution related to a number of factors including, 
the presence of co-transcriptional splicing (Chapter 1.2.8.4), constantly expressed 
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vs. intermittently expressed genes, the number of exons and length of the transcript 
(Rabani et al. 2011). 
Splicing of pre-mRNA occurs within the nucleus of the cell.  That said, splicing has 
been shown to occur outside the nucleus in some situations e.g. splicing of the 
cytokine interleukin-1 (IL-1) occurs in the cytoplasm of anucleate platelets (Denis et 
al. 2005). The splicing reaction is a culmination of an intricate series of interactions 
principally between the pre-mRNA, the spliceosome and a number of snRNP 
associated and non-associated proteins (figure 1.2.4.B).  With the formation of 
each complex numerous proteins associate and disassociate. Conformational 
changes may be mediated by DExD/H ATPases/RNA helicases and peptidyl-prolyl 
isomerases (PPIases) (Staley et al. 1998). The function of the involved proteins 
may be switched by post-translational modification including phosphorylation, 
ubiquitination and acetylation to allow further regulation (Mathew et al. 2008; 
Bellare et al. 2008; Kuhn et al. 2009).  
The splicing choices at any given point are based on a snapshot configuration of a 
multitude of competing factors including splice site strength, exon and intron length 
and the distribution of splicing enhancers and inhibitors. Splicing choices are tissue 
specific and are influenced by the expression of tissue specific or ubiquitous 
splicing regulators (Chen et al. 2009). These factors interplay to determine splicing 
choices.  
The process is most well characterised in yeast. At the core of the reaction is the 
removal of the intron and ligation of exons via two transesterification reactions at 
the 5′ and 3′ splice site (Staley et al. 1998). The first transesterification reaction 
consists of the 2-hydroxyl group of an A residue in the branch sequence attacking 
the phosphate forming the 3’-5’ phosphodiester bond at the 5’ splice site. The 
second step involves the 3-hydroxyl group of the upstream exon attacking the 3’ 
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end of the lariat intron. Both splicing steps have been shown to be reversible in 
vitro (Tseng et al. 2008).   
 
The E (early or commitment) complex forms with binding of U1 snRNP to the 5′ 
splice site independent of ATP. SF1 binds the branch point sequence. U2 auxiliary 
factors (U2AF), consisting of 65 and 35 kDa subunits, binds both the polypyrimidine 
tract and the AG dinucleotide at the 3′ splice site respectively. Studies indicate that 
U1C, a U1 snRNP associated protein, is involved in recognition of the 5’ splice site 
via RNA-protein interactions prior to base-pairing between U1 snRNP and the 5’ 
splice site (Du et al. 2002). 
SF1, via its RNA recognition motif (RRM) domain, co-operatively binds to the 
U2AF65 subunit. X-ray structural examination reveals that dimerisation between 
the U2AF subunits occurs via an atypical RRM of U2AF35 which behaves as a 
peptide binding motif. This motif facilitates a protein-protein interaction with a 
polyproline helix of U2AF65 via reciprocal tryptophan side-chain residues (Kielkopf 
et al. 2001). 
The U2AF35-AG interaction is stabilised by the phosphorylated RNA-associated 
protein, DEK which also limits binding of the U2AF65 to a polypyrimidine tract when 
not followed by the AG dinucleotide (Soares et al. 2006).  
U2AF65 plays a role in determining splicing efficiency based on the strength of the 
polypyrimidine tract along with its role as a scaffold splicing factor. U2AF65 
contains a pair of RRM domains, RRM1-RRM2. A strong polypyrimidine tract 
results in the RRM1-RRM2 taking up an open conformation leading to enhanced 
U2 snRNP recruitment (Mackereth et al. 2011). 
The choice of splice sites and potential alternative sites has traditional been 
thought to be determined with the initial binding of the spliceosome, thus the E 
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complex is also known as the ‘commitment’ complex. However alternative splicing 
decisions may occur later than this. An upstream AG dinucleotide is chosen as a 3’ 
splice site in preference to a downstream AG in intron 2 of the Drosphila Sex-lethal 
(SXL) pre-mRNA in the presence of the splicing factor SPF45 only just prior to the 
second step of splicing (Lallena et al. 2002). 
 
The A complex is formed when SF1 is released from the BPS and U2 snRNP, 
which is thought to loosely bind to the BPS in the E complex independently of ATP, 
becomes stably bound sequence via ATP hydrolysis (Das et al. 2000). This 
process is facilitated by the DExD/H-type RNA-dependent ATPases/helicases 
Sub2/UAP56 and Prp5. Base-pairing between U2 snRNP and the BPS is stabilised 
by the 14 KDa subunit of SF3b (SF3b p14) binding to the adenine of the BPS and 
SF3b 155 subunit to the RRM of U2AF65 (Will et al. 2001; Gozani et al. 1998). 
 
The complex B forms as the tri-snRNP U4/U6.U5 binds the 5′ splice site facilitated 
by the U5 associated splicing factor, Prp8 (human U5-220 KDa) (Maroney et al. 
2000). U5 binds both the 5’ and 3’ exons. The 3’ end of U6 and the 5’ end of U2 
base-pair (Valadkhan et al. 2000). U4 and U6 are bound such that the catalytic 
core of U6 is inactive. 
 
The B* complex (activated spliceosome) forms with release of U1 from the 5′ splice 
site. Characterisation of the B* complex identified over 100 associated proteins 
including cyclophilins, the RNA helicases Prp22 and p68 and a number of proteins 
belonging to the Prp19 (NineTeen Complex or NTC) complex (Makarova et al. 
2004). For the 1st step to proceed the 5’ splice site, bound to the U6-GAAACA 
sequence is repositioned to the first step catalytic center of U6 (sequence-
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ACAGAG) under the influence of the Prp28 protein and the Prp19-associated 
complex (Chan et al. 2003). The helicase Brr2, component of the U5 snRNP, 
unwinds the U4/U6 complex under the control of the associated proteins Prp8 and 
the GTPase Snu114 (Small et al. 2006).  The U4/U6 associated proteins and those 
holding U5 in place disassociate. Further U6:U2 duplexes are formed.    
The Prp19 complex has been shown to play a crucial role in the U4/U6.U5 snRNP 
interactions with the pre-mRNA. The Prp19 complex becomes associated with the 
spliceosome after U1 and U4 have dissociated. It mediates interactions between 
the 3’ terminal tract of U6 and the intron near the 5’ splice spite which is initiated 
when the 3’ terminal of U6 is exposed following the destabilisation of LSm proteins  
bound to it (Chan et al. 2003). 
 
The C complex signifies catalytic activity of the spliceosome. In the C1 complex U4 
is released via ATP hydrolysis and U6/U2 catalyses the 1st transesterification step 
with cleavage at the 5′ splice site and formation of the lariat. The 5’ splice site 
interaction with the U6 snRNA (ACAGAG) is disrupted prior to the second step 
(Konarska et al. 2006). Complex C2 signifies the 2nd transesterification reaction 
with cleavage at the 3′ splice site, exon ligation and lariat release.  
 
Comparison of purified catalytic spliceosome C complex with B complex in man has 
identified differences in the associated protein content (Bessonov et al. 2008). The 
B complex was shown to be associated with 130 proteins in comparison to the 150 
proteins with the C complex. One hundred and five proteins where found to be 
common between both complexes. More precisely, in association with the C 
complex the Prp19 complex was enriched while two multi-subunit complexes SF3a 
and SF3b were depleted. Thirty-seven proteins were identified to be tightly bound 
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in the C complex following treatment with 1M salt indicating their likely role in the 
catalytic activity of the C complex. These included the Prp19 complex, U5-220 
(yeast equivalent Prp8), U5-116 (Snu114), U5-40K (Prp8-binding protein). Other 
second step factors found in the C complex and not associated with the B* complex 
include hPrp17, the RNA helicase DDX35, and HSP73 (Makarov et al. 2002). 
The components of the spliceosome making up the catalytic core are still debated. 
Protein free RNA complex associated with fragments of U2 and U6 snRNA in vitro 
demonstrate the 2’OH group of a adenine at the branch site attacking a 
phosphodiester bond akin to the first step of splicing, suggesting that these snRNA 
make up the essential catalytic core of this RNA enzyme (Valadkhan et al. 2001). 
However several protein components remain near the catalytic active site, namely 
the U2 specific SF3b 14a/p14 and U5-specific Prp8 and may also play a role (Will 
et al. 2001; Abelson 2008). 
Once splicing has occurred and the mRNA has been generated, the ATP-
dependent DExH box RNA helicase, Prp22 mediates mRNA release (Company et 
al. 1991). This leaves the lariat with various remnant RNPs from the spliceosome 
designated the Intron large (IL) complex (Yoshimoto et al. 2009). Spliceosome 
disassembly is mediated by the DExH box RNA helicases, Prp43, Brr2 and the 
GTPase Snu114 bound to GTP (Arenas et al. 1997; Small et al. 2006). Prp43 is 
found in the trimeric NTR complex in association with two splicing factors Ntr1 and 
Ntr2. Ntr1 contains a G-patch domain (RNA binding domain) that binds Prp43 and 
induces its helicase activity in spliceosome disassembly (Tsai et al. 2005; Tanaka 
et al. 2007). Once the snRNPs are released the Intron Small (IS) complex is 
generated which can undergo degradation more readily than the IL complex. The 
lariat is linearised by the debranching enzyme DBR1 and then degraded (Moore 
2002).  
 





Figure 1.2.4.B  
Figure 1.2.4.B The splicing mechanism. Schematic figure demonstrating the 
splicing mechanism. Exons are given as grey boxes and introns as black lines. 
Various intermediate complexes in the splicing reaction are shown. These include 
complexes E, A, B and C.  Other intermediate complexes and splicing factors are 
involved in the splicing process but have been omitted for clarity. 
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1.2.5 Splicing enhancers and repressors 
 
1.2.5.1 Cis- acting elements. 
Sequences within the pre-mRNA are known to influence the choice between splice-
sites to allow accurate and reproducible splicing at the latter. Exonic and intronic 
splicing enhancer sequences (ESE and ISE, respectively), which tend to be purine 
rich, have been characterised, and in general act by binding SR proteins which 
interact with the spliceosome to enhance the use of particular splice sites (Liu et al. 
1998; Fairbrother et al. 2002; Zhang et al. 2004). Intronic and exonic splicing 
silencer sequences (ISS and ESS, respectively) have also been identified on 
functional and bioinformatic grounds (Wang et al. 2004; Zhang et al. 2004; Yu et al. 
2008). Using an in vitro SELEX approach with in vivo confirmation, ISS and ESS 
sites were identified on the basis of selecting an upstream weak 5’ splice site for U1 
snRNP binding in preference to a downstream consensus 5’ splice site (Yu et al. 
2008).  The silencer sites often interact with members of the family of 
heterogeneous nuclear ribonucleoproteins (hnRNPs) including hnRNP A1, 
polypyrimidine tract binding protein and hnRNP H, to suppress the use of particular 
splice sites (Chen et al. 1999; Del Gatto-Konczak et al. 1999). 
 
 
 1.2.5.2 Trans-acting elements. 
Trans-acting factors include splicing enhancers in the form of SR proteins (see 
section 1.2.5.3.) and splicing silencers such as the hnRNP family. These 
sequences interact with cis-acting elements as described above and enhance or 
inhibit the splicing process via several different mechanisms. The balance between 
enhancing factors e.g. SF2/ASF and silencing factors e.g. hnRNP A1 determines 
the overall outcome of splicing (Mayeda et al. 1992; Bai et al. 1999). The effects of 
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trans-acting elements on splicing are more complex, however, than simply those 
that enhance and those that inhibit splicing. For instance, the NOVA1 protein acts 
as a splicing enhancer by causing exon 9 inclusion when bound to an ISE in the 
GABA A receptor ү2 and as a splicing repressor for exon 4 of its own pre-mRNA 
when bound to an ESS (Dredge et al. 2005). 
 
 1.2.5.3 Splicing enhancers. 
The SR proteins are the major family of trans-acting splicing factors which play a 
role both in constitutive and alternative splicing. Further studies have also identified 
that SR proteins have other diverse roles in mRNA nuclear export, translation and 
nonsense mediated decay (Caceres et al. 1998; Sanford et al. 2004; Zhang et al. 
2004). These proteins consist of arginine/serine rich repeat domains also known as 
RS domains (RS or SR denotes single letter notation for arginine - ‘R’ and serine - 
‘S’) at the C-terminus and a number of RRMs at the N-terminus. The RRM domain, 
which can bind to specific RNA sequences, specifically interacts with the pre-
mRNA while the RS domain can mediate both protein-protein and protein-RNA 
interactions. Splicing enhancers may mediate their effects by recruiting relevant 
components of the spliceosome, other splicing factors or by antagonising silencer 
elements (Zuo et al. 1996; Blencowe 2000; Graveley et al. 2001; Kan et al. 1999). 
The RS domain also plays a role in SR protein cellular localisation via interactions 
with transportin-SR, the SR protein nuclear import receptor (Lai et al. 2000).  
Post-translational modification of SR proteins can modify their effect. The SR 
protein SRp38, a splicing repressor in the dephosphorylated state becomes an 
activator in the phosphorylated state by recruiting and stabilising U1 and U2 snRNP 
(Shin et al. 2002; Feng et al. 2009). 
SR proteins appear to be regulated in part by ultraconserved genomic elements, 
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defined as regions of at least 200 nucleotides of perfect identity between the 
human, mouse and rat genomes, found within their coding genes (Bejerano et al. 
2004). These elements code either alternative poison cassette exons or the 3’ UTR 
of the gene and allow transcript degradation, postulated to be a means of self 
regulation (Lareau et al. 2007).  
SR-related proteins, a further group of splicing factors which contain an RS domain 
but may not have an RRM domain also play roles in splicing and other cellular 
functions (Boucher et al. 2001). 
 
1.2.5.4 Splicing silencers 
The best characterised family of silencing factors is the Heterogeneous nuclear 
ribonucleoproteins (hnRNP) family of proteins which work by interacting with 
negative cis-acting regulators. HnRNP were originally defined as proteins 
associated with RNA in the cell nucleus. These are a heterogeneous family of 
proteins with marked structural and functional diversity. The mammalian hnRNP 
family consists of over 20 distinct polypeptides (Swanson et al. 1988). Like SR 
proteins, hnRNP proteins consist of one or more RNA-binding domains associated 
with an auxiliary domain which is involved in protein-protein interactions. Mayeda 
and colleagues established that hnRNP A1 is able to modulate 5′ splice site 
selection directly (Mayeda et al. 1993). HnRNP A1 and hnRNP H (PTB) are the 
best characterised members of the family which play a clear role in splicing 
repression. Despite this, there is evidence that they positively modulate the splicing 
process depending on their binding position (Xue et al. 2009).  Analysis of PTB-
RNA interactions across the genome using high-throughput sequencing of RNA 
isolated by crosslinking immunoprecipitation (HITS-CLIP or CLIP-seq) 
demonstrated that PTB binding near constitutive splice sites enhances the inclusion 
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of adjacent alternative exons. HnRNP proteins also appear to play roles in 
transcription, telomere biogenesis, polyadenylation, translation, RNA editing and 
mRNA stability (Krecic et al. 1999).  
 
Putative mechanisms have been invoked to explain the action of splicing silencers 
(figure 1.2.5.A) (Cartegni et al. 2002).  
 
1. Occlusion - Splicing silencers such as hnRNP A1, hnRNP and hnRNP H may 
directly compete with enhancer factors to occlude binding sites in close 
apposition to each other in a mutually exclusive manner resulting in an inhibition 
of splicing.  
2. Nucleation and co-operative binding - ESS sites may exert an inhibitory effect 
on distant ESE sites by binding an inhibitory factor e.g. hnRNP which nucleates 
the co-operative polymerisation of further inhibitory factors to displace or inhibit 
enhancer factors binding (Zhu et al. 2001). 
3. Loop-out - Silencer splicing factors, bound to ISS elements either side of a 
given exon may dimerise and loop-out the exon resulting in an inhibition of 
splicing (Blanchette et al. 1999). The binding of pre-mRNA to the RNA binding 
domains of PTB will tend to result in ‘looping-out’ of a single strand of RNA 
(Oberstrass et al. 2005). 
4. Repression of pseudo and cryptic splice sites - hnRNP binding sites have been 
identified in close proximity to pseudo and cryptic splice sites and are thought to 












Figure 1.2.5.A  Mechanisms of splice silencing. Schematic diagram shows a portion of 
pre-mRNA. Exons are shown as grey boxes and introns are denoted as black lines. Cis-
acting enhancer sequences (ESE and ISE) and inhibitory sequences (ESS and ISS) are 
labelled accordingly. Splicing factors are given as shaded circles with a + denoting a 
splicing enhancer and – denoting an inhibitory factor. The four figures illustrate 
mechanisms of splice silencing A. Silencing by occlusion. B. Silencing by nucleation and 
co-operative binding. C. Silencing by exon looping. D. Silencing pseudo splice sites by 
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1.2.6 Intron and exon definition. 
 
Two potential mechanisms exist to explain how the spliceosome identifies intron-
exon boundaries in the pre-mRNA. Exon definition postulates that pre-spliceosomal 
components identify and bind to pairs of splice sites around an exon (5’ splice site 
and the upstream 3’ splice site). Intron definition suggests that pairs of splice sites 
around introns are defined initially. Whilst clearly both processes occur, the 
dominant mechanism will, in part, be determined by the ability of the cross intron or 
cross exon complex to span the divide. The predominant mechanism in higher 
order eukaryotes, in which introns tend to be significantly longer, appears to be 
exon definition (Robberson et al. 1990). 5′ splice site mutational studies confirm this 
by demonstrating more proximal exon skipping rather than distal intron retention in 
keeping with exon definition models (Nakai et al. 1994).   
Inherent exonic features which determine splicing choices include exon length and 
splice site strength. The inherent strength of splice sites is an important factor in 
splice site choice (figure 1.2.7.A) which may be estimated using a consensus 
scoring matrix (Shapiro et al. 1987). 
The majority of exons are between 50-300 nucleotides in length with an average of 
120 nucleotides (Dominski et al. 1992; Ast 2004). Evidence for the proposition that 
there is an optimum length for an exon includes the fact that only 1% of exons are 
longer than 400 nucleotides (Berget 1995); exons shortened to less than 50 
nucleotides are more likely to be skipped compared to longer exons (Dominski et 
al. 1991); constitutive exons expanded to greater than 300 nucleotides are 
increasingly skipped (Robberson et al. 1990) and cryptic splice sites often emerge 
very near to mutated splice sites, again suggesting that there is an optimum range 
for exon length. Very short constitutively spliced exons do exist e.g. NCAM has a 3 
nucleotide exon (Santoni et al. 1989).   
 




Less favourable exon lengths may be overcome by optimising splice site strength 
and near-by enhancer sequences (Black 1991; Dominski et al. 1992).  
 
Intron definition is considered more likely to occur when the length of the intron is 
less than 200 nucleotides (Fox-Walsh et al. 2005). Highly expressed genes tend to 
have shorter introns than genes that are expressed less (Castillo-Davis et al. 2002). 
Constitutively splice exons which are expanded until they are skipped may again be 
constitutively spliced if the surrounding introns are shortened (splicing by intron 
definition) (Chen et al. 1994).   
Figure 1.2.7.A  Splice site strength.  Schematic diagram of pre-mRNA with 
consensus sequence splice sites. Exons are represented as boxes and the 
intron as a black line. The three boxes below represent the frequency with which 
nucleotides appear in a given position at the 5′ splice site, branch point 
sequence and 3′ splice site. Adapted from Cartegni et al. 2002 {Cartegni, 2002 
#709}. 
Figure 1.2.7.A  
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Exon definition by spliceosomal components must convert to intron definition prior 
to intron excision. Though the mechanisms for this are poorly understood, insights 
into this process come from Schneider et al. using a trans-splicing approach to 
demonstrate that cross exon complexes include not only the U1 and U2 snRNP but 
also the tri-snRNP U4/U6-U5, which is able to positionally convert from a cross 
exon defined complex to bind the upstream 5’ splice site across the intron 
(Schneider et al. 2011). Binding to the 5’ splice site occurs via a U6 interaction 
suggesting a mechanism to convert cross exon to cross intron complexes. U6 can 
bind directly to the 5’ splice site in the absence of U1 snRNP to form a B complex 
suggesting it is possible to bypass the need for a prior A complex (Schneider et al. 
2011).  
The conversion from exon to intron definition can also be used as a point of 
regulation. The RNA-binding motif protein 5 (RBM5) appears to regulate splicing of 
exon 6 of the apoptotic factor FAS by inhibiting the conversion of the exon defining 
to intron defining complex (Bonnal et al. 2008). This is achieved by inhibiting the 
binding of the tri-snRNP U4/U6-U5 to the flanking introns leading to exon 6 
exclusion. 
Splicing around exon 4 of the CD45 pre-mRNA is preceded by the formation of an 
A-like exon definition complex (AEC) across exon 4. The binding of hnRNP L to an 
exonic splicing silencer (ESS) in exon 4 appears to inhibit cross intron definition by 
U1 and U2 snRNP to inhibit splicing (House et al. 2006). 
 
Several mechanisms have been put forward to explain how the spliceosome might 
link splice sites across huge introns. The Ultrabithorax gene of Drosophila contains 
a 74 KB intron and provides an example of ‘recursive’ splicing whereby consecutive 
sections of intron are spliced out between the upstream 5’ splice site and 
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sequential downstream 3’ splice site (‘‘ratcheting point’’ or RP-sites) within the 
intron. Each time a section of intron is spliced out the spliceosome forms repeatedly 
using the upstream 5’ splice site and the next 3’ splice site down the intron until it 
splices an entire long intron (Hatton et al. 1998). 
Recursive splicing is not thought to be a significant mechanism to manage long 
introns in mammals however. Bioinformatic studies in vertebrates suggest an 
alternative strategy using short and long interspersed element repeats (SINE and 
LINE) which are able to form stems to loop out large lengths of intronic sequence 
thereby bringing the 5’ and 3’ splice site closer together to enhance intron definition 
and splicing (Shepard et al. 2009).  
 
1.2.7  RNA secondary and tertiary structure  
RNA secondary and tertiary structure can influence the rate and extent of 
alternative splicing. The secondary structure of RNA refers to sequences of 
classical Watson-Crick base-paired and unpaired ribonucleotides and may be 
represented in a two dimensional fashion. It includes structures such as the hairpin 
loop, bulges, internal loops and stem loops (Chastain et al. 1991). RNA tertiary 
structure is the three dimensional interaction of secondary structure elements and 
includes the ribose zipper, coaxial stacking, kissing hairpin loops and tertraloops 
(Hermann et al. 1999).  
In vivo studies have demonstrated that secondary structure formation following 
transcription can affect alternative splicing choices (Eperon et al. 1988). Secondary 
structure may either enhance exon skipping or inclusion by bringing relevant splice 
sites into close apposition or by obscuring sites from spliceosome recognition. 
Analysis suggests that splicing enhancer and inhibitory motifs tend to appear in 
predicted single strand rather than double stranded RNA sequences where they 
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are able to exert an effect (Hiller et al. 2007). Indeed the effects of enhancer and 
inhibitory motifs are modified according to the secondary structure conformation 
they are found within (Buratti et al. 2004).  
The effects of secondary structure on alternative splicing were demonstrated by 
Graveley in the 48 potential isoforms of exon 6 of the DSCAM gene in Drosophila 
melanogaster (Graveley 2005). Using comparative genomics to look at genomes of 
16 different insects, two types of conserved sequence were identified. The docking 
sequence appeared upstream of all exon 6 variants and selector sequences 
appeared upstream of each potential exon 6 variant. The presence of 
complimentary sequences in the docking sequence with each of the selector 
sequences provides a mechanism where-by any of the exon 6 variants may be 
selected in a mutually exclusive secondary structure by binding of the docking 
sequence to a given selector sequence. 
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1.2.8  Environmental cues to splicing 
As part of the cellular response to environmental cues, modulation of splicing by 
intracellular and extracellular changes in the environment might be expected. 
Evidence is now accumulating for the influence of environmental cues on the 
process of splicing.   
Changes in oxygen tension have been shown to regulate cellular alternative 
splicing in the tumour antigen gene MGEA6 (Webby et al. 2009). The splicing factor 
U2AF65 undergoes lysyl-hydroxylation by a homologue of the oxygen sensitive HIF 
asparaginyl hydroxylase, the dioxygenase Jumonji domain-6 protein (jmjd6) 
(Webby et al. 2009). Jmjd6 knockdown resulted in altered splicing of the MGEA6 
gene (exon 19 skipping) linking environmentally triggered cues to changes in 
splicing.  
Another example of an environmental trigger affecting splicing comes from the 
splicing repressor SRp38 and cellular heat shock. Heat shock results in 
dephosphorylation of SRp38 which interferes with the U1 snRNP-5’ splice site 
interaction and causes a reduction in splicing efficiency (Shin et al. 2002). 
 
Extracellular cues transduced via extracellular-signal-regulated kinase/ mitogen-
activated protein kinase (ERK/MAP-kinase) within the RAS pathway may influence 
the alternative splicing of exon v5 of the adhesion transmembrane molecule, CD44 
(Matter et al. 2002). Sam68, an RNA-binding protein binds to exonic splicing 
regulatory elements resulting in exon v5 inclusion when phosphorylated by ERK. 
 
Riboswitches are cis-acting RNA elements found predominately in bacteria but also 
plants and fungi which respond to a metabolite and can regulate not only 
transcription and translation but also alternative splicing. Thiamine pyrophosphate 
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(TPP) - responsive riboswitches in the filamentous fungus Neurospora crassa have 
been shown to both activate and repress gene expression by modulating 
alternative splicing (Cheah et al. 2007). In the case of the N-myristoyltransferase 1 
(NMT1) pre-mRNA which itself is involved in thiamine metabolism, the riboswitch, 
bound to thiamine, unmasks an alternative downstream 5’ splice site. This results in 
the generation of the alternative isoform, I-2 which competes with the constitutive 
isoform for translation.  
 
1.2.9  Chromatin structure and histone modification  
The nucleosome consists of a number of histone proteins bound within a DNA 
strand and constitutes the basic building block of chromatin. The binding of the 
nucleosome to exons and introns influences both transcription and splicing. Several 
lines of evidence support the notion that chromatin structure plays a role in 
alternative splicing. DNA topoisomerase I (Top1), involved in relaxing DNA 
supercoiling prior to transcription by RNA polymerase II, is known to phosphorylate 
SR proteins including ASF/2SF, essential in mediating exon skipping decisions 
(Rossi et al. 1996). Furthermore the SR protein B52 has been shown to play an 
essential role in localising the Drosphila DNA topoisomerase I to active 
transcription sites as well as in mRNA release following transcription (Juge et al. 
2010). Genome wide mapping of chromatin structure identifies that nucleosomes 
are placed non-randomly (nucleosome phasing) in the vicinity of exons rather than 
introns, constitutive rather than alternatively spliced exons and are less frequent at 
the site of pseudoexons (Spies et al. 2009; Tilgner et al. 2009; Kolasinska-Zwierz et 
al. 2009). 
There are many examples to illustrate the association between chromatin structure 
and alternative splicing outcomes. Inclusion of the exon E33/EDI of the fibronectin 
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pre-mRNA is dependant on chromatin arrangement (chromatinisation) of the 
plasmid (Kadener et al. 2001).  Methylation of histones drives interactions with 
splicing factors via chromatin adaptor proteins to alter splicing choices. Splicing 
factors have been shown to bind to the nucleosome via histone modifications.  
Histone modification, in the form of trimethylation of lysine 36 of histone H3 
(H3K36me3) leads to PTB binding via the chromatin adaptor proteins MRG15 and 
a reduction of the inclusion of a PTB-dependent exon (exon IIIb) in the human 
fibroblast growth factor receptor 2 (FGFR2) gene (Luco et al. 2010).   
 
1.2.10  Natural antisense transcripts (NAT)  
Recent genome wide studies of the eukaryotic transcriptome have focused 
attention on the diverse non-coding RNAs (ncRNA) which include natural antisense 
transcripts (NAT) generated from the antisense (second) DNA strand. NATs appear 
to play a role in regulating gene expression at all levels of transcriptional and post-
transcriptional control including alternative splicing. NATs may bind to sense pre-
mRNA transcripts and block spliceosome and splicing factor interactions. 
The expression of the thyroid hormone receptor gene, ErbAa in B lymphocytes has 
been shown to be regulated by antisense RNA strands (Hastings et al. 1997). 
NATs have been shown to down-regulate E-cadherin expression by binding the 
mRNA of Zeb2, a transcriptional repressor of E-cadherin. NAT binding leads to   
intron retention at the 5’UTR which contains a key ribosomal site required for Zeb2 
protein expression (Beltran et al. 2008). 
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1.2.11  Co-transcriptional splicing 
Co-transcriptional splicing is the process whereby splicing occurs concurrently with 
transcription and is mediated by RNA Pol II linking the splicing machinery with 
transcriptional elements (Perales et al. 2009). Post-transcriptional splicing does 
occur, predominantly with introns towards the 3’ end of the transcript (Bauren et al. 
1994). Evidence for co-transcriptional splicing comes from several sources; the 
observation that chorion gene transcripts in Drosophila shortened (i.e. spliced) 
whilst still attached to chromatin and RNA Polymerase (Osheim et al. 1985); the 
presence of introns in an RNA transcript increased transcriptional efficiency 
(Brinster et al. 1988) and the rate of RNA Pol II transcription significantly alters the 
rate of alternative splicing (de la Mata et al. 2003). Chromatin immunoprecipitation 
(ChIP) is a technique in which a protein of interest is cross-linked, using agents 
such as formaldehyde, to target DNA which may subsequently be retrieved and 
sequenced to establish interacting partners. ChIP studies have confirmed that 
elements of the spliceosome (U2, U5 snRNP, Prp19) assemble on intron containing  
genes prior to the completion of its processing by RNA Pol II (Gornemann et al. 
2005).  
Aubeouf et al. demonstrated that the addition of transcriptional co-regulators e.g. 
the DEAD-box RNA helicase p72 and the heterogeneous nuclear 
ribonucleoprotein-like protein CoAA (coactivator activator), can alter splicing in a 
transfected minigene construct (CD44) in which a steroid responsive promoter is 
inserted (ERE-CD44) in response to cellular stimulation with oestrogen (Auboeuf et 
al. 2002). 
 
Two models of co-transcriptional splicing exist, the recruitment model and the 
kinetic model. The recruitment model suggests that alternative splicing is either 
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enhanced or repressed by the interaction between RNA Pol II and splicing factors. 
De la Mata and Kornblihtt demonstrate that the C terminal domain (CTD) of RNA 
Pol II interacts with SRp20 to inhibit the inclusion of the alternative EDI exon of the 
fibronectin gene (de la Mata et al. 2006). 
 
The kinetic model postulates that the likelihood of an alternative exon being 
included depends of the rate of transcription as the result of RNA Pol II. Evidence 
for this postulation comes from in vivo experiments in which a splice site within a 
stem structure is utilised depending on size of an intervening loop suggesting that 
the rate of transcription determines the secondary structure formation possible and 
ultimately the use of a given splice site (Eperon et al. 1988). Below a threshold loop 
size secondary structure is able to form and sequester the splice site. Above the 
threshold loop size the stem formation is delayed allowing the splice site to be 
utilised. The splice site was poorly utilised in vitro irrespective of the loop size as 
the transcript is pre-formed and there is no impediment to secondary structure 
formation. Another study demonstrated that the degree of inclusion of alternative 
exons with weak splice splices increased when transcription speeds were 
decreased as the result of a point mutation in RNA Pol II (de la Mata et al. 2003).  
 
There are multiple examples of interactions between the process of transcription 
and splicing. TAT-SF1, an elongation factor, interacts with U2 snRNP to stimulate 
splicing and concurrently promote transcriptional elongation via interactions with a 
component of the transcription elongation complex, P-TEFb (Fong et al. 2001). 
Interactions between U1 snRNP and several splicing regulatory proteins allows 
RNA Pol II to transcribe more efficiently than with other polymerases e.g. T7 phage 
which do not (Das et al. 2007). The splicing factor SC35 is known to promote more 
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efficient transcription elongation (Lin et al. 2008). Long introns may be degraded by 
exonucleases as transcription takes place or so called co-transcriptional cleavage 
of introns. Splicing remains unaffected as the upstream exons is held by the 
polymerase elongation complex (Dye et al. 2006). 
1.2.12  Polyadenylation 
Polyadenylation is the addition of a multiple adenine nucleotides at the 3’ end of the 
transcript after transcription and marks the generation of a mature mRNA. The 
process of polyadenylation and splicing are again linked. Polyadenylation signals 
enhance with terminal intron definition and binding of the 3’ splice site processing 
machinery. Both U2AF and components of the U2 snRNP binding the terminal 3’ 
splice site interact directly with the poly(A) complex component, the 73-kDa subunit 
of cleavage and polyadenylation specificity factor (CPSF-73) (Kyburz et al. 2006). 
The U1 snRNA binding to the 5’ splice site has been shown to suppress potential 
upstream intronic polyadenylation signals. This was demonstrated using whole viral 
genome studies with antisense knockdown of U1 snRNA (Kaida et al. 2010). 
Cleavage at the poly(A) site at the end of an mRNA transcript is mediated by a 
component of the poly(A) complex with endonuclease activity, CPSF-73 (Mandel et 
al. 2006). Degradation of RNA transcripts beyond the poly(A) tail comes via a 
complex with 5’-3’ exonuclease activity including polypeptides Rtt103, Rat1 and 
Rai1 in yeast (Kim et al. 2004). Higher eukaryotes require additional mechanisms 
to cleave and degrade the RNA transcript beyond the poly(A) tail. These include 
transcriptional pauses allowing the 5’-3’ exonuclease Xrn2 (Rat1) to degrade the 
transcript and the presence of a termination element approximately 1Kb 
downstream of the poly(A)  site which allows co-transcriptional cleavage (Kaneko et 
al. 2007; West et al. 2004). 
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1.2.13  mRNA  Export 
Nuclear export of the resulting mRNA from the nucleus to the cytoplasm occurs in 3 
distinct stages; firstly mRNP formation; secondly, targeting and translocation 
through the nuclear pore complex (NPC) and finally mRNP release and 
disassembly (Carmody et al. 2009). The mRNA is transported in association with 
proteins involved in RNA processing and export as a messenger ribonucleoprotein 
(mRNP). Some of these are a part of the family of hnRNPs. Processing, from 
transcription to nuclear export are closely linked (Kohler et al. 2007). Surveillance 
mechanisms are in place to ensure nuclear processing is complete prior to nuclear 
export.  Transfer is as part of a cargo-carrier module via a NPC. NPCs are conduits 
between the nucleus and cytoplasm by which macromolecules are transferred and 
are made up of nucleoporins.  
Several complexes including the THO/TREX complex and TREX 2 in man play a 
central role in mRNA export but also appear to be linked to transcription and  
splicing (Strasser et al. 2002; Luna et al. 2009). The THO/TREX complex consists 
of the heterotetrameric TREX ('transcription/export') complex and the THO complex 
consisting of the mRNA export factor Yra1 (REF/Aly in mammals) and the DEAD 
box protein Sub2 (UAP56 in mammals). Sub2 also plays a role in spliceosome 
assembly (Shen et al. 2008).  In man TREX is bound to the 5’ end of the mRNA via 
a combination of cap-binding proteins, Yra1 (Aly/REF) and exon junction complex 
(EJC) factors (Cheng et al. 2006).   
 
 NXF1-NXT1/TAP-p15 (Mex67-Mtr2 in yeast), a conserved export carrier and 
TREX 2 bind the mRNA to the NPC (Gruter et al. 1998; Jani et al. 2012).  This may 
occur directly or via several proteins including Yra1 (Aly/REF), Sub2 (UAP56) and 
the RNA-binding protein Np13 in S. Cerevisiae (Lund et al. 2005).  SR proteins e.g. 
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SRp20, 9G8 and ASF/SF2 may also serve as export adaptors to export receptors 
such as NXF1-NXT1/TAP (Huang et al. 2005). 
The DEAD box helicase DpB5 initiates mRNP disassembly on the cytoplasmic side 
of the NPC following activation by other factors involved in translocation of mRNA 
including the NPC-associated Gle1 and inositol hexakisphosphate (InsP6)  
(Alcazar-Roman et al. 2006). These factors also appear to play significant roles in 
protein translation and termination.  
 
1.2.14  Translation 
Recently spliced mRNAs are able to engage the translational machinery more 
efficiently leading to a higher yield of protein than equivalent cDNA of the same 
transcript suggesting a facilitative link between splicing and the translational 
machinery (Le Hir et al. 2003). This appears to be mediated via the EJC bound 
ribosomal complex, SKAR (S6 kinase 1 Aly/REF-like target), a target for the 40S 
ribosomal protein S6 kinase 1 (S6K1) which enhances translation initiation at the 5’ 
cap of the mRNA (Ma et al., 2008). S6K1 is also recruited by other splicing factors 
such as ASF/2AF to encourage translation. 
Wang et al demonstrated that translational nonsense codons are able to influence 
alternative splicing (Nonsense-associated altered splicing). Splicing rates of a T cell 
receptor β (TCR β) ‘alternative mRNA’, which in fact skips the mutation that 
generates the nonsense codon, are increased in its presence (Wang et al. 2002). 
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1.2.15  RNA surveillance and degradation 
A pre-mRNA may be mis-spliced as the result of a mutation in a splice site or a 
splicing regulatory element. A number of surveillance and degradative mechanisms 
are in place, in both the nucleus and cytoplasm to identify and degrade mis-spliced 
transcripts. Nonsense mediated decay (NMD) remains the noted degradative 
pathway but other NMD independent pathways exist.  
 
1.2.15.1 Nonsense-mediated decay 
Nonsense-mediated decay is a RNA surveillance mechanism via which RNA is 
targeted for degradation if it contains a premature termination codon (PTC) 
significantly upstream from an exon-exon junction (Maquat 2004). NMD occurs 
during the pioneer round of translation in mammals and provides not only a means 
to degrade prematurely truncated transcripts, generated as the result of  mutations, 
but also plays a routine role in the regulation of normal non-mutated transcripts. 
Again, elements of the splicing machinery are inextricably linked to the process of 
NMD.  The splicing factor ASF/2AF appears to influence the degree of NMD 
(Gudikote et al. 2005). Indeed a number of splicing factors self-regulate their own 
expression by inducing NMD when in excess (McGlincy et al. 2008). 
NMD is triggered when a PTC is found more than 50 nucleotides upstream of the 
last exon-exon junction bound by an EJC (Chang et al. 2007). The EJC consists of 
4 proteins, namely; eIF4AIII; Barentsz [Btz]; Mago and Y14 which are associated 
with the mRNA 20-25 nucleotides upstream of the exon/exon junction (Bono et al. 
2006). On encountering a PTC significantly upstream of the EJC on an mRNA 
transcript, the ribosome undergoes a translational pause. Eukaryotic translation 
release factors eRF1 and eRF3 bind the RNA helicase Upf1 and the PIK-related 
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protein kinase SMG-1 to form the SURF complex (Kashima et al. 2006). The SURF 
complex binds the EJC, precipitating phosphorylation of Upf1 by SMG-1. 
Phosphorylated Upf1 recruits the serine/threonine-protein kinase SMG-5, SMG-6, 
SMG-7 and leads to both translational repression by inhibiting conversion to the 
transcriptionally active 80S ribosome complex and recruitment of decay factors 
Dcp1a, Xrn1, and Rrp4 necessary for NMD (Isken et al. 2008).  Degradation via the 
NMD pathway is mediated by the 5’-3’ exonuclease Xrn-1, following decapping at 
the 5’ end of the transcript and 3’-5’ nucleases following deadenylation at the 3’ end 
of the transcript (Lejeune et al. 2003; Chen et al. 2003).  SMG-6 appears to have 
endonuclease activity and may also contribute to degradation (Huntzinger et al. 
2008). 
 
1.2.15.2 NMD independent surveillance/degradation 
Within the spliceosome, the associated DExD/H box ATPases Prp5p, Prp16p, and 
Prp22p play a proofreading role (Smith et al. 2008; Koodathingal et al. 2010; 
Burgess et al. 1993; Xu et al. 2007). In the case of Prp16p, proof-reading of the 5’ 
splice site cleavage is determined by the rate of 5’ cleavage (sub-optimal 5’ splicing 
occurs at a slower rate). Stalled transcripts were discarded with the assistance of 
the DExD/H box ATPase Prp43 (Koodathingal et al. 2010). 
Proteins such as the yeast Mlp1p/Mlp2p may assist in the process of surveillance 
and degradation, acting as retention factors which hold unspliced transcripts 
awaiting nuclease degradation (Dziembowski et al. 2004; Galy et al. 2004).  
 
Non-stop decay (NSD) and no-go decay (NGD) are two further degradative 
pathways. NSD is a process in which mRNA transcripts, attached to ribosomes, are 
released and diverted towards exosomal degradation if no stop codon is identified 
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(Vasudevan et al. 2002). If ribosomal translational of an mRNA is impeded due to a 
defect in the mRNA then the transcript is said to undergo NGD. In NGD the mRNA 
transcript is snipped at the defect site. Ribosome release is mediated by two 
proteins, Dom34p and Hbs1p and nucleases are recruited to degrade the mRNA 
fragments (Doma et al. 2006). 
 
1.2.15.3  Endoribonucleases and exoribonucleases 
Endoribonucleases and exoribonucleases play a major role in degradative 
pathways. Exoribonucleases mediate either 5’-3’ decay or 3’-5’ decay of mRNA 
which requires prior deadenylation of the poly(A) tail and  5’ decapping of the 
transcript via a decapping protein complex (Fenger-Gron et al. 2005). 5’-3’ 
exoribonucleases in S. cerevisiae include the predominantly cytosolic 
Xrn1p/Kem1p, involved in degradation of decapped mRNA and the predominantly 
nuclear Rat1p/Xrn2p and its activating partner Rai1/Dom3Z (Xiang et al. 2009).  3’-
5’ mRNA decay is instigated by the exosome, a protein complex found both in the 
nucleus and cytoplasm. The exosome has both exoribonuclease and 
endoribonuclease activity and plays a key role in RNA surveillance. Enzymatic 
activity of the complex is derived from the hydrolytic nuclease, Rrp44/Dis 3 which 
harbors both exoribonuclease and endoribonuclease activity via its PIN domain 
(Dziembowski et al. 2007; Schneider et al. 2009). The human auto-antigen 
PM/Scl100kDa, a homologue to the S. cerevisiae protein Rrp6, is associated with 
the exosome in the nucleus and cytoplasm and also confers 3’-5’ exoribonuclease 
activity to the exosome (Allmang et al. 1999).  
Endoribonucleases degrade RNA via cleavage of phosphodiester bonds within a 
transcript. Exosome associated enzymes with endoribonuclease activity including 
Rrp44/Dis3 and Swt1, allowing endoribonucleic followed by exoribonucleic 
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degradation in a co-ordinated fashion (Schneider et al. 2009; Skruzny et al. 2009). 
Endoribonucleases can be broadly divided into those involved in degradation 
pathways which are sequence specific including siRNA and miRNA mediated 
decay (DICER and AGO2) or those involved in pathways which are not sequence 
specific e.g. inositol requiring enzyme-1 (IRE1), RNase L, aldolase C, activator of 
RNA decay (ARD-1), Ras-GTPase activating protein SH3 domain-binding protein 
(G3BP) and apurinic⁄apuridinic endonuclease 1 (APE1) (reviewed in Li et al. 2009). 
 
1.2.15.4  RNA interference 
RNA interference is a cellular process whereby mRNA is degraded and silenced by 
complementary double stranded RNA. RNA interference includes silencing via 
small interfering RNA (siRNA), microRNA (miRNA) and piwi-interacting RNA 
(piRNA) providing a further mechanism for genetic regulation. 
siRNA is a short sequence (21-25 nucleotides long) cleaved from a double 
stranded RNA molecule which may be generated endogenously or synthetically.  
Endogenous siRNAs are generated via cleavage of longer dsRNA by the nuclease 
enzyme DICER followed by separation of the strands by a helicase. The guide 
strand is incorporated into the RISC (RNA-induced silencing) complex. The guide 
strand then binds to its target mRNA and induces cleavage by the catalytic 
component of the RISC complex, Argonaute (Liu et al. 2004). 
miRNAs are short non-coding RNAs (~21nucleotides) which bind to complimentary 
RNA sequences leading to transcript degradation or repression of translation. 
miRNAs are derived from genome-coded precursors known as primary miRNAs 
(pri-miRNAs) generated by RNA Pol II. These precursors fold to create 
intramolecular hairpins which are then processed by a member of the RNase III 
family, Drosha,	  to generate the stem-loop miRNA precursor (pre-miRNA). The pre-
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miRNA is then transported to the cytoplasm to be processed by DICER via the 
common pathway with siRNA. miRNAs have been shown to play a role in the 
regulation of alternative splicing e.g. miR-133 suppresses the production of PTB2 
while miR-1 suppresses both PTB1 and PTB2 which play an important role in 
repressing the splicing of muscle specific exons until myotube differentiation takes 
place in precursor muscle cells (Boutz et al. 2007). 
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1.2.16  Pseudosplice sites and pseudoexons. 
Pre-mRNA contains sequence elements defining the 5′ and 3′ ends of introns and 
the branch point. In mammals, the consensus sequences of these elements are 
highly degenerate (Shapiro et al. 1987). As a result, matches to these consensus 
sequences are highly prevalent throughout the genome (Fairbrother et al. 2000) 
and outnumber genuine splice-sites by an order of magnitude in the human 
hypoxanthine guanine phosphoribosyl transferase (hprt) gene (Sun et al. 2000). 
These pseudo splice-sites or cryptic splice sites are not employed in wild type 
splicing. How the spliceosome is able to differentiate the few genuine splice sites 
from numerous pseudo splice sites is as yet unclear. Most of the pseudo splice 
sites in the human genome reside in introns, by virtue of their long lengths 
(Fairbrother et al. 2000; Sun et al. 2000). 
A pseudoexon is a sequence between 50 to 200 base pairs within an intron which 
is bound by a potential 3′ pseudo splice site in association with a downstream 5′ 
pseudo slice site (Sun et al. 2000). Therefore very large exons contain many 
pseudoexons. How these large exons are spliced intact again remains unclear.  
 
1.2.17 Splicing and disease 
Whilst splicing provides an additional level of control for gene expression, the 
corollary is an increased susceptibility to disease when the process becomes 
misregulated. It has been estimated that aberrant splicing accounts for the defect in 
genetic disease caused by point mutations in up to 50% of cases   (Teraoka et al. 
1999; Ars et al. 2000). Endocrine disease states as a consequence of disruption of 
splicing are numerous. Disease causing mutations may affect splicing in a number 
of ways: 
 




1. Primary splicing defects - mutations may cause primary splicing defects 
directly in the given gene.  
2. Secondary splicing defects - mutation not directly resulting in a splicing defect 
in the given gene but which alter splicing in a secondary fashion. Mutations in 
genes coding trans-acting components of the splicing machinery may result in 
this type of defect.  
3. Tertiary splicing defects - mutations which cause disease due to defects in 
splicing by mechanism other than primary or secondary splicing defects. 
 
1.2.17.1 Primary splicing defects.  
Primary splicing defects result from cis-acting mutations that alter splicing. These 
mutations may cause disease in one of several ways including; mutating  a 
constitutive splice site;  creating a cryptic splice site; altering secondary structure 
such that splicing is affected; altering enhancer or silencer elements or generating 
premature stop codons and thus stimulating nonsense-mediated decay (NMD) or 
nonsense-associated altered splicing (NAS) (Dietz et al. 1993; Hentze et al. 1999; 
Mendell et al. 2001). The gene responsible for Beta thalassemia, the beta-globin 
gene, provides the classic example of a primary splicing defect. Here, a single base 
substitution in the small intervening sequence (IVS1) of the beta-globin mRNA 
precursor results in alternative splicing and retention of the 3′ terminal 19 bases of 
IVS1 ahead of exon 2 (Fukumaki et al. 1982). There are numerous examples of 
endocrine disease resulting from primary splicing defects. 
Isolated growth hormone deficiency type II is an autosomal dominant disease 
characterised by the failure to generate and traffic full length growth hormone (22 
kDa). Several mutation affecting the splice sites of exon 3 or key ESEs result in 
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exon 3 being skipped and the production of a defective 17.5kDa growth hormone 
transcript. Exon skipping appears to be mediated by enhanced SC35 binding to 
local ESSs (Solis et al. 2008).  
Laron’s syndrome, or inherited growth hormone insensitivity is a syndrome 
characterised by mutations causing disruption of the growth hormone receptor.   A 
point mutation has been identified which strengthens a 5’ splice site for an intronic 
pseudoexon. One hundred and eight nucleotides between exon 6 and 7 are 
included in the growth hormone receptor transcript  resulting in the addition of a 36 
amino acid sequence which renders the receptor defective  (Metherell et al. 2001). 
Mutations of the genes encoding the succinate dehydrogenase subunit are known 
to predispose to the familial paraganglioma syndromes associated with 
catecholamine excess. We have demonstrated that a novel mutation in a subject 
with multiple paragangliomata (c. 169 + 1 G>A) results in disruption of the 5’ splice 
site of exon 2  which is thus skipped, leaving a defective transcript including exon 
1,3 and 4  (Srirangalingam et al. 2010).  
Medium-chain acylCoA dehydrogenase (MCAD) deficiency is an example of a 
disease in which disruption of a splicing regulator element leads to an alteration in 
splicing. Patients with a missense mutation in exon 5 of the medium-chain acylCoA 
dehydrogenase (MCAD) are unable to generate a functional protein leading to 
MCAD deficiency and a resulting syndrome of hypoglycaemia, hyperammonaemia 
and increased risk of sudden death due to an inability to mobilise fatty acid for 
oxidation and energy production. The missense mutation inactivates an exonic 
splicing enhancer which is required to select a sub-optimal 3’ splice site for exon 5 
(Nielsen et al. 2007). 
Thyrotropin-secreting pituitary adenomas (TSHomas) are rare pituitary tumours 
characterised by a raised thyroid stimulating hormone (TSH) levels despite 
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elevated thyroid hormone levels due to the failure of negative feedback. Some 
TSHomas contain an aberrantly spliced variant of the thyroid hormone receptor 
beta 2 (TRβ2spl) lacking 40 amino acids of the ligand binding domain (Ando et al. 
2001). Thus T3, the ligand, is unable to bind the receptor which would normally 
result in down regulation of TSH secretion.   
Splicing mutations are known to be involved in the disease process of several other 
endocrine tumours including insulinoma, thyroid and prostate carcinoma (Minn et 
al. 2004; Narla et al. 2005; Baitei et al. 2009). 
 
1.2.17.2 Secondary splicing defects.  
Secondary splicing defects may result from mutations in genes coding trans-acting 
components of the splicing machinery. Unlike cis-acting mutations causing primary 
splicing defects in one gene, mutations affecting components of the splicing 
machinery have the potential to affect many other genes. Diseases associated with 
such defects include Prader-Willi syndrome and retinitis pigmentosa (Kishore et al. 
2006; Deery et al. 2002). 
Prader-Willi syndrome results from the loss of the maternally imprinted region of 
chromosome 15q11-q13 via a number of mechanisms (deletions of the paternal 
region accounting for the majority of cases). Though many genes have been 
identified in this region e.g. SNURF-SNRPN, NDN, MKRN3, MAGEL2, PWRN1, 
PWRN2, IPW, PAR-1, PAR-4, PAR-5, C15orf2, it remains unclear which ones are 
responsible for the phenotypic features of disease (Butler 2011). One of these gene 
loci, the SNURF–SNRPN locus encodes the small nuclear RNA, C/D box snoRNA-
HBII-52. A secondary splicing defect results from the loss of expression of HBII-52 
(Kishore et al. 2006). HBII-52 binds a silencer element in exon Vb of the human 
serotonin receptor 2C mRNA leading to exon exclusion. The lack of HBII-52 in 
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affected subjects leads to alternative splicing and an abnormal serotonin receptor. 
Bioinformatic and experimental studies have identified five further pre-mRNAs 
(DPM2, TAF1, RALGPS1, PBRM1 and CRHR1) that appear to be alternatively 
spliced by the mouse homolog of the human snoRNA HBII-52, MBII-52 (Kishore et 
al. 2006). 
 
1.2.17.3   Tertiary splicing defects. 
Tertiary splicing defects cause disease as a result of abnormalities in splicing via 
mechanisms other than primary or secondary splicing defects. 
Myotonic dystrophy, a microsatellite-expansion disorder, characterised by myotonia 
and insulin resistance provides an example of a tertiary splicing defect.  This 
occurs, in part, as the result of sequestration of the splicing factor muscleblind like 
protein 1 (MBNL1) in nuclear foci made up of a CTG trinucleotide expansion in the 
3′ untranslated region (3′ UTR) of the dystrophia myotonica-protein kinase (DMPK). 
These expanded RNA products localise as nuclear foci. The lower levels of the 
MBNL1 splicing factor result in a misregulation of alternative splicing for a subset of 
genes leading to the clinic phenotype of disease (Kuyumcu-Martinez et al. 2007). 
 
1.3 Modification of Splicing.  
 
1.3.1 Chemical and hormonal modification of splicing.  
Splicing may be modulated both chemically and hormonally. Many chemical 
compounds have been identified which may modulate splicing choices and may 
provide potential therapeutic options (Bracco et al. 2003; Soret et al. 2006). These 
compounds are thought to work via several different mechanisms including 
alterations in; the steady state of splicing transcripts; the phosphorylation states of 
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SR proteins; the intracellular distribution of splicing factors and protein–protein 
interactions (Xiao et al. 1997; Graveley 2000). Several large scale screens to 
identify inhibitors for various splicing factors have been undertaken (Blanchette et 
al. 2005; Soret et al. 2006).  For example, several indolozole derivative compounds 
have been identified which inhibit the kinase activity of topoisomerase I (topo I), a 
compound which is known to phosphorylate SR proteins (Soret et al. 2006).  
Many examples of hormonally mediated splicing events have now been 
documented (Akker et al. 2001). These include the regulation of the IR exon 11 
splicing by dexamethasone, insulin and glucose and the regulation of IGF-1 splicing 
by growth hormone (Chew et al. 1995). 
 
1.3.2 Antisense strategies. 
The unifying element of antisense strategies is the specific binding of an 
oligonucleotide sequence by Watson and Crick base-pairing to a given pre-mRNA 
sequence. The chemistry of the oligonucleotides backbone and additional 
modifications may vary and can influence efficacy and function. Antisense 
strategies broadly work in one of two ways. Base-pairing results in either the RNA 
being degraded or modified. RNA degradation may be caused by one of several 
mechanisms including degradation via RNaseH, RNaseP or RNA interference via 
siRNA and miRNA. Antisense strategies to modify RNA may occur by a number of 
different mechanisms: 
1. Blockade of cis-acting elements e.g. splice sites. 
2. Recruitment of trans-splicing factors e.g. TOES and ESSENCE. 
3. Replacement of spliced mRNA via a trans-splicing reaction e.g. SMaRT. 
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1.3.2.1 Antisense strategies – RNA degradation 
The first ASO approved by the FDA was Fomivirsen (Vitrvene) in 1998, a 
phosphorothioate oligonucleotide against Cytomegalovirus (CMV). This was 
achieved by targeting the major immediate early region 2 (IE2) mRNA of the human 
CMV for degradation via RNaseH. IE2 protein is essential for virus survival. 
RNaseH is an endonuclease which degrades RNA within RNA-DNA hybrids by 
hydrolysis of phosphodiester bonds.  Administration, via intraocular injection was 
indicated for the treatment of CMV retinitis in subjects with acquired 
immunodeficiency syndrome (AIDS).  
Gapmers were second generation ASOs which consist of a central chain of 
nucleosides, typically a phosphothorothiate backbone flanked by nucleosides with 
modifications e.g. 2'-O-methoxyethyl (2'-MOE) and 2'-O-methyl (2'-OMe) which 
rendered them resistant to degradation by exonucleases but still a target for 
degradation by RNaseH.  This antisense technology is being applied for therapeutic 
benefit. A large number of oligonucleotides are now in phase I and II trials and 
several compounds have reached phase III studies. Isis pharmaceuticals have 
developed Mipomersen targeting APOB 100 and OGX-011 targeting Clusterin.  
Mipomersen is a gapamer with a phosphorothioate oligonucleotide and 2’-O-
methoxyethyl modified ribose sugars at either end. Mipomersen targets the full 
length APOB 100, the lipoprotein component of the atherogenic LDL responsible 
for familial hypercholesterolaemia with a predisposition to cardiovascular disease.  
OGX-011 is another gapmer targeting clusterin, a secreted protein involved in 
resistance to apoptosis and anti-cancer agents. It has been used as adjunctive 
therapy in association with docetaxel for prostate, non-small cell lung and breast 
carcinoma and improved median survival has been noted in phase II trials with the 
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addition of the drug (Laskin et al.; Saad et al.; Chia et al. 2009).  
 
Other degradative pathways such as that via RNaseP have been employed to 
target mRNA encoding a chloramphenicol-resistance protein in E. Coli using 
peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) 
(Wesolowski et al. 2011). RNA interference, described in section 1.2.8.5, has been 
extensively exploited experimentally using siRNA to knockdown proteins but may 
also provide potential therapeutic options in the future.  
 
1.3.2.2 Antisense strategies: Blockade of cis-acting elements. 
ASOs may be designed to block key cis-acting elements, in a gene specific 
manner, which are critical to the splicing process. Importantly the ASO chemistry 
must be modified in order to prevent RNaseH mediated degradation. The use of 
such ASOs may result in either exon inclusion or exclusion. ASOs targets include 
constitutive or cryptic splice sites and enhancer (ESE, ISE) or silencer (ISS, ESS) 
sites.  The mechanisms by which the targeting ASO cause the desired effect vary. 
Commonly, targeting ASOs causes exon skipping or inclusion which alters the 
resulting protein but other mechanisms also exist.  
A recent phase II study using the antisense oligonucleotide PRO051, 
administered subcutaneously in subjects with muscular dystrophy, was shown to 
result in new dystrophin expression (which is lacking in affected subjects) of up to 
approximately 16% of normal expression levels in the tibilialis anterior muscle 
(Goemans et al. 2011). PRO051 is a 2′-O-methyl–substituted ribose molecule with 
phosphorothioate internucleotide linkages designed to bind to exon 51 and cause 
exon skipping. This is mediated by the conversion of an out-of-frame transcript to 
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an in-frame shortened transcript which is nevertheless functional. This was 
demonstrated to be clinically relevant as exertional capabilities increased with a 
short period of therapy. 
 
Spinal muscular atrophy (SMA) is caused by a defective survival of motor neuron 
(SMN1) gene resulting in spinal neurone degeneration and consequent muscle 
wasting. The paralogous gene, SMN2, is unable to replace the defective SMN1 as 
a C to T change at position +6 in exon 7, results in the loss of a SF2/ASF enhancer 
site and skipping of exon 7. An ASO targeting an ISS flanking exon 7 of the SMN2 
gene resulted in exon inclusion thus partially restoring some SMN protein 
expression (Hua et al. 2007). This ASO (ASO-10-27) has been delivered 
systemically and intracerebroventricularly in mouse models of spinal muscular 
atrophy resulting in prolonged survival (Hua et al. 2011). 
Other targets with translational potential include skipping of a pseudoexon in the β-
globin gene using a PPMO targeting an intron 2 mutation (IVS2-654) responsible 
for β-thalassemia which results in low haemoglobin levels. This was combined with 
siRNA mediated degradation targeting the alpha globin subunit, levels of which 
tend to be elevated in β-thalassemia, to increase haemoglobin levels in a mouse 
model (Xie et al. 2011).  
Another mechanism appears to mediate ASOs targeting the CUG expansion 
repeats in myotonic dystrophy.  The ASOs bound to the CUG repeats appear to 
displace the binding of muscleblind like protein 1 (MBNL1), a splicing factor, the 
lack of which contributes to the mis-splicing of several genes which are responsible 
for the phenotype seen in subjects with myotonic dystrophy e.g. muscle-specific 
chloride channel protein 1. Restoration of splicing of the muscle-specific chloride 
channel protein 1 reduced myotonia in mice injected with a 25-mer 
 
Chapter 1                                                                                            Introduction 
 
73 
phosphorodiamidate morpholino oligomers (PMO) targeting the CUG repeats 
(Wheeler et al. 2009). 
 
1.3.2.3 Antisense strategies: Recruitment of trans-splicing factors.   
Tailed oligonucleotide enhancement of splicing (TOES) compounds consist of an 
ASO annealing base targeted to a designated site with an attached RNA sequence 
that mimics an ESE  (Skordis et al. 2003; Ghigna et al. 2010). The purpose of the 
tail is to provide a trans-acting factor capable of recruiting either an enhancing or 
inhibitory splicing factor. Additional enhancements e.g. a U7 stem loop have been 
added in some cases to enhance the effectiveness of the compounds (Baughan et 
al. 2009; Meyer et al. 2009).  These compounds have been extensively  tested in 
exon 7 of the SMN2 pre-mRNA, involved in SMA both in vitro, in vivo in cultured 
fibroblasts from subjects with SMA, parenterally (peripherally and centrally) and 
transgenically in mouse models (Skordis et al. 2003; Meyer et al. 2009; Baughan 
et al. 2009). Increasing amounts of the ASO hybrid compounds increased the 
proportion of the exon 7 included in the SMN2 mRNA transcripts. 
Exon-specific splicing enhancement by small chimeric effectors (ESSENCE) is a 
technique that has successfully been used in vitro to restore exon 18 inclusion in 
BRCA1, exon 7 inclusion in SMN2 (Cartegni et al. 2003) and in vivo to enhance 
splicing of the pro-apoptotic bcl-xS isoform in preference to the anti-apoptotic bcl-xL 
isoforms (Wilusz et al. 2005). This technique employs chimeric molecules 
incorporating an antisense PNA oligonucleotide targeting an exon, linked to a 
peptide tail containing ten RS (arginine/serine) repeats. This RS domain tail 
simulates the function of an SR splicing factor thus facilitating the inclusion of the 
targeted exon.  
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1.3.2.4 Antisense strategies: Replacement of mRNA via trans-splicing 
reaction. 
Spliceosome-mediated RNA trans-splicing (SMaRT) creates a chimeric mRNA 
through a trans-splicing reaction mediated by the spliceosome between the 5′ 
splice site of an endogenous target pre-mRNA and the 3′ splice site of an 
exogenously delivered trans-splicing RNA molecule (Puttaraju et al. 1999). These 
compounds consist of a binding domain to an intronic region of the targeted gene 
and a trans-splicing domain containing coding sequence corresponding to the new 
3′ sequence (Puttaraju et al. 1999). This technology has been used in several 
scenarios, notably the functional repair of the CFTR∆F508 mutation of the cystic 
fibrosis transmembrane conductance regulator in human airway epithelial cells (Liu 
et al. 2002) and the phenotypic correction of haemophilia A in mice (Mansfield et al. 
2004).  
Fronto-temporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) 
is caused by mutations in the gene encoding the microtubule-associated protein, 
tau. A 34% efficiency in converting exon 10- tau RNA to exon 10+ RNA using this 
technology has been demonstrated in vivo (Rodriguez-Martin et al. 2005).  
Mechanisms to enhance efficacy are becoming increasingly sophisticated. Shababi 
et al. report the use of an enhanced trans-splicing systems to rescue the disease 
phenotype in a mouse model of spinal muscular atrophy. A single plasmid vector 
system was constructed which coded a trans-splicing RNA (tsRNA), an ASO 
designed to block a downstream endogenous splice site and the cDNA for the 
neuroprotectant, IGF-1 (Shababi et al. 2011). Intracerebroventricular injection of 
this vector into an SMN mouse model resulted in increase levels of SMN in the 
central nervous system associated with significant improvements in weight gain 
and survival compared to untreated mice. 
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1.3.3 Antisense oligonucleotides chemistry. 
Over time several modifications to the basic chemistry of the ASOs have been 
made to improve their delivery, stability and affinity. The transfection efficiency for 
an ASO with a ribose-phosphate backbone may be limited by its negative charge. 
The first generation ASOs were phosphorothioate (PS) modified in which a sulphur 
molecule replaces one of the non-bridging oxygen atoms. Phosphorothioate 
modified ASOs have an increased resistance to nuclease degradation, increased 
bioavailability and stimulate RNaseH mediated degradation when duplexed with a 
target RNA (Eckstein 2000).  
Second generation modification involved the development of 2′-alkyl modifications 
of the ribose ring including 2′-O-methyl (2′-OMe) and 2′-O- Methoxyethyl (2′-MOE) 
modifications. These modifications further increase binding affinity to the target 
RNA and increased nuclease resistance. Importantly, these second generation 
modifications did not support RNaseH mediated degradation and were therefore 
useful when the remit was other than transcript degradation e.g. increasing splicing 
of an exon (Altmann et al. 1996).  
Third generation modifications introduce further changes to the chemistry of the 
backbone such as peptide nucleic acids (PNA), locked nucleic acid (LNA) and 
phosphorodiamidate morpholino oligomer (PMO). PNA oligonucleotides replace the 
phosphodiester backbone with a	  pseudopeptide polymer (N-(2-aminoethyl)glycine). 
Bases were attached to the backbone via methylene carbonyl links (Egholm et al. 
1993). The neutral charge of the PNA backbone increased cell permeability and 
stability. PNA molecules are resistant to degradation by RNaseH mediated 
degradation (Egholm et al. 1993). Locked nucleic acid (LNA) contains a 2′-O,4’-C-
methylene bridge in the ribose ring which confers high stability and increased 
affinity to RNA. LNA binding does not stimulate RNAseH mediated degradation 
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(Vester et al. 2004; Kurreck et al. 2002).	   PMOs are generated by replacing the 
ribose ring with a morpholino ring and a phosphorodiamidate in place of the 
phosphodiester bond. Resistance to RNaseH and nuclease degradation is 
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1.4 Insulin receptor. 
1.4.1 Insulin receptor: introduction. 
 
The insulin receptor (IR) cDNA (OMIM – 147670) is encoded by a genomic region 
located on chromosome 19p which is comprised of 22 exons (figure 1.4.1.A). The 
IR is synthesised as a ~180 kDa pro-receptor which is cleaved into α–β monomers, 
linked by disulphide bonds. The IR monomer homodimerises with itself to form the 
IR, or with IGF-I receptor to form a heterodimer (Soos et al. 1990). The α subunit is 
the extra-cellular domain that binds insulin. The ß subunit contains a short 
extracellular domain, a transmembrane domain and cytoplasmic domain. The 
cytoplasmic domain has an intrinsic tyrosine kinase activity (Ebina et al. 1985; 
Ullrich et al. 1985). 
 
1.4.2 Insulin receptor and signalling cascade. 
The binding of insulin to the α-subunit of IR leads to a conformational change 
resulting in the autophosphorylation of the tyrosine residues of the β-subunit 
(Frattali et al. 1992) (figure 1.4.2.A). The intrinsic tyrosine kinase activity of the β-
subunit phosphorylates a number of docking proteins (IR substrate (IRS)) via a 
phospho-tyrosine binding module (White 1997; Giovannone et al. 2000). The IRS 
proteins dock with Src Homology 2 (SH2) domain proteins, one being the p85 
regulatory subunit of phosphatidylinositol 3-kinase (PI3K). Movement of the 
catalytic p110α-subunit to the plasma membrane and phosphorylation of PI(4,5)-
biphosphate (PIP2) to PI(3,4,5)-triphosphate (PIP3) follows (Fruman et al. 1998). 
PIP3 activates the 3′ phosphoinositide-dependant kinase-1 (PDK-1) and protein 
kinase B (PKB or AKT). Substrates for PDK-1 include PKB and atypical forms of 
Protein Kinase C (PKC) (Kotani et al. 1998). These substrates mediate several 
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cellular metabolic changes (figure 1.4.2.A) including the effects of glucose transport 





Figure 1.4.1.A  The insulin receptor. The IR gene is located on chromosome 19 and 
consists of 22 exons. The IR is composed of a pair of α (extracellular) and β 
(transmembrane) subunits linked together by disulphide bonds. The 2 isoforms of the IR 
differ by the absence or presence of 12 amino acids at the carboxy terminus of the α 
subunit corresponding to the alternative splicing of exon 11. The insulin receptor A 
isoform (IR-A) excludes exon 11 and the insulin receptor B isoform (IR-B) includes exon 
11 (shown in figure). 
Figure 1.4.1.A 
 




Figure 1.4.2.A  Insulin signalling. Schematic diagram showing a portion of the 
cellular plasma membrane and downstream signalling via the IR. Insulin binds the IR 
and leads to a signalling cascade culminating in the translocation of GLUT4 from the 
intracellular pool to the plasma membrane to allow cellular glucose influx. Multiple 
other pathways and cellular effects are involved in insulin signalling but are not shown 
here for clarity. IRS - insulin receptor substrate; PI3K - phosphatidylinositol-3-kinase;  
PIP3 - phosphatidyl inositol-3,4,5-trisphophate; PIP2 - phosphatidylinositol-4,5-
bisphosphate; PDK1 - PIP3-dependent protein kinase; PKB - protein kinase B (AKT); 
GSK3 - glycogen synthase kinase-3; mTOR - mammalian target of rapamycin; PKC - 
protein kinase C.  
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1.4.3 Role of insulin. 
Insulin has wide-spread effects on cellular metabolism, growth, differentiation and 
survival. Insulin causes cellular glucose uptake, glycogen synthesis, lipogenesis 
and anabolic effects via protein synthesis. Indeed the importance of insulin and its 
effects via its receptor can be seen in mouse knockout studies. Disruption of the IR 
gene in mice pancreatic β cells results in impaired glucose secretion and glucose 
intolerance (Kulkarni et al. 1999). A more generalised knockout of the IR results in 
a 10% reduction in birth weight in mice which die after a few days due to keto-
acidosis (Accili et al. 1996), suggesting a pivotal role of the IR in growth and 
glucose metabolism. Further tissue-specific knock-outs suggest roles for the IR in 
neovascularisation (Kondo et al. 2003), adipogenesis (Entingh et al. 2003), glucose 
disposal in muscle and adipose tissues (Lauro et al. 1998), and hepatic 
gluconeogensis (Fisher et al. 2003). 
 
1.4.4 Alternative splicing of IR. 
The elucidation of the structure of the IR revealed the presence of two isoforms 
(Ebina et al. 1985; Ullrich et al. 1985). These isoforms differ by 12 amino acids 
(residues 717-728) located at the C-terminus of the α-subunit. Alternative splicing 
of the in-frame 36 nucleotide exon 11 is responsible for this. The IR-A isoform 
excludes exon 11 and the IR-B isoform includes exon (Seino et al. 1989). 
At 36 nucleotides in length, the IR exon 11 is short in comparison to the average 
exon, the result being that exon 11 is alternatively spliced and the proportion of 
each isoforms varies on the basis of the species and tissue involved.  
The preponderance of the isoforms varies between tissues, during development, 
and pathophysiologically. IR-A is found exclusively in the spleen, peripheral blood 
cells and brain whilst IR-B is markedly predominant in the liver. There was noted to 
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be marginally more IR-B compared to IR-A in muscle, adipocyte and fibroblasts 
(Moller et al. 1989; Seino et al. 1989; Mosthaf et al. 1990). In fetal tissue, however, 
IR-A is the predominant isoform in kidney, muscle, liver and fibroblasts (Frasca et 
al. 1999). IR-A also appears to play a role in tumourigenesis, being upregulated in 
several form of cancer (Frasca et al. 1999; Sciacca et al. 1999). 
 
1.4.5 Splicing influences on the insulin receptor exon 11. 
Alternative splicing decisions appear to also be hormonally mediated. It has been 
demonstrated that dexamethasone can induce a switch in splicing from IR-A to IR-
B in cultured HepG2 cells (Kosaki et al. 1993; Norgren et al. 1994) as can 
triiodothyronine to a lesser degree (Kosaki et al. 1993). Insulin appeared to 
significantly increase the proportion of IR-B in a rat hepatoma cell line (Sell et al. 
1994) as did hyperglycaemia in human islets and RIN beta-cells (Hribal et al. 2003) 
though these findings were not confirmed in all studies (Norgren et al. 1994).  
Intronic and exonic sites involved in alternative splicing of exon 11 in the IR have 
been more specifically studied using minigene constructs inserted via plasmids in 
HepG2 cells (Kosaki et al. 1998). A minigene is a simplified laboratory version of a 
natural gene that lacks one or more of the gene’s exons and introns, or portions of 
them (Cartegni et al. 2002). Minigenes may be cloned into expression vectors and 
expressed in cells for in vivo analysis of alternative splicing mechanisms. To be a 
useful representation of an endogenous gene the minigene musts at a minimum 
have all the necessary RNA element of a gene to allow equivalent splicing of the 
minigene. 
 A 48-nucleotide purine-rich sequence at the 5′ end of intron 10 enhances exon 11 
inclusion whilst a 43-nucleotide sequence at the 3′ end of intron 10 upstream of the 
branch point sequence causes exon skipping (Kosaki et al. 1998). Introducing a 
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four-point mutation in the middle of the exon 11 caused this to be spliced 
constitutively whilst a 8 nucleotide deletion towards the 3′  end or insertion of three 
thymidine residues resulted in significant exon 11 exclusion. Previous work from 
our laboratory has shown that mutating sub-optimal splice sites flanking exon 11 to 
consensus sequences causes it to be constitutively spliced in in-vivo and in-vitro 
models (Webster et al. 2004). Further evidence comes from studies involving CUG-
BP1, a regulator of pre-mRNA splicing. Deletion of a 110 nucleotide intronic 
sequence abolishes the ability of this factor to up-regulate the splicing of IR-A in 
fibroblasts from patients with myotonic dystrophy (Savkur et al. 2001). 
During the initial stages of this work the splicing factors involved in the splicing of 
the IR exon 11 had not been identified. In 2009 Sen et al. published data which 
identified the key players in this process (Sen et al. 2009). These findings, which 
are clearly relevant to the current work are discussed in detail in Chapter 4 in 
relation to the findings of this study. 
 
1.4.6  What are the differences between IR-A and IR-B? 
Differing properties have been noted between the isoforms though there is 
conflicting data in this area. The IR-A isoform has a two-fold higher affinity for 
insulin than IR-B in transfected mammalian cells (Mosthaf et al. 1990; Yamaguchi 
et al. 1991; Yamaguchi et al. 1993) however there is an equivalent response to 
insulin binding in terms of metabolic (glucose uptake) and mitogenic consequences 
(thymidine incorporation) (Yamaguchi et al. 1991). IR-B has a higher degree of 
autophosphorylation and greater kinase activity (Kellerer et al. 1992; Kosaki et al. 
1995) but this was not found in all studies (Yamaguchi et al. 1991). Some studies 
using transfected cells suggest IR-A shows higher rates of internalization, recycling, 
and insulin-induced down-regulation of the receptor (Vogt et al. 1991; Yamaguchi 
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et al. 1991; Yamaguchi et al. 1993) though again, this is not confirmed in all studies 
(McClain 1991). 
The insulin-like growth factors also bind the IR, and there is evidence for 
differences in the way they interact with the IR isoforms. Both IGF-I and IGF-II 
binds with higher affinity to IR-A versus IR-B (Yamaguchi et al. 1993; Frasca et al. 
1999), IGF II binds with significantly higher affinity than IGF-1 to IR-A (Denley et al. 
2004). However IGF/IR hybrid receptor studies carried out recently suggest that 
there is little difference between the isoforms in terms of ligand binding and 
activation of the receptor (Benyoucef et al. 2007). 
 
1.4.7 Clinical significance of IR alternative splicing.  
As IR-A and IR-B appear to differ in their affinity and their response to insulin, 
several groups have addressed the possibility that the alternative splicing of IR may 
play a key role in the pathogenesis of insulin resistance in type II diabetes. The 
data is conflicting however. Several studies quantifying either the presence of 
alternative mRNA or protein isoforms of the IR in samples of adipose tissue and 
skeletal muscle suggest an increase of IR-B isoforms in human subjects with 
insulin resistance or type II diabetes, compared with non-diabetic subjects (Mosthaf 
et al. 1991; Sesti et al. 1991; Kellerer et al. 1993; Mosthaf et al. 1993; Norgren et 
al. 1993; Sesti et al. 1995). However, other studies showed no difference in the 
ratio of the isoforms between subjects (Benecke et al. 1992; Anderson et al. 1993; 
Hansen et al. 1993). It has been shown in spontaneously obese diabetic Rhesus 
monkeys that hyperinsulinaemia (early diabetes) rather than hypoinsulinaemia (late 
diabetes) is associated with increased levels of IR-A in skeletal muscle (Huang et 
al. 1994). In the human liver both at an mRNA and protein level several studies 
have shown a marked predominance of IR-B of between 75-90% in non-diabetic 
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individuals (Moller et al. 1989; Seino et al. 1989; Benecke et al. 1992; Norgren et 
al. 1994). However hepatoma cell lines in the rat (Sell et al. 1994) and humans 
(Kosaki et al. 1993) shows the reverse. In the liver of diabetic rhesus monkeys 
there appears to be an increase in the proportion of IR-A (Huang et al. 1996).  
Studies using ASOs which acutely downregulated IR by 95% in mice did not alter 
insulin action on glucose production suggesting the role the IR plays might be 
relatively minor (Buettner et al. 2005). Several reasons have been postulated to 
explain the discrepancy between studies including different species, cell lines, 
detection methods, PCR protocols, contamination of samples and the variable 
metabolic status of the diabetic subjects from hyperinsulinaemia to 
hypoinsulinaemia (Huang et al. 1996; Sesti et al. 2001). 
Both myotonic dystrophy type 1 and type 2 are associated with insulin resistance 
(Savkur et al. 2001; Savkur et al. 2004). Insulin resistance appears to be very 
strongly correlated to a predominance of IR-A in this condition. Studies of skeletal 
muscle cells cultured from these subjects shows a predominance of IR-A (Savkur 
et al. 2001). Mis-splicing of other genes such as cardiac troponin T (Philips et al. 
1998) and the muscle chloride channel (Charlet et al. 2002) underlie the other 
clinical features of myotonic dystrophy, i.e. the muscular dystrophy and myotonia 
respectively. Overactivity of the splicing proteins CUG-BP and hnRNP H and loss 
of the activity of proteins in the muscleblind-like family have been postulated to 
cause these specific splicing abnormalities (Philips et al. 1998; Savkur et al. 2001; 
Ho et al. 2004; Paul et al. 2006). 
The visceral and temporal distribution of the IR isoforms and the effect these 
changes play in insulin resistance may be significantly more complex than 
assigning a simple role for each isoform (Guiraud-Dogan et al. 2007). A study 
examining the distribution of the IR isoforms in transgenic mice containing the 
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human CUG-containing DMPK transcripts in various insulin sensitive tissues found 
that the isoform proportion varied in different tissues, at different times and 
associated with variable responses to glucose. Indeed the complexity extended to 
differences within different muscle groups at different times. (Guiraud-Dogan et al. 
2007).  This underlines the difficultly in matching the molecular changes with the 
metabolic consequences.  
The IR may have a role in mitogenesis and tumour development. It has been 
shown that tumour cells show a different proportion of the IR isoforms compared 
with normal cells (Frasca et al. 1999; Sciacca et al. 1999). IR-A appears to be 
upregulated in several cancers including colonic (Frasca et al. 1999), breast 
(Sciacca et al. 1999), ovarian (Kalli et al. 2002) and thyroid cancer (Vella et al. 
2002). In hepatoblastoma cells IR-B has been shown to be down-regulated (von 
Horn et al. 2001). Hybrid receptors of IGF-1R and IR are found in increased levels 
in thyroid (Belfiore et al. 1999) and breast cancer (Pandini et al. 1999). IGF-II has 
predominant mitogenic effects and only binds to IR-A, not IR-B (Frasca et al. 1999). 
It leads to cell proliferation in breast cancer cells (Sciacca et al. 1999) and 
resistance to apoptosis in leiomyosarcoma cells (Sciacca et al. 2002). Studies 
show that both that IGF-II and IR-A levels increase as thyroid cancer progresses 
suggesting a possible autocrine stimulatory loop between the two (Vella et al. 
2002). 
 
1.4.8  Insulin receptor: summary. 
In summary it appears the relative proportions of the IR isoforms vary depending on 
tissue, species and underlying metabolic status. There is a significant body of 
conflicting data with regard to the relationship between insulin resistance and the 
proportion of IR isoforms though some explanations for this have been offered. It is 
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unclear whether these differences are a cause of, a result of, or merely an 
epiphenomenon of insulin resistance. The role of the IR-A isoform in insulin 
resistance in myotonic dystrophy and cellular proliferation in tumourigenesis 
appears more robust however. Clarifying differences between the IR isoforms has 
been hindered by experiments with methodological weakness. Many experiments 
have used isoform cDNAs over expressed in cell lines which do not naturally 
contain IR. In studies which use cell lines which naturally contain IR, the switch in 
alternative splicing is induced with dexamethasone and triiodothyronine, a method 
which is not specific and which is likely to alter many other metabolic and 
proliferative pathways.  
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1.5 Apolipoprotein B. 
1.5.1 Apolipoprotein B: introduction. 
Apolipoprotein B (APOB - OMIM 107730) is the main apolipoprotein in both 
chylomicrons and low density lipoproteins (LDL) but is also a component of VLDL, 
IDL and Lp(a) particles (Chan 1992). The human APOB gene is located on 
chromosome 2 and consists of 29 constitutively spliced exons. As with the IR there 
are 2 principal isoforms derived from the APOB gene, though their means of 
generation are distinct. The APOB100 isoform represents the full transcript while 
APOB48 is a C-terminal truncated isoform (literally 48% of APOB100). APOB100 is 
synthesized in the liver, is required for the assembly of lipoproteins and is the 
ligand for the LDL receptor.  Elevated levels of APOB100 are associated with 
raised levels of LDL and Lp(a) and a concomitant rise in cardiovascular risk via 
accelerated artherogenesis (Jialal 1998). APOB48 is present only in the intestine 
and is involved in chylomicron assembly and transport of intestinal fat.  It lacks the 
C-terminal domain which is required for lipoprotein binding to the LDL receptor. As 
a result chylomicron clearance occurs via Apolipoprotein E (APOE) and a 
chylomicron remnant receptor instead of the LDL receptor (Chester et al. 2000). 
The truncated APOB48 isoform is generated within the intestine following RNA 
editing via a complex known as the editosome. Editing occurs in exon 26 at position 
6666 of the mRNA converting a C to a U, generating a PTC to produce the C-
terminal truncated isoform (Chester et al. 2000).  This isoform is then able to join 
the chylomicron and allows intestinal fat to be absorbed.  Clinical interest in APOB 
exon 26 lies in the fact that preferential conversion to APOB48 in preference to 








1.5.2 Apolipoprotein B: a therapeutic target. 
Reductions in the level of APOB should lead to a reduction in LDL cholesterol and 
hence cardiovascular risk. Given this, APOB continues to be an important target for 
therapeutic manipulation (Akdim et al. 2007). Several approaches have been 
employed. Stimulating RNA editing by overexpression of the catalytic subunit of the 
editosome, APOBEC-1, increases the conversion of atherogenic APOB100 to 
APOB48. This has been associated with a reduction of LDL levels in transgenic 
mouse models (Yamanaka et al. 1995). Further approaches include ASO mediated 
degradation of APOB mRNA (Soutschek et al. 2004; Crooke et al. 2005; 
Zimmermann et al. 2006). There remains concern that knockdown of APOB100 
would result in lower levels of APOB48 and lead to intestinal fat malabsorption. 
Evidence for the effect of reducing APOB synthesis comes from several sources. 
Patients with familial hypobetalipoproteinemia (FHBL) provide some insight into the 
effect of reducing APOB. Heterzygote subjects have a 50% reduction in the levels 
of APOB and appear to have a reduce risk of developing atherosclerosis (Tarugi et 
Figure 1.5.1.A 
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al. 2007) while homozygotes, who have very low levels of APOB suffer with fat and 
fat soluble vitamin malabsorption, progressive neurologic degenerative disease, 
retinitis pigmentosa, acanthocytosis (spiculated red blood cells) and hepatic 
steatosis. Thus it is clear that that the aim of therapy would be a reduction of APOB 
rather than complete elimination. A more precise strategy would be to reduce the 
APOB 100 isoform without reducing the APOB 48 isoform thus reducing LDL 
cholesterol without affecting intestinal absorption.  
Studies of the APOB synthesis inhibitor Mipomersen (Isis pharmaceuticals) a 20-
mer antisense chimeric phosphorothiate oligonucleotide targeting APOB reveal 
than 10 to 15% of subjects developed a transaminitis in phase II and III studies 
(Akdim et al. 2010; Raal et al. 2010).  
 
1.5.3 APOB exon 26 - long constitutive exon  
Long exons such as APOB exon 26 contain many pseudo splice sites. Given this, 
correctly orientated pseudo 3′ and 5′ splice-sites should trigger exon definition and 
erroneous splicing within the exon 26 sequence. The genuine splice sites may 
however be identified via a process of intron definition. This relies on the 
recognition of 5′ and 3′ splice site pairs over short introns of <100 nucleotides in 
Drosophila (Talerico et al. 1994). In human nuclear extracts and in HeLa cells, 
intron definition appears to operate below a threshold of 200-250 nucleotides (Fox-
Walsh et al. 2005). Intron definition, therefore, cannot easily explain the splicing of 
APOB exon 26 as the upstream and downstream introns are too long at 506 and 
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1.5.4 Apolipoprotein B: previous work. 
Previous work done in our laboratory suggests that APOB exon 26 contains many 
pseudo splice sites within it, some of which are predicted to be stronger that the 
constitutive splice sites. It was hypothesised that exon 26 contains multiple ESS 
which block these alternative splice sites from being recognised. Using an in vitro 
heterologous splicing reporter, DNA ligase III, substituting sequences (400 
nucleotides long) of exon 26 into an ESS position in the reporter allowed the 
definition of areas which were rich in silencing elements. These areas were 
delineated further by using 25 nucleotide sequences within a given 400 nucleotide 
sequence. The activity of these sequences was further confirmed in the β-globin 
splicing reporter Hβ∆6. There appeared to be multiple silencer regions 
heterogenously spread through-out the exon with particular areas e.g. the central 
4800 nucleotides being rich with these silencer elements.  
 
1.6  Why study the IR exon 11 and APOB exon 26? 
The IR exon 11 and APOB exon 26 provide examples of exons at the extremes of 
the size spectrum. The IR exon 11 and the APOB exon 26 are some of the shortest 
and longest spliced exons in the genome. They contrast in relation to the fact that 
the IR exon 11 is alternatively spliced while APOB exon 26 is constitutively spliced 
despite being significantly longer than the optimal length defined for efficient 
splicing.  While the basic principles of splicing will hold their relative importance will 
vary considerably in the context of each model.  Understanding how splicing is 
regulated as a result of these differences is of interest. In the case of the IR exon 
11 - how does its small size impact on the ability to manipulate the splicing 
process? In the case of APOB exon 26 - how does the configuration of ESE and 
ESS within the pre-mRNA impact on the reproducibility of splicing in long exons? 
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1.7   Why use antisense oligonucleotides?  
Antisense strategies provide an attract approach to modulating the splicing process 
for a number of reasons. Watson and Crick base-pairing allows the precise 
targeting of specific pre-mRNAs. ASOs provide a variety of strategies to modulate 
splicing which can be customised to each splicing scenario. They may be used to 
increase our understanding of the splicing process both as a normal molecular 
mechanism but also in disease as a pathological process. Antisense technology 
has already received approval for therapeutic use in some cases with a significant 
amount of drug development in the pipeline. As antisense chemistries and drug 






















The ability to modify the splicing process provides significant opportunities to both 
study endocrine systems and manipulate them for therapeutic purposes. Previous 
studies utilise hormonal manipulation and minigene approaches which are 
cumbersome, non-specific and not easily translatable for therapeutic application. 
By contrast, the advantage of work with DNA and RNA is that Watson-Crick base-
pairing allows the specific targeting of putatively important sequence elements by 
oligonucleotides with technology which is readily translatable.  
 
The aim of the current study therefore is to use ASO technology to modify the 
splicing choices in two contrasting metabolic models of endocrine splicing, namely 
the short alternatively spliced IR exon 11 and the long constitutively spliced APOB 
exon 26.  
 
More specifically, with regard to the alternatively spliced IR exon 11, the aim was to 
use ASOs with varying chemistries and modifications to cause exon 11 skipping 
and inclusion. This included the use of PNA-peptide hybrid ASOs to drive exon 11 
inclusion. 
 
Previous analysis has suggested the long constitutively spliced APOB exon 26 
contains pseudoexons which remain unspliced in preference to the constitutive 
exon, as a result of the presence of multiple inhibitory exonic splicing silencer 
(ESS) elements along its length.  The aim of the current study was to build on this 
work by confirming that ASOs, targeting some of these silencer elements can result 
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2.1 Antisense oligonucleotide design. 
 
ASOs were designed complementary to the DNA sequence of the IR and the 
APOB gene as taken from the Ensembl Genome Browser (http://www.ensembl.org/ 
index.html). Figure 2.1.A illustrates the base-pairing design for the 2′-O-methyl RNA 




2.1.1  ASOs targeting the IR exon 11. 
2.1.1.1   2′-O-methyl RNA ASOs. 
2′-0-methyl RNA ASOs were ordered from Dharmacon (Lafayette, CO, USA). Sites 
targeted for blocking intronic regions surrounding the IR exon 11 included the 3′ 
splice site, 5′ splice site and branch point sequence (see Chapter 3.1.1). These 
sites were identified and 18mer 2′-O-methyl RNA ASOs were designed. ASOs 
combining these sites were designed i.e. INSR 3B, INSR 5B, INSR 53. These were 
36mers. Exonic ASOs were designed as 18mers (INSR ex1, INSR ex2, INSR ex3) 
and a combination ASO (INSR ex1+2) spanning the whole exon was designed 
(36mer). Sequences are listed in Chapter 6.1 - appendix. Two further ASOs were 
Figure 2.1.A  ASO design: base-pairing with the IR exon 11. 
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designed and tested following initial experiments with the aforementioned ASOs. 
These included the intronic ASO INSR 6/7 and the exonic ASO INSR ex3. 
 
2.1.1.2  Scramble ASOs. 
Scramble ASO sequences of targeted ASOs to IR exon 11 were designed as 
controls (see Chapter 3.1.2). These scramble sequences had the same 
composition and number of oligonucleotides as the targeted ASOs. These ASOs 
were designed using a web-based tool (www.sirnawizard.com) to scramble 
sequences. 
 
2.1.1.3 Immunofluorescent ASOs. 
The effective ASO INSR ex1+2 and its scramble sequences INSR ex1+2scram had 
5′ fluorescein tails added (see Chapter 3.1.4). These were designed to ensure ASO 
and scramble sequences localised appropriately and similarly. 
 
 
2.1.1.4 TOES ASOs. 
These modified ASOs (see Chapter 3.1.5) consisted of a 2′-O-methyl RNA ASO 
backbone (INSR ex1) with the addition of a 3′ or 5′ tail which mimicked an ESE 
(Chapter 6.1 – appendix for sequence) as used in another study (Skordis et al. 
2003). This sequence was utilised because it has been shown to be efficacious but 
also because it attracted the splicing factor SF2/ASF which has been postulated to 
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2.1.1.5 PNA ASOs. 
The basic backbone used for PNA design was the repeating N-(2-aminoethyl)-
glycine unit.  Various modifications to the PNA backbone have been trialled to 
improve the functionality of the ASO with respect to DNA binding, sequence 
specificity and bioavailability. Modifications include those with acyclic structures 
such as substitution or addition to the C2 or C5 carbon or PNAs with cyclisation of 
the backbone either on the aminoethyl side or on the glycine side. (Corradini et al. 
2011). The PNA backbones here were designed as three 12mers across the exon 
(INSR PNA ex4, INSR PNA ex5, INSR PNA ex6) (see Chapter 3.2.). A further PNA 
and its PNA scramble equivalent were designed to match the 2′-O-methyl RNA 
ASO INSR ex2. These were designated INSR PNA ex2 (18mer) and INSR PNA 
ex2scram (18mer). Two further 15mer PNA ASOs targeting the 5′ and 3′ end of 
exon 11, named INSR PNA ex1 and INSR PNA ex2 respectively were also 
designed. These two ASOs did not bind the 3 bases at the exon/intron boundaries 
and were used as the basis of the PNA-peptide hybrid ASOs. 
 
 2.1.1.6 PNA-peptide hybrid ASOs. 
The PNA base was placed at both the 3′ and 5′ end of exon 11 in the equivalent 
INSR ex1 and INSR ex2 positions minus three nucleotides at the exon/intron 
junctions (see Chapter 3.2.3 and 3.2.4). It was assumed that an ASOs binding near 
or across the splice site may interfere with splice site recognition and inhibit exon 
splicing thus reducing the potential efficacy of compounds designed to enhance IR 
exon 11 inclusion. A glycine/glycine bridge then attached the RS (arginine/serine) 
repeat tail. The RS domain was repeated x10 in keeping with previous studies 
which showed an optimum response with this length of tail (Cartegni et al. 2003). 
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2.1.2 Apolipoprotein B exon 26 ASOs. 
2′-O-methyl RNA ASOs were designed on the basis of previous work from our 
laboratory to identify ESS within APOB exon 26 (unpublished data). We identified 
the strongest ESS sequences (APOB exon 26 - 65-89(1), 2319-2343 (4)) based on 
2 in-vitro reporter systems (DNA ligase III and the β-globin splicing reporter Hβ∆6) 
and designed complementary sequences (Chapter 6.1 - appendix). We chose 2 
adjacent ESSs close to the strongest ESS (APOB exon 26 - 97-121(2), 129-153(3)) 
in order to test the effects of blocking multiple adjacent silencer elements. Regions 
which had no apparent silencing activity were also targeted (APOB exon 26 - 93-
217(5) and 2191-2215(6)) as controls (see Chapter 3.3). 
 
Chapter 2                                                                           Materials and methods 
98 
 
2.2 Cell culture. 
2.2.1 Cell lines. 
 
The cell line used in this study was the HepG2 cell line (Human hepatoblastoma 
derived cell line). Cells used were between passage 2 and 23. HepG2 retain many 
liver specific functions including the production of apolipoproteins.  (Pullinger et al. 
1989). APOB, with a molecular mass of approximately 500kDa, is secreted from 
HEPG2 cells and the  22 KDa  mRNA coding for APOB can be isolated from these 
cells, suggesting the full length APOB is produced (Thrift et al. 1986; Huang et al. 
1985). 
 
2.2.2 Maintenance of cells. 
Materials: 
•  Minimum Essential Medium (MEM), (Invitrogen, Carlsbad, CA, USA). 
• Foetal Bovine Serum (FBS), (Sigma,  Dorset, UK) 
Method: 
The maintenance media consisted of MEM and 10% FBS. This was pre-warmed to 
37ºC before use. Media was added to the flask/dish containing cells. Media was 
replaced every 48 hours. The passage number was recorded on each flask/dish. 
 
 2.2.3 Passaging cells. 
Materials: 
• Autoclaved 1x PBS (pH 7.4) (Sigma,  Dorset, UK) 
• Trypsin/EDTA (Tryple, Gibco/Invitrogen, Paisley, UK) 








Following 48 hours incubation of HepG2 cells in MEM/10% FBS, the petri dish was 
removed from the incubator and placed under the microscope to estimate cell 
confluency. If greater than 80% confluence, the cells were prepared for division. 
The media in the petri dish was aspirated. Cells were then washed in 8ml of PBS. 
PBS was aspirated and 1.5ml of trypsin/EDTA was added per 100mm petri dish. 
The petri dish was then placed in the incubator at 37ºC for 10 minutes to activate 
the trypsin.  Following this, the dish, once removed from the incubator, was gently 
tapped to ensure the cells were displaced. Fresh MEM/10% FBS (8.5ml) of was 
added to the dish to neutralise the effects of trypsin. The cell suspension was 
placed in a 50ml Falcon tube. With a 200µl pipette tip inserted onto the tip of a 5ml 
pipette the cell suspension was drawn through the pipette 5-10 times in order to 
disperse the HepG2 cells.  Then the cell suspension was divided into 2-3 petri 
dishes with the addition of further MEM to a final volume of 15ml/dish. The petri 
dish was then labelled with the passage number and placed in the incubator at 
37ºC, 5% CO2 . 
 
2.2.4 Thawing of cells. 
The cryotube containing 1ml of frozen cell suspension in FBS/DMSO was removed 
from the liquid nitrogen storage unit and thawed in a 37ºC incubator for 
approximately three minutes. The cell suspension was then added to a cell culture 
flask with fresh media at 37ºC and incubated. 
 
2.2.5 Freezing down cells. 
Materials: 
• FBS (Sigma,  Dorset, UK) 
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• DMSO (Sigma,  Dorset, UK) 
Method: 
Cells were trypsinised as described above. The cell suspension was then spun at 
1000rpm for three minutes. The supernatant was aspirated and the cell pellet was 
resuspended in 1ml FBS+10% DMSO. The cell suspension was placed in a 
cryotube and placed in an isopropranol freezing chamber in a -80ºC freezer to allow 
gradual freezing (1ºC/min). Once frozen the cells were transferred to the liquid 
nitrogen store within 24 hours. The passage number was recorded on the cryotube. 
 
2.2.6 Counting cells. 
Materials: 
• Neuberg haemocytometer 
Method:  
Cells were counted in a Neuberg haemocytometer to determine cell concentration. 
The chamber was cleaned with 70% ethanol. A cover slip was then placed over the 
counting area. 25µl of trypsinised cells diluted in media (HepG2 cells from a 
100mm Petri dish dissolved in a 10ml suspension) was injected beneath the cover 
slip. The 1mm2 counting grid was focussed on a microscope and the cells within it 
were counted. Cell concentration (x104/ml) was determined on the average of two 
counts per a given field view. 
 
2.2.7 Reverse-transfection of ASOs into mammalian cell lines. 
Materials: 
• Lipofectamine 2000 (Gibco/Invitrogen, Paisley, UK) 
• MEM/10% FBS (Gibco/Invitrogen, Paisley, UK) 
• Opti-MEM I (Gibco/Invitrogen, Paisley, UK) 
 




HepG2 cells were divided once 80% confluent as per the protocol (Chapter 2.2.3). 
Media was added to trypsinised cells. The cell concentration was determined with a 
Neuberg haemocytometer and diluted with further media to a concentration of 50 × 
104 cells/ml. 1ml of cell suspension each was added to the required number of 
wells in a twelve well plate. One well was required for one transfection reaction. 
Lipofectamine 2000 and ASOs were gently mixed with relevant volumes of warmed 
Opti-MEM I and left to stand for five minutes. The lipofectamine 2000/Opti-MEM I 
(100µl) and ASO/Opti-MEM I (100µl) solutions were gently mixed to the relevant 
volume (200µl) and left to stand for twenty minutes. The lipofectamine 
2000/ASO/Opti-MEM I solutions (200µl) were added to each well of cell suspension 
and gently mixed and placed in the incubator at 37ºC for 48 hours. Total volume 
per well was 1.2 ml.  
 
2.3  RT-PCR. 
2.3.1 Primers. 
Primers for human IR exon 11 and APOB exon 26 are shown in Chapter 6.1 - 
appendix. Primers were ordered from Sigma (Sigma, Dorset, UK). Primer design 
was either based on primers reported in the literature specific to the sequence 
required or designed from sequences published in the DNA genomic database; 
ensembl (www.ensembl.org). Primers were designed using the program, 
Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer 3plus.cgi). 
 
2.3.2.  dNTP mix (10nM). 
Materials: 
• 100nM stock dATP, dTTP, dCTP, dGTP (Promega, Southampton, UK) 
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• RNase free water (Qiagen, Valencia, CA) 
 
Methods: 
A 10nM solution of dNTP (dATP, dTTP, dCTP, dGTP) was prepared from 100nM 
stock solutions of each deoxynucleotide according to the following mix: 
    Volume 
dATP (100nM)    20µl 
dTTP (100nM)    20µl 
dCTP (100nM)    20µl 
dGTP (100nM)    20µl 
dH20    120µl 
Total volume (10nM dNTP) 200µl 
 
2.3.2 RNA extraction. 
Materials: 
• Monoject Insulin syringe (Tyco Healthcare, Gosport, UK) 
• RNeasy Micro kit (Qiagen, Valencia, CA) 
• TurboDNase (Ambion, Huntingdon, UK) 
Method:  
RNA extraction was carried out in an RNA free environment using the RNeasy 
Micro kit according to the manufacturer’s instructions as follows. After 48 hours 
incubation, transfection media was removed from each well and 350µl of RLT/β-
mercaptoethanol (containing guanidine thiocyanate) solution was added where cell 
concentration was less than 5x106 cells. The contents of each well was syringed 
five times through a 25G Monoject Insulin syringe and transferred to an eppendorf 
tube. 350µl of 70% ethanol was homogenised with the contents of each eppendorf 
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tube. The contents (700 µl) were transferred to a spin column mounted inside an 
eppendorf collection tube. The columns were spun in a microcentrifuge at 
10,000rpm for 30 seconds. The flow through was discarded. 350µl of RW1 wash 
was added to each spin column. Spin columns were then spun at 10,000rpm for 30 
seconds and the flow through was discarded.  DNA digestion was undertaken by 
adding a 70µl solution, consisting of 69µl RDD buffer and 1µl TurboDNase to each 
spin column and left for fifteen minutes at room temperature. Following this, 350µl 
of RW1 wash was added to each spin column and centrifuged at 10,000rpm for 30 
seconds and the flow through was discarded. The eppenderf collection tubes were 
replaced. 500µl of RPE washing buffer was added to each column and spun at 
14,000rpm for one minute. The flow through was discarded. Then 500µl of 80% 
ethanol was pipette into each column and spun at 14,000rpm for one minute and 
the flow through was discarded. The eppendorf collection tubes were then changed 
and spun at 14,000rpm for five minutes. The spin columns were then placed in new 
eppendorf tubes. To elute the RNA, 14µl of RNAse free water was added to each 
column and spun at 14,000rpm for 1 minute.  Eppendorf tubes were labelled and 
immediately stored at -80ºC. 
 
2.3.3 RNA quantitation. 
2.3.3.1 QuantIt Ribogreen quantification. 
Materials: 
• QuantIt Ribogreen kit (Gibco/Invitrogen, Paisley, UK) 









Total RNA was quantified using the QuantIt Ribogreen kit according to the 
manufacturer’s instructions. TE solution x1 was prepared from TE stock (x20) using 
RNase free water. The standard RNA provided (100µg/ml) was serially diluted in 
TE from a stock solution at a concentration of 2µg/ml to give the following 
concentrations; 31.25ng/ml; 62.5ng/ml; 125ng/ml; 250ng/ml; 500ng/ml; 1000ng/ml.  
RNA test samples were diluted one in ten in TE solution. 100µl of RNA standard 
and test solutions were placed in a 96 well plate in triplicate. Blank wells in triplicate 
contained TE alone. A 100µl of a ribogreen solution (stock solution diluted 1 in 200 
in TE) was placed in each well. The sample fluorescence of the RNA standards and 
test samples were measured using a spectrofluorometer.  An absorbance at 260 
nm (A260) in a cuvette with a 1 cm path length of 0.05 corresponds to 2 µg/mL 
RNA. The concentration of RNA was quantified against standard curves generated 
for standard RNA samples. 
 
2.3.3.2. NanoDrop® ND-1000 UV-Vis Spectrophotometer. 
Early experiments made use of the Ribogreen Kit for RNA quantification. In 
subsequent experiments the NanoDrop spectrophotometer was used. Several test 
samples were measured using both methods that confirmed equivalent 
quantification (Table 3.1.1.B). 
1µl of total RNA was pipetted onto the fibre optic cable receiving platform and the 
second fibre optic cable arm brought into apposition with the receiving platform. 
The spectrophotometer (using a CCD array) then analyses absorbance of the 
sample following a flash pulse of xenon light. Data is transformed to give a 
concentration of RNA in ng/µl. 
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RNA purity was assessed by calculating the ratio of the absorbance of an RNA 
sample at two wavelengths (A260/A280). Adequately purified RNA was deemed to 
have a ratio of between 1.8 and 2. 
 
2.3.4 Reverse transcription (RT). 
Materials: 
• 100nM stock dATP, dTTP, dCTP, dGTP (Promega, Southampton, UK) 
• Transcriptor reverse transcriptase (Roche, Burgess Hill, UK)  
• Protector RNase inhibitor  (Roche, Burgess Hill, UK)  
• RT buffer (x5) (Roche, Burgess Hill, UK)  
• Oligo dT15 primer (0.5µg/µl) (Roche, Burgess Hill, UK)  
• RNase free water (Qiagen, Valencia, CA) 
• Total RNA sample 
Method: 
cDNA was synthesized from extracted RNA using RNase free materials. 2.5µg of 
RNA per reaction was used. As the concentrations of the harvested RNA varied 
between samples the following calculation was undertaken to correct for this and 
give the required volume of sample to give 2.5µg of RNA per reaction: 
 
Desired weight in µg (in this case 2.5 µg) / Actual concentration in µg/µl 
 
The RNA sample was pipetted into a sterile RNase-free microcentrifuge tube and 
RNase-free water was then added to a total volume of 6µl. 0.5µl of oligo dT15 
primer was then added and gently mixed. The tube was heated for ten minutes at 
65ºC to remove secondary structure within the template and subsequently at 4ºC to 
maintain this. A -RT control sample was also mixed in which the RNA sample was 
 
Chapter 2                                                                           Materials and methods 
106 
 
replaced by 3.5µl RNase-free water. The following RT mix was prepared and 3.5µl 
was pipetted and gently mixed to each tube to give a final volume of 10µl.  
 
RT mix (per reaction) 
• RT buffer (x5)            2 µl 
• dNTPs (10nM conc. dATP, dTTP, dCTP, dGTP)       1 µl 
• Protector RNase inhibitor       0.25 µl 
• Transcriptor reverse transcriptase    0.25 µl 
 
Each RT sample was placed in the PCR machine and samples were subjected to 
the following programme: 
Temp   Time/min:sec 
 
1. 65oc  for  10:00 
2. 4oc  for continuous  
add RT mixture 
 
3. 50oc  for 60:00 
4. 85oc  for 5:00 
5. End 
 
2.3.5 PCR reaction. 
PCR reactions were carried out to amplify cDNA. FastTaq DNA polymerase was 
utilised for PCR reactions relating to IR exon 11. EXL DNA Polymerase, more 
suitable for the PCR of longer products, was used for the PCR of products from 
experiment involving APOB exon 26. 
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2.3.5.1 FastTaq DNA Polymerase PCR. 
FastTaq DNA Polymerase was used in PCR for the IR exon 11. 
Materials: 
• 10nM concentration dATP, dTTP, dCTP, dGTP (Promega) 
• FastTaq DNA polymerase, (Roche, Burgess Hill, UK)  
• PCR buffer x10 (MgCl2), (Roche, Burgess Hill, UK)  
• Forward + reverse primer (concentration 50µM), (Sigma,  Dorset, UK) 
•  [α-32P] dCTP (Perkin-Elmer, Wellesley, USA)  
• dH20  
Methods: 
The volume of [α-32P] dCTP added per reaction was adjusted according to α-32P 
activity.  Specific primer pairs were used for a given reaction (Chapter 6.2 -
appendix). The typical reaction mixture was as follows: 
 
PCR buffer (x10)      1 µl 
dNTPs (10nM conc. dATP, dTTP, dCTP, dGTP)  0.2 µl 
Forward primer      0.2 µl 
Reverse primer      0.2 µl 
FastTaq DNA polymerase     0.1 µl 
0.05 µl (0.5µ Ci) [α-32P] dCTP    0.05 µl 
cDNA sample       0.25 µl 
dH20        8 µl 
  
Total volume       10 µl 
 
The PCR was carried with the following programs (Chapter 2.3.6.1).   
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2.3.5.2  EXL DNA Polymerase PCR. 
EXL DNA Polymerase was used in PCR for APOB exon 26 given the 
long length of the product (approximately 7.5 Kb product). 
Materials: 
• 10nM mix dATP, dTTP, dCTP, dGTP (Promega, Southampton, UK) 
• EXL® DNA polymerase (5 U/ µl) (Stratagene, CA,USA) 
• EXL reaction buffer x10 (Stratagene, CA,USA) 
• Dimethyl Sulfoxide (DMSO) (Stratagene, CA,USA) 
• Stabilizing Solution (Stratagene, CA,USA) 
• Forward + reverse primer (concentration 50µM), (Sigma,  Dorset, UK) 
• [α-32P] dCTP (Perkin-Elmer, Wellesley, USA)  
• dH20  
Method: 
The volume of [α-32P] dCTP added per reaction was adjusted according to α-32P 
activity.  The typical reaction mixture was as follows: 
 
EXL reaction buffer  (x10)     2.5 µl 
dNTPs (10nM conc. dATP, dTTP, dCTP, dGTP)  1.05 µl 
Forward primer      0.25 µl 
Reverse primer      0.25 µl 
EXL® DNA polymerase     0.5 µl 
DMSO        0.75 µl 
Stabilizing Solution      0.5 µl 
0.05 µl (0.5µ Ci) [α-32P] dCTP    0.2 µl 
cDNA sample       0.25 µl 
dH20        18.75 µl 
 




Total volume       25 µl 
The PCR was carried with the following programs (Chapter 2.3.6.2).   
 
2.3.6 PCR thermocycling conditions. 
The number of cycles was adjusted for each oligonucleotide pair to allow 
amplification in the exponential phase (Chapter 6.2 - appendix). 
 
 
Chapter 2                                                                           Materials and methods 
110 
 
2.3.6.1  FastTaq DNA polymerase PCR (GAPDH/IR). 
 
Temp   time/min:sec 
1. Denaturation 95oc  for  2:00 
2. Denaturation 95oc  for 0:30 
3. Annealing  58oc  for 0:30 
4. Extension  72oc  for 0:30 
5. Remove GAPDH reactions 
6. Denaturation 95oc  for       0:10 
7. Annealing  58oc  for 0:30 
8. Extension  72oc  for 0:30 
9. End 
10. Remove IR reactions 
 
 
2.3.6.2 Exl DNA polymerase PCR program (APOB exon 26). 
  Temp   Time/min:sec                    
   
1. Denaturation            92oc  for  2:00 
2. Denaturation            92oc  for 0:10 
3. Annealing             58oc  for 0:30 
4. Extension            68oc  for 7:30 
5. Denaturation            92oc  for       0:10 
6. Annealing            58oc  for 0:30 




} repeat 10 times 
} repeat 22 times 
} repeat 10 times 
} repeat 20 times 
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2.3.7 Optimising PCR thermocycling conditions 
PCR reactions were run with each primer pair over a range of cycle lengths. The 
products were then run on a polyacrylamide gel and autoradiographed to determine 
the optimum number of cycles required to allow amplification in the exponential 
phase. The subsequent number of cycles per PCR reaction for a given set of 
primers was fixed accordingly.  
 
2.4 Gel electrophoresis. 
 
2.4.1 Polyacrylamide gel. 
Materials: 
• Acrylamide solution 30%, (Biosynthesis, Hercules, CA, USA) 
• Tetramethylethylenediamine (TEMED) (BDH labs, Poole, UK) 
• 10% ammounium persulphate  (APS) solution (Sigma,  Dorset, UK) 
• TBE x1 
• dH20 
• Plain and notched glass VGT2 plates 
• VGT2 tank 
 
Method: 
6-8% polyacrylamide gels were generally run. Gels were made according to the 
following: 
 
6% Polyacrylamide gel 
• 10.5ml dH20 
• 1.5ml TBE x1 
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• 2.99ml of 30% acrylamide solution  
• 5.25 µl TEMED 
• 240 µl 10% APS 
 
8% Polyacrylamide gel 
• 9.5ml dH20 
• 1.5ml TBE x1 
• 3.99ml of 30% acrylamide solution  
• 5.25 µl TEMED 
• 240 µl  10% APS 
 
Gels were prepared as above with APS solution being added last. Gel solutions 
were poured between two VGT2 plates and 0.38-0.400mm combs inserted. Gels 
were allowed to set for 45 minutes. The combs were then removed and the gel was 
then placed in a VGT2 tank filled with TBE x1. Gels were pre-run for 10 minutes. 
The products and DNA marker ladders were loaded. Eight percent polyacrylamide 
gels were run for experiments involving the IR exon 11 at 12W. Six percent gels 
were run for experiments involving APOB exon 26 at 35W. Once run, gels were 
dried and autoradiographed and/or exposed to the phosphor-imager plate.  
 
2.4.2 Agarose gel. 
Materials: 
• Agarose (electrophoresis grade), (Gibco/Invitrogen, Paisley, UK) 
• Ethidium Bromide (500µg/ml), (Sigma,  Dorset, UK) 
• TAE × 50, (National Diagnostics, Atlanta, GA, USA) 
• DirectLoad™ Wide Range DNA Marker (Sigma,  Dorset, UK) 
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• Loading dye (Promega, Southampton, UK) 
Method: 
0.8-1.0% agarose gels were run. A 1.0% agarose gel consisted of 2g agarose, 4ml 
TAE x50, 10µl ethidium bromide, dH20 up to 200ml. The gel was melted until liquid 
and then poured into a cast and a coomb was inserted to construct wells. Once set, 
the cast was placed in a tank filled with TAE solution (1 litre - 20ml TAE x50, 50 µl 
ethidium bromide, 980ml dH20) and the coomb was removed. 4 µl of a sample was 
generally run with 1 µl of a loading dye. 5 µl of a DirectLoad™ Wide Range DNA 
Marker ladder was run with samples to determine fragment size. The voltage used 
across the tank was 150 mV.  
 
2.4.3 Gel imaging. 
2.4.3.1 Agarose gels. 
Agarose gels were visualized under ultraviolet light (Unvidoc UV Transilluminator) 
and images were recorded with the Kodak Electrophoresis and Documentation 
analysis system (Kodak, Herefordshire, UK). 
 
 
2.4.3.2 Polyacrylamide gels. 
2.4.3.2.1 Phospho-imager. 
Quantitation of polyacrylamide gels was carried out using a Molecular Dynamics 
Typhoon PhosphorImager and ImageQuant software (GE Healthcare Life 
Sciences, Piscataway, NJ). Polyacrylamide gels were dried and exposed to a 
blanked phosphor-imager plate in a black-out cassette for 1-2 hours depending of 
the level of exposure required. The ImageQuant software allowed bands to be 
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quantified and corrected for background counts. The quantified bands were 
normalized according to the GC content.  
 
2.4.3.2.2 Autoradiography. 
Autoradiographs of wet or dry polyacrylamide gels were taken. If wet the gel was 
first covered with saran wrap prior to being exposed to a radiograph (Kodak Xomat 
L5 Film, Hertfordshire, UK) placed in a black-out cassette. The cassette was placed 
at -800C for between 1-24 hours depending on the level of exposure required. The 
autoradiograph was developed using a laboratory developer (CompactX4, Xograph 




• 6 chamber slide wells 
• PBS x1 (Sigma,  Dorset, UK) 
• 4% paraldehyde/PBS (Sigma,  Dorset, UK) 
• 4’,6-diamidino-2-phenylindole satin (DAPI), (Sigma,  Dorset, UK) 
• Fluorescent Mounting Medium (DAKO) (DakoCytomation, Glostrup, 
Denmark) 
• Fluorescent confocal microscope (Zeiss LSM510) 
Method: 
Cell suspensions were transfected according to Chapter 2.2.7 with fluorescein 
tagged ASOs and the relevant controls. 300 µl of transfected cell suspension was 
added to a 6 chamber slide well. These were incubated at 37ºC for 48 hours. Media 
was then removed and 2 washes with 350 µl of PBS at 4ºC were carried out. 
Fixation occurred using 350 µl of 4% paraldehyde/PBS placed in each well for ten 
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minutes. Two further 350 µl PBS washes were carried out. A 2 µg/ml DAPI solution 
was prepared from stock (10mg/ml). 350 µl DAPI was applied for 30 seconds 
followed by two 350 µl PBS washes. The plastic chamber and silicon seals were 
peeled off to leave the slide and fixed cells. One drop of DAKO mounting media 
was applied to each well and a cover slip applied. The slide was placed in a 
fluorescent confocal microscope and appropriate images recorded. Slides were 
stored in the dark. 
 
2.6  DNA sequencing. 
2.6.1 Purifying bands. 
Materials: 
• TE x1 (Gibco/Invitrogen, Paisley, UK) 
• 3M NaOAc pH 5.2 
• Carrier tRNA, (Qiagen, Valencia, CA) 
• Ethanol (VWR international, Lutterworth, UK) 
Method: 
PCR products were run on a polyacrylamide gel according to protocol (Chapter 
2.4.1). The gel was transferred to blotting paper with fluorescent markers applied 
for positioning, exposed to an autoradiograph and placed at -80ºC for between 4-24 
hours depending on the level of exposure required. The film was developed and 
placed on the thawed gel according to the position of the markers. The bands of 
interest were identified, cut from the gel with a scapel, and placed in an eppendorf 
tube. The gel was mashed up in 25 µl of TE x1 and placed at 42ºC for 30 minutes. 
The supernatant was collected and the process repeated to give a final volume of 
50 µl of supernatant. 5 µl of 3M NaOAc pH 5.2, 0.5 µl of carrier RNA and 100 µl of 
100% ethanol were added to precipitate the DNA. The mixture was then placed at -
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80ºC for 30 minutes.  Following this it was spun at 14,000rpm, 4ºC for 15 minutes. 
The supernatant was removed and 100 µl of 70% ethanol was added and spun at 
14,000rpm/4ºC for a further 15 minutes. The supernatant was removed and the 
DNA sample left to dry. The sample was eluted in 10 µl of TE x1. 
 
2.6.2 DNA sequencing. 
PCR product sequencing was carried out at the Genome centre, William Harvey 
Research Centre. An ABI 3700 automated DNA/RNA Sequencer (Applied 
Biosystems) was used employing the ABI Prism Big Dye sequencing Kit. Data 
Collection software 2.0 was used to collect data and results were analysed with the 




2.7  Miscellaneous – buffer solutions/markers/ladders. 
 




• EDTA, (Sigma,  Dorset, UK) 
• NAOH, (Sigma,  Dorset, UK) 
• dH20  
Method: 
In order to produce 1 litre solution of 0.5M pH 8.0 EDTA the constituents were 
mixed as follows: 
• EDTA   186.1 g 
• dH20      500 ml 
• NAOH  added to a pH 8.0 
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EDTA was dissolved in 500ml of dH20. NaOH was then added gradually whilst 
assessing the pH of the solution until it reached pH8.0. The remaining dH20 was 
added to make 1 litre.  
 
2.7.2 Tris/Borate/EDTA (TBE) buffer. 
 
Materials: 
• Tris base, (Sigma,  Dorset, UK) 
• Boric acid,  (Sigma,  Dorset, UK) 





To make a x10 solution of TBE buffer, the above mentioned materials were mixed 
in the following quantities: 
• Tris base   108 g 
• Boric acid        55 g  
• EDTA 0.5M pH8.0     40 ml  
• dH20    960 ml 
Once mixed, samples were filtered prior to storage. The solution was diluted 1 in 10 








• TAE x50, (National Diagnostics, Georgia, USA) 
• Ethidium bromide, (Sigma,  Dorset, UK) 
• dH2O 
 





The constituents above were mixed in the following quantities to give TAE buffer 
x1: 
 
• TAE x50          20 ml 
• Ethidium bromide stock    50 µl 






2.7.4 Sodium Acetate (NaOAc) solution (3.0M). 
 
Materials: 
• NaC2H3O2 ,  (Sigma,  Dorset, UK) 
• dH20  
Method: 
To make a 3.0M Sodium Acetate solution, 246.09g of NaC2H3O2  were taken and 








• Escherichia coli Pol buffer (New England Biolabs, Ipswich, MA, USA) 
• pBr 322/MSpI digest (New England Biolabs, Ipswich, MA, USA) 
                       or 
 N32325 (New England Biolabs, Ipswich, MA, USA) 
• Klenow buffer x 10 (New England Biolabs, Ipswich, MA, USA) 
• dTTP, dATP, dGTP (Promega, Southampton, UK) 
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5 µl [α-32P] dCTP, 1 µl E.Coli Pol buffer, 1 µl pBr 322/MSpI digest (or N32325)  and 
1 µl of Klenow buffer (x10) were added to a eppendorf tube and left at room 
temperature for ten minutes. The 1 µl each of dTTP, dATP and dGTP was added 
and left at room temperature for a further ten minutes. Then 190 µl of dH20 was 
added to make the stock solution. According to the [α-32P] dCTP activity, this stock 
was diluted with dye and TE to make ladder markers for the polyacrylamide gel. 
 




• Sucrose 50%  
• EDTA 0.5M, (Sigma,  Dorset, UK) 
• Tris  pH 8.0, (Sigma,  Dorset, UK) 
• Bromophenol blue,  (Sigma,  Dorset, UK) 
• Xylene cyanolone, (Sigma,  Dorset, UK)  
Method: 
The above constitutes were mixed to give 10mls of dye: 
 
 
• Sucrose 50%       5  g 
• EDTA 0.5M 60mmol    1.2  ml 
• Tris  pH 8.0 10mmol   100  µl 
• Bromophenol blue 0.03%   2.3  mg 
• Xylene cyanole 0.03%       2.3  mg 
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On account of the significant sucrose content, the solution was passed through a 
bacterial filter to avoid bacterial contamination prior to storage. 
2.8  Computational identification of exonic splicing enhancers. 
ESEfinder (http://rulai.cshl.edu/tools/ESE/), RESCUE-ESE (http://genes.mit. 
edu/burgelab/rescue-ese/index.html) and PESXs server (http://cubweb.biology 
.columbia.edu/pesx/) were used to search the IR exon 11 sequence for exonic 
splicing enhancers. The FAS-ESS web server (http://genes.mit.edu/fas-ess/) 
provides predictions for ESS sequences. 
ESEfinder 3.0 is a web-based tool utilising the SELEX approach (systematic 
evolution of ligands by exponential enrichment) to identify ESE motifs for splicing 
factors; SF2/ASF; SRp55; SRp40 and SC35. SELEX employs an in iterative 
enrichment process to identify sequences with enhancer properties using an in vitro 
or in vivo minigene model and provides weight score matrices to assess a given 
sequence. 
RESCUE-ESE uses a hybrid computational/experimental approach to identify 
hexamers with enhancer characteristics (Fairbrother et al. 2002). Computational 
analysis identified sequences occurring at high frequency in positions where 
enhancer sequences may be expected to reside i.e. in exonic rather than intronic 
sequences and in exons with weaker, non-consensus splice sites rather than exons 
with strong consensus splice sites which are constitutively spliced. These identified 
sequences were then experimental tested in minigene reporter constructs to 
assess their enhancer properties. 
PESX Server (Putative Exonic Splicing Enhancers/Silencers) uses a purely 
bioinformatics process to identify octamer enhancer sequences (Zhang et al. 2004). 
Octamers from internal noncoding exons (high content of ESE sequences) were 
compared with sequences predicted to have a low content of ESE sequences i.e. 
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unspliced pseudo exons and 5′ untranslated regions of transcripts of intronless 
genes. This method circumvents the ‘noise’ produced by coding exonic sequences 
by using non-coding exon sequences.  
The FAS-ESS server provides predictions for potential ESS sequences (Wang et 
al. 2004). The program is based on experiments identifying sequences with silencer 
activity using an in vivo splicing reporter system based on Green Fluorescent 
Protein (GFP). 
 
2.9 Statistical analysis. 
Statistical analysis and graphing was carried out using Prism 4.0c software 
(GraphPad Software, San Diego, CA). Three replicates for each experiment were 
carried out unless stated otherwise. Relevant statistical test were carried out as 














          
  
 






Modification of insulin receptor exon 11 splicing using 
antisense oligonucleotides. 
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3.1.1  A pilot study: 2′-O-methyl RNA ASOs targeting the insulin receptor 
exon 11.  
 
Background 
Exon 11 of the IR pre-mRNA can be alternatively spliced to give two isoforms which 
vary by exon 11 skipping (isoform IR-A) and inclusion (isoform IR-B). The 
proportions of these isoforms vary between organs, metabolic states and species. 
Previous studies have altered exon 11 splicing using deletion studies in minigenes 
in cell culture (Kosaki et al. 1998) and via hormonally-mediated methods (Kosaki et 
al. 1993). However these approaches suffer from a lack of physiological relevance 
or are confounded by various hormonal treatments.  ASOs bind to the native pre-
mRNA and their mechanism of action is thought to be either via blocking access of 
trans-acting splicing factors or altering pre-mRNA secondary structure and splicing 
efficiency. This can cause exon skipping, or the use of an alternative or cryptic 
splice site.  
The aim of the present study was to alter exon 11 splicing using ASOs designed to 
bind the pre-mRNA by Watson-Crick base-pairing.  The prediction was that certain 
2′-O-methyl RNA ASOs would enhance either exon skipping or inclusion by   
targeting key intronic and exonic sites influencing IR exon 11 splicing as guided by 
the work of Kosaki et al. (Kosaki et al. 1998). 
 




To change splicing of the IR exon 11 in cell culture using 2′-O-methyl RNA ASOs 
targeted to key intronic and exonic sites around exon 11 of the IR pre-mRNA.  
 
Methods 
The initial ASO chemistry used was 2′-O-methyl RNA. These oligonucleotides 
contained a phosphate-ribose backbone and a methyl group in place of a hydroxyl 
group in the 2 position of the ribose ring. This chemistry was chosen because of the 
increased binding capacity to pre-mRNA and resistance to RNase mediated 
degradation.  2′-O-methyl ASOs were ordered from Dharmacon (Lafayette, CO, 
USA). They were designed to bind and occupy pre-mRNA sequences by Watson-
Crick base-pairing to the INSR sequence as taken from the Ensembl Genome 
Browser (http://www.ensembl.org/index.html). ASOs were either 18 or 36 
nucleotides in length, in-line with previous studies, such that targeted sequences 
were adequately covered (Khoo et al. 2007). ASO sequences are given in Chapter 
6.1 - appendix. These experiments were carried out at a point when the key 
splicing factors binding sites within exon 11 had not yet been fully elucidated (see 
Chapter 4.2). 2′-O-methyl RNA ASOs were designed complementary to single 
intronic sites, 18 nucleotides long (figure 3.1.1.A); the 3′ splice site (designated 
INSR 3); the 5′ splice site (designated INSR 5) and the branch point sequence 
(designated INSR B). The ASOs binding the 3′ and 5′ splice sites were designed 
without overlapping the intron/exon boundaries. ASOs which targeted two intronic 
sites within the same oligonucleotide, 36 nucleotides long, were also synthesised. 
These included ASOs to the 3′ splice site and branch point sequence (designated 
INSR 3B); the 5′ splice site and the branch point sequence (designated INSR 5B) 
and the 3′ splice site and 5′ splice site (designated INSR 53).  
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Exonic-targeted ASOs, 18 nucleotides long, were designed (figure 3.1.1.B) to bind 
the 5′ half of exon 11 (designated INSR ex1) and the 3′ half of exon 11 (designated 
INSR ex2).  An ASO, 36 nucleotides long, was designed to block the whole of exon 
11 (designated INSR ex1+2). 
Following initial experiments with the above-mentioned sequences, two further 2′-
O-methyl RNA ASOs were designed and subsequently tested (figure 3.1.1.C). 
These included the ASO INSR 6/7, which was a 43 nucleotide sequence targeting 
an intron 10 sequence, 52 nucleotides upstream of the 3′ splice site. This sequence 
has been identified as having an inhibitory influence on IR exon 11 splicing from a 
previous study in which it has been identified as sequence 6/7 (Kosaki et al. 1998). 
A further exonic sequence was targeted by the ASO INSR ex3 which was an 18mer 
targeting the central portion of IR exon 11. INSR ex3 was tested to further delineate 
influential sites in the IR exon 11. 
Detailed methodology is provided in Chapter 2 - materials and methods. 
Essentially, ASOs were reverse-transfected into cultured HepG2 cells using the 
transfection agent Lipofectamine 2000 (Gibco/Invitrogen, Paisley, UK). ASOs were 
transfected at a concentration of 250 nM, in keeping with similar previous studies 
(Khoo et al. 2007). Dose titration experiments were also carried out to establish a 
dose-response relationship (Chapter 3.1.3). ASOs were incubated with HepG2 
cells for 48 hours at 37oC/5% CO2. HepG2 cells were used as they represent a 
well-established model of IR expression and action. They also retain much of 
normal hepatocyte function (Javitt 1990). RNA was subsequently harvested and 
subjected to RT-PCR. The PCR primers allowed identification of the 2 isoforms of 
the IR and GAPDH run as a control for mRNA quantity and quality. Products were 
run on an 8% polyacrylamide gel. The PCR incorporated the radioactive nucleotide 
[α-32P] dCTP (Perkin-Elmer, Wellesley, USA) allowing relevant bands to be 
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identified and quantified using a Phosphorimager. Radioactive counts were 
corrected for GC content. The effects of the ASOs were expressed by measuring 
the amount of IR-B (IR isoform including exon 11) as a percentage of total IR (IR-A 
+ IR-B).  
The GAPDH control was included to demonstrate appropriate loading of samples 
and a marker of RNA quality but this was not used to correct for well loading. The 
reason for this was that the figure being compared (IR-B/ (IR-A+IR-B)) for each 
column was a proportional rather than an absolute figure which would eliminate 
differences according to sample loading if corrected for GAPDH. If the sample 
loaded in a particular column happened to be lower then IR-B and IR-A+IR-B would 
be proportionally reduced by the same amount thus eliminating any effect. This 
assumption was corroborated by calculations from initial experiments which 
demonstrate the percentage IR-B with respect to total IR was identical whether or 
not it was corrected for GAPDH.   
Statistical analysis was carried out using a one-way repeat ANOVA to assess for 
overall statistical significance between the groups. A Dunnett’s multiple comparison 
test was used to assess for statistical differences between the proportion of exon 
11 inclusion in the no-oligo control cells compared with cells transfected with each 
of the ASOs (significance p<0.05). Each experiment was repeated in triplicate.  
An analysis of the IR exon 11 using web-based tools (Chapter 2.8) capable of 
identifying sequences with ESS and ESE activity was undertaken to compare the 
findings generated from this study.  
Figure 3.1.1.I shows data from equivalence studies for RNA quantification 
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Figure 3.1.1.A  Intronic ASOs targeting targeting regions surrounding the IR. 
Schematic diagram shows a portion of the IR pre-mRNA from exon 10 to exon 12 (not to 
scale).  Exon 11 and surrounding intronic sequences are shown. Exons are delineated 
by the grey shading, the rest of the sequence being intronic. ASOs are illustrated above 
the IR pre-mRNA.  ASOs, 18 nucleotides long, were designed to block the 3′ splice site 
(designated INSR 3), the 5′ splice site (INSR 5), the branch point sequence (INSR B). 
Combinations of these ASOs, 36 nucleotides long, were also designed to block two sites 
simultaneously. These included the 3′ splice site and the branch point sequence 
(designated INSR 3B), the 5′ splice site and the branch point sequence (INSR 5B) and 
the 3′ splice site and the 5′ splice site (INSR 53). The dotted line schematically 
represents sequences in apposition to each other rather than a linker sequence between 
them. Cells were transfected with ASOs at varying concentrations. RT-PCR was carried 
out on the total RNA extracted from these cells after 48 hours. 
 
Figure 3.1.1.A  
 






Figure 3.1.1.B   Exonic ASOs targeting the IR exon 11. Schematic diagram shows a 
portion of the IR pre-mRNA from exon 10 to exon 12 (not to scale).  IR exon 11 and 
surrounding intronic sequences are shown. Exons are delineated by the grey shading, 
the rest of the sequence being intronic. ASOs are illustrated above the IR pre-mRNA.  
ASOs, 18 nucleotides long, were designed to block the two halves of exon 11 i.e. INSR 
ex1 and INSR ex2. A combination of these ASOs, designated INSR ex1+2 (36 
nucleotides long) blocked both sites simultaneously. Cells were transfected with ASOs 
at varying concentrations. RT-PCR was carried out on the total RNA extracted from 
these cells after 48 hours. 
Figure 3.1.1.B 
 





Figure 3.1.1.C   2′-O-methyl RNA ASOs targeting intron 10 and exon 11 of the IR 
pre-mRNA. Schematic diagram shows a portion of the IR pre-mRNA from exon 10 to 
exon 12 (not to scale).  Exon 11 and surrounding intronic sequences are shown. Exons 
are delineated by the grey shading, the rest of the sequence being intronic. ASOs are 
illustrated above the IR pre-mRNA.  An ASOs 18 nucleotides long, designated INSR 
ex3, was designed to block the central portion of the IR exon 11. An intronic ASO 
targeting a 43 nucleotide sequence in intron 10, 52 nucleotides upstream of the 3′ splice 
site of exon 11 was designed. Cells were transfected with ASOs at varying 
concentrations. RT-PCR was carried out on the total RNA extracted from these cells 
after 48 hours. 
 








Figure 3.1.1.D  IR exon 11 splicing in the presence of targeted 2′-O-methyl RNA 
ASOs. Polyacrylamide gel from a representative experiment showing IR isoforms 
from HepG2 cells transfected with ASOs. Each column represents a well of 
transfection with ASOs marked above the column. The left side of the figure 
represents the two IR isoforms - IR-B (exon 11 inclusion) and IR-A (exon 11 
exclusion). The right side of the figure represents GAPDH run as a control for mRNA 
quantity and quality.  
Figure 3.1.1.D 
 





Figure 3.1.1.E  IR exon 11 splicing in the presence of targeted 2′-O-methyl 
ASOs. The graph shows percentage IR-B with respect to total IR (IR-A + IR-B) 
following transfection by ASOs in HepG2 cells at a concentration of 250nM. 
Quantitative data from three independent replications of the experiment (error bars 
show the S.E.M.). Overall one-way repeated measures ANOVA p-value was 
<0.0001, indicating statistically significant differences between groups. Dunnett’s 
multiple comparison test was used to compare the no-oligo control versus ASO 
transfected cells: statistically significant differences were found with ASO INSR 3B, 
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Figure 3.1.1.F  IR exon 11 splicing in the presence of the 2′-O-methyl RNA ASOs 
INSR 6/7 and INSR ex3. Polyacrylamide gel showing IR isoforms from cells transfected 
with 2′-O-methyl RNA ASOs INSR 6/7 and INSR ex3 - IR-B (exon 11 inclusion) and IR-
A (exon 11 exclusion). 2′-O-methyl RNA ASO INSR ex2 was run as a positive control. 
GAPDH was run as a control for mRNA quantity and quality.  
Figure 3.1.1.F 
 
Chapter 3                                                                                                   Results 
134 
 
Figure 3.1.1.G Alternative splicing of the IR exon 11 induced by 2′-O-methyl RNA 
ASOs INSR 6/7 and INSR ex3. The graph shows percentage IR-B with respect to total 
IR (IR-A + IR-B) following transfection by 2′-O-methyl RNA ASOs INSR 6/7 and INSR 
ex3 at a concentration of 250nM. Quantitative data from three independent replications 
of the experiment (error bars show the S.E.M.). Overall one-way repeated measures 
ANOVA p-value was <0.0001 indicating statistically significant differences between 
groups. Dunnett’s multiple comparison test was used to compare the no-oligo control 
versus 2′-O-methyl RNA ASOs transfected cells. Neither INSR 6/7 or INSR ex3 were 
effective at altering IR splicing. The 2′-O-methyl RNA ASO INSR ex2, run as a positive 
control, was the only effective ASO. 
Figure 3.1.1.G 
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Table 3.1.1.A  
 
 
Program ESS/ESE Position in IR exon 11 Sequence 
    
ESE Finder SRp40 (ESE) 9-15 CTTCAGG 
  15-21 GCACTGG 
 SC35   (ESE) 28-35 GGACCCTA 
  29-36 GACCCTAG 
 SF2/ASF(ESE) 16-22 CACTGGT 
  21-27 GTGCCGA 
  24-30 CCGAGGA 
    
PESX ESE 8-15 TCTTCAGG 
  25-34 CGAGGACCCT 
 ESS - - 
    
RESCUE-ESE ESE 2-7 AAAACC 
  3-8 AAACCT 
  8-13 TCTTCA 
  9-14 CTTCAG 
    
FAS-ESS ESS - - 
    
 
Table 3.1.1.A   Predicted enhancer/silencer sites in the IR exon 11. Column 1 lists the 
web-based tools used to identify potential enhancer and silencer elements in the IR exon 
11. URLs for these tools are provided in Chapter 6.3 - appendix.  Column 2 gives the type 
of element (ESE or ESS) identified. ESE finder specifies several ESEs including SRp40, 
SC35 and SF2/ASF. Column 3 provides the location for the given ESS or ESE with exon 
11, numbering between 1-36 nucleotides from the 5′ end of the exon. Column 4 gives the 
precise sequences of the predicted ESSs and ESEs. 
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Figure 3.1.1.H  Predicted ESEs in the IR exon 11- generated by the ESE finder 
analysis. (Chapter 6.3 - appendix for URL) Graphical representation of predicted ESE sites 
in the IR exon 11 for SF2/ASF, SC35, SRp40 and SRp55. IR exon 11 sequence given on 
the x axis, matrix score (predicted strength of ESE) given on the y axis. ESE are predicted 
in the centre and to the 3′ half of IR exon 11. The strongest prediction is that for a SC35 
binding site at position 24-30 (matrix score 4.99).  
 
 








1.2 1.6 2 2.4














   2.10 2.27 6 
1.20 1.41 11 1.54 1.84 5 
1.40 1.27 10 1.88 1.99 4 
1.45 1.48 9 1.35 1.69 3 
1.39 1.47 8 1.41 1.53 2 













1 1.2 1.4 1.6 1.8 2 2.2 2.4













Figure 3.1.1.I  RNA quantification equivalence studies - NanoDrop ND-1000 
UV-Vis Spectrophotometer vs. Ribogreen QuantIT estimation. A. RNA 
concentrations measured with two methods. B. Scatterplot of RNA concentrations 
measured by two methods. The calculated correlation co-efficient was 0.88.           
C. Bland-Altman plot of mean RNA concentration against difference in RNA 
concentration (bias) for each pair of readings (Ribogreen QuantIT – Nanodrop). 
Mean bias was 0.10 ug/ul (towards Ribogreen QuantIT) with a 95% limit of 










Figure 3.1.1.D and 3.1.1.F show representative gels from experiments involving the 
transfection of 2′-O-methyl RNA ASOs into cultured HepG2 cells. In native HepG2 
cells without the addition of ASOs (figure 3.1.1.D and 3.1.1.F - lane 2 designated 
‘no oligo’) there is a predominance of exon 11 skipping (IR-A) over exon 11 
inclusion (IR-B). The proportion of IR-B with respect to the total IR (IR-A + IR-B) 
was approximately 30% in keeping with reported proportions where HepG2 have 
not been manipulated with the use of minigenes containing IR transcripts (Kosaki et 
al. 1993).  
Data from three experimental replicates was combined and represented graphically 
in figure 3.1.1.E and 3.1.1.G. Data was represented as the change in the proportion 
of exon 11 included isoform with respect to the total IR (exon 11 included isoform + 
exon 11 skipped isoform) for each ASO transfected.  
Intron-targeted ASOs against single sites (INSR 3, INSR 5, INSR B) did not 
significantly alter exon 11 splicing (figure 3.1.1.D - lanes 3, 4, 5 respectively). This 
includes the long ASO INSR 6/7 (figure 3.1.1.F - lane 3) targeted to a 43 nucleotide 
intronic site. Combination ASOs, blocking two intronic sites simultaneously (INSR 
3B, INSR 5B and INSR 53) and at the same concentration as ASOs targeting 
single sites (figure 3.1.1.D - lanes 6, 7 and 8 respectively), significantly increased 
exon 11 skipping (i.e. reduce proportion IR-B) in the order INSR 53>INSR 
5B>INSR 3B. The intronic combination ASOs which spanned the exon (INSR 5B, 
INSR 53) were more effective (p<0.01) than the ASO INSR 3B (p<0.05) which did 
not.  
Exonic ASOs INSR ex2 and INSR ex1+2 (figure 3.1.1.D - lanes 10 and 11) were 
the most effective at causing exon 11 skipping (p<0.01), with INSR ex1+2 being 
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more potent than INSR ex2. INSR ex1 (figure 3.1.1.D - lane 9) and INSR ex3 
(figure 3.1.1.F - lane 4) had no significant effect on splicing.  
The lack of efficacy of 2′-O-methyl RNA ASOs targeted to single intronic sites 
around the IR exon 11 may be ascribed to either technical factors in the 
methodology or a factor inherent to ASOs targeted to single intronic sites. 
Technical factors include issues relating to transfection efficiency and ASO design.  
Transfection efficiency was not formally assessed in this study. However, ASOs 
transfected in identical conditions were noted to have significant effects on IR exon 
11 splicing e.g. INSR ex2.  It is possible that different ASOs had different 
transfection efficiency rates. Variations in transfection efficiency could explain the 
differential effects of these ASOs. Against this are the facts that the effective ASO 
INSR ex2 also had a similar design (2′-O-methyl RNA backbone) to the ineffective 
ASOs targeted to single intronic sites (INSR 3, INSR 5, INSR B). The 18mer INSR 
ex2 was more effective that the 36mers INSR 3B, INSR 5B and INSR 53 but less 
effective than the 36mer, INSR ex1+2. It would therefore be unlikely that ASO 
length was a predominant factor for poor efficacy of ASOs targeting single intronic 
sites.  
If the lack of efficacy related to a factor inherent to ASOs targeted to single intronic 
sites it suggested there was functional redundancy in the system i.e. blocking of 
single intronic sites was not rate-limiting to the splicing of IR exon 11. This is in 
contrast to the finding that ASOs which targeted two intronic sites simultaneously 
appeared to enhance IR exon 11 skipping.   
Exonic ASOs spanning the whole exon and the 3′ half of the IR exon 11 both 
appeared to cause maximal skipping of exon 11. Those targeting the 5′ and central 
portion of the exon (INSR ex1 and INSR ex3) had no overall effect on splicing. This 
data would therefore suggest the 3′ end of exon 11 harbours an enhancer 
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sequence important for exon inclusion. ASOs spanning the IR exon 11, whether 
targeting intronic (INSR 5B and INSR 53) or exonic sites (INSR ex1+2) were more 
effective at causing exon 11 skipping than 36mer ASOs that did not span the exon 
(INSR 3B). Both the 5B and 53 ASO appear to cause IR exon 11 skipping.  In 
terms of binding, three possibilities exist; the ASOs are binding to two sites 
simultaneously (5’ splice site and 3’ splice site or BPS); the ASOs bind only one of 
the two sites they target (5’ splice site, 3’ splice site or BPS), in other words only 
half the intended target (50%) is blocked, or a combination of these two 
possibilities. If the ASOs are binding the two sites simultaneously then the 
assumption is that they are blocking the exon. However the fact that these ASOs 
are not as effective as INSR ex1+2 suggests that they are not blocking the exon in 
the same way. On the basis of current data it is not possible to speculate beyond 
this. 
While these experiments demonstrated that IR exon 11 skipping could be induced 
easily, no ASO tested caused increased exon 11 inclusion. The possible 
explanations for this finding was that there were no silencer elements in the areas 
targeted, or that the ASOs were unable to block any silencer elements due to a 
methodological problem. 
Using a range of computational and experimental modelling programmes available 
via the web, the IR exon 11 was analysed to identify possible enhancer/silencer 
binding sites (table 3.1.1.A and figure 3.1.1.H). Tools identified predicted ESE sites 
through-out the IR exon 11. ESE finder identified potential binding sites for the 
splicing factors SRp40, SF2/ASF and SC35 which were found in the centre and 3′ 
end of exon 11 (figure 3.1.1.H).  RESCUE-ESE identified sites predominantly at the 
5′ end and centre of exon 11 while PESX predicted enhancer sequences both in 
the 5′ half (position 8-16) and the 3′ half of exon 11 (position 25-34). Data from the 
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current study suggests a possible enhancer region in the 3′ half of exon 11 in 
keeping with RESCUE-ESE and PESX. Tools capable of predicting ESS sites 
(PESX and FAS-ESS) did not predict any ESS sites in exon 11 which may explain 
the inability of ASOs to cause IR exon 11 inclusion. 
In summary, the findings of these initial experiments fulfil the aim by demonstrating 
that 2′-O-methyl RNA ASOs targeting key sites in and around the IR exon 11 can 
alter its splicing. Importantly however, while various 2′-O-methyl RNA ASOs were 
able to cause IR exon 11 skipping, no ASO was identified which could enhance 
exon 11 inclusion.  
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The use of ASO technology for both experimental and therapeutic purposes relies 
on specific ASO binding. ASOs may cause non-specific effects by inadvertently 
binding similar sequences in other pre-mRNAs. Non-specific ASO binding may be 
minimised by designing longer ASOs, thereby reducing the chance of matches 
elsewhere in the genome. ASO may also be checked against other genomic 
sequences using web-based bioinformatics tools e.g. ‘BLAST’ (http://blast.ncbi.nlm 
.nih.gov/blast/Blast.cgi) to avoid matches.  
Are the effects of 2′-O-methyl RNA ASOs targeting the IR exon 11 specific? This 
question can be addressed in two ways. The effect of ASO scrambles, with the 
same nucleotide composition but randomly sequenced, on the splicing of the IR 
exon 11 could be tested. Alternatively the effect of ASOs targeting the IR exon 11 
on other alternatively spliced exons from different genes could be assessed. 
The aim of the following experiments was to confirm that 2′-O-methyl RNA ASOs 
effects on splicing of the IR exon 11 were targeted and specific. The prediction was 
that scramble ASOs based on effective 2′-O-methyl RNA ASOs (chapter 3.1.1) 
would have no effect on IR exon 11 splicing. 
 
Aim 









ASOs were designed using a web-based tool (www.sirnawizard.com) to scramble 
sequences. These included scrambles of the effective targeted ASOs INSR 53, 
designated INSR 53scram; ASO INSR ex2, designated INSR ex2scram and ASO 
INSR ex1+2, designated INSR ex1+2scram. A scramble sequence of the non-
effective ASO INSR ex1, designated INSR ex1scram was also constructed as a 
further control.  BLAST scans (http://blast.ncbi. nlm.nih.gov/blast/Blast.cgi) were 
carried out to confirm the absence of sequence homology. Scramble ASOs were 
transfected into HepG2 cells at a concentration of 250 nM as described in Chapter 
2 - materials and methods. Effective ASOs identified in Chapter 3.1.1 were also 
transfected as positive controls. ASOs were incubated with HepG2 cells for 48 
hours at 37oC/5% CO2. RNA was harvested and subjected to RT-PCR for the IR 
and GAPDH as a control for mRNA quantity and quality. Products were run on a 
polyacrylamide gel and radioactivity quantified using a Phosphorimager. Each 
experiment was replicated in triplicate.  
 




Figure 3.1.2.A  Scramble ASOs targeting the IR exon 11. Schematic diagram shows 
a portion of the IR pre-mRNA from exon 10 to exon 12 (not to scale).  Exon 11 and 
surrounding intronic sequences are shown. Exons are delineated by the grey shading, 
the rest of the sequence being intronic. ASOs are illustrated above the IR pre-mRNA. 
Scramble ASOs (INSR 53scram, INSR ex1scram, INSR ex2 scram, INSR ex1+2scram) 
were designed to assess ASO specificity. The dotted line schematically represents 
sequences in apposition to each other rather than a linker sequence between them. 
Cells were transfected with scramble ASOs at 250 nM. RT-PCR was carried out on the 
total RNA extracted from these cells after 48 hours.The scramble ASOs were 
transfected alongside the non-scramble ASOs; INSR 53; INSR ex1; INSR ex2 and INSR 
ex1+2 for comparison (not shown in figure). 
Figure 3.1.2.A 
 








Figure 3.1.2.B  IR exon 11 splicing in the presence of 2′-O-methyl RNA ASO 
scrambles. Polyacrylamide gel from a representative experiment showing IR isoforms 
from HepG2 cells transfected with ASOs. Each column represents a well of transfection 
with ASOs marked above the column. The left side of the figure represents the two IR 
isoforms - IR-B (exon 11 inclusion) and IR-A (exon 11 exclusion).  ASO INSR 53, INSR 
ex1, INSR ex2, INSR ex1+2 were run as positive controls. The right side of the figure 











Figure 3.1.2.C IR exon 11 splicing in the presence of 2′-O-methyl RNA ASO 
scrambles. The graph shows percentage IR-B with respect to total IR (IR-A + IR-B) 
following transfection by 2′-O-methyl ASOs and ASO scrambles at a concentration of 
250nM. Quantitative data collated from three independent replications of the experiment 
(error bars show the S.E.M.). Overall one-way repeated measures ANOVA of the 
dataset showed p<0.0001, indicating statistically significant differences between groups. 
Dunnett′s multiple comparison test was used to compare the no-oligo control versus 
ASO transfected cells: statistically significant differences were found with ASO INSR 53, 









The effect of scramble ASOs on IR exon 11 splicing is demonstrated in a 
representative gel in figure 3.1.2.B and graphically in figure 3.1.2.C providing the 
cumulative data from three replicate experiments.  
INSR 53scram, INSR ex1scram, INSR ex2scram and INSR ex1+2scram (lanes 3, 
4, 5 and 6 respectively) did not alter the proportion of IR-B following transfection. 
No differences were noted between scramble ASOs of different lengths, from 
18mers (INSR ex1scram and INSR ex2scram) to 36mers (INSR 53scram and INSR 
ex1+2scram). Positive control ASOs INSR 53, INSR ex2 and INSR ex1+2 (lanes 7, 
9, 10) all cause exon skipping while INSR ex1 (lane 8) had no overall effect, in 
keeping with previous data (Chapter 3.1.1). The data shown for ASOs INSR 53, 
INSR ex2, INSR ex1+2 and ASO INSR ex1 represents 3 separate replicates 
experiments and is separate from data shown in Figure 3.1.1.E. 
These results confirm the prediction that scramble ASOs had no effect on IR exon 
11 splicing suggesting that 2′-O-methyl RNA ASOs effects on splicing of the IR 
exon 11 were specific. Further confirmation of ASO specificity could be obtained by 
demonstrating the lack of efficacy of 2′-O-methyl RNA ASOs targeting the IR exon 
11 on other alternatively spliced genes (see Chapter 4.3 - discussion). 
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3.1.3.  Optimising the concentration of 2′-O-methyl RNA ASOs via titration. 
 
Background 
The results from Chapter 3.1.1 and 3.1.2 have confirmed that ASOs targeting the 
IR exon 11 can influence splicing and that these effects are sequence specific. Are 
these effects dose-related? Do ASOs identified to be ineffective in Chapter 3.1.1, 
remain so at varying concentrations? Below optimum concentrations, ASOs would 
have little effect on splicing and above which there may be cell toxicity.  The 
prediction was that effective ASOs would alter splicing in a dose-related manner 
while ineffective ASOs would not. 
 
Aim 
To confirm the dose-related effects on splicing of ASOs targeting the IR exon 11.  
 
Methods 
Detailed methodology is provided in Chapter 2 - materials and methods. The 
effective ASOs INSR 53 and INSR ex1+2 along with the ineffective ASO INSR ex1 
were used in this set of experiments. ASOs were reverse-transfected into HepG2 
cells at concentrations between 10-500 nM. Serial dilution using Opti-MEM I 
(Gibco/Invitrogen, Paisley, UK) were undertaken to achieve this. ASOs were 
incubated with HepG2 cells for 48 hours. Cells were assessed by microscopy. RNA 
was harvested and subjected to RT-PCR to identify the two isoforms of the IR and 








Figure 3.1.3.A  Titration of ASOs targeting the IR exon 11. Schematic diagram 
shows a portion of the IR pre-mRNA from exon 10 to exon 12 (not to scale).  Exon 11 
and surrounding intronic sequences are shown. Exons are delineated by the grey 
shading, the rest of the sequence being intronic. ASOs are illustrated above the IR pre-
mRNA.  INSR ASOs including INSR 53, INSR ex1 and INSR ex1+2 were transfected at 
increasing concentrations into HepG2 cells. RT-PCR was carried out on the total RNA 
extracted from these cells after 48 hours. 
Figure 3.1.3.A 
 










Figure 3.1.3.B  Titration of 2′-O-methyl RNA ASO INSR 53 targeting the IR exon 11. 
Polyacrylamide gel showing IR isoforms from cells transfected with increasing 
concentrations of ASO INSR 53 (10-250 nM). IR-B (exon 11 inclusion) and IR-A (exon 
11 exclusion) marked in the figure relate to the insulin receptor isoforms (left-side), not 
GAPDH. The ASO INSR ex1+2 was run as a positive control. The right side of the figure 








Figure 3.1.3.C  Titration of 2′-O-methyl RNA ASO INSR ex1 targeting the IR exon 
11. Polyacrylamide gel showing IR isoforms from cells transfected with increasing 
concentrations of ASO INSR ex1 (10-250 nM). IR-B (exon 11 inclusion) and IR-A (exon 
11 exclusion). The right side of the figure represents GAPDH run as a control for mRNA 
quantity and quality.  
Figure 3.1.3.C 
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Figure 3.1.3.D  Titration of 2′-O-methyl RNA ASO INSR ex1+2 targeting the IR exon 
11. Polyacrylamide gel showing IR isoforms from cells transfected with increasing 
concentrations of ASO INSR ex1+2 (10-500 nM). IR-B (exon 11 inclusion) and IR-A 
(exon 11 exclusion). The right side of the figure represents GAPDH run as a control for 
mRNA quantity and quality.  
Figure 3.1.3.D 
 






Figure 3.1.3.E Titration of 2′-O-methyl ASOs targeting the IR exon 11.The graph 
shows percentage IR-B with respect to total IR (IR-A + IR-B) following transfection by 
increasing concentrations  (0-250nM) of ASOs INSR 53, INSR ex1 and INSR ex1+2. 
Quantitative data from 3 replicate experiments. IR exon 11 skipping increased with 
increasing concentration of ASO INSR 53 and INSR ex1+2. INSR ex1+2 appear more 
potent than INSR 53 ASO for a given concentration. INSR ex1 had no significant effect 
on IR exon 11 splicing.  
Figure 3.1.3.E 
 




This set of experiments investigated the dose-response relationship of ASOs 
targeting the IR exon 11. The concentration of ASOs transfected into HepG2 cells 
was between 10 nM to 500 nM. At these concentrations there was no evidence of 
cellular death, as shown by unchanged GAPDH expression, or upon light 
microscopy. Cumulative data for the three ASOs assessed is represented 
graphically in figure 3.1.3.E. With increasing concentrations of effective ASOs INSR 
53 (figure 3.1.3.B) and INSR ex1+2 (figure 3.1.3.D), an increase in IR exon 11 
skipping was noted. The graph does demonstrate that at 250nM concentration, 
INSR53 has not reached its maximum effect as the curve has yet to plateau. 
However for a given concentration, INSR ex1+2 appears more potent than INSR 
53. The ASO INSR ex1, previously noted to be ineffective at altering IR exon 11 
splicing, was ineffective at all transfection concentrations (figure 3.1.3.C). This 
confirms the lack of effect of INSR ex1 on IR exon 11 splicing was not a dose-
related effect. In keeping with the prediction these results demonstrate that ASOs 
known to alter the IR exon 11 splicing, do so in a dose-dependent manner. ASOs 
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3.1.4  Assessment of ASO cellular localisation using fluorescein-tagging.  
 
Background 
To modify pre-mRNA splicing, ASOs need to localise in the nuclear cellular 
compartment. Cationic liposomal transfection agents, such as Lipofectamine 2000 
(Gibco/Invitrogen, Paisley, UK), overcome the electrostatic repulsion between the 
net negatively charged ASO and the negatively charged plasma membrane by 
forming liposomal complexes. Following cellular internalisation the ASOs, now 
within an endosomal vesicle, are released from the endosome to traverse to the 
nucleus. The exact mechanism for this process is unclear.  
Differences in cellular localisation between effective ASOs and ineffective ASOs 
may be an explanation for differences in efficacy. Therefore to further confirm the 
specificity of effective ASOs it is necessary to demonstrate a similar cellular 
localisation for both effective and ineffective (scramble) ASOs. 
Fluorescein-tagged ASOs allowed direct visualisation of cellular localisation using 
confocal microscopy. Fluorescein-tagged ASOs may also be used to assess 
transfection efficiency.    
The prediction for this set of experiments was that all equivalent ASOs transfect 
and localise in a similar manner and that both a fluorescein-tagged ASO and its 
equivalent fluorescein-tagged scramble would localise in a similar way, with a 
predominance in the cellular nuclei. 
 
Aim 
To identify the cellular localisation of transfected ASOs and confirm a similar 
cellular distribution between effective and scramble ASOs. 
 
 




ASO INSR ex1+2 and its equivalent scramble INSR ex1+2scram were labelled at 
the 5′ end with fluorescein (Dharmacon, Lafayette, CO, USA). The untagged ASO 
INSR ex2 was run as a control. ASOs were transfected into HepG2 cells at 
concentrations 250 nM and incubated for 48 hours at 37oC/5% CO2. Three hundred 
microlitres of transfected cell suspension was added to a 6 chamber slide well and 
incubated separately at 37ºC for 48 hours. The chamber wells were subjected to a 
series of PBS washes and fixation with 4% paraldehyde/PBS. Three hundred and 
fifty microlitres of a 2 µg/ml DAPI solution was added to each chamber to visualise 
the cellular nuclei. DAKO mounting media was applied, cover slips applied and 
slides were viewed with a fluorescent confocal microscope.  Further detailed 
methodology is given in Chapter 2 - materials and methods. The remaining 
transfection reactions were processed as before. RNA was harvested, subjected to 
RT-PCR and run on a polyacrylamide gel to identify the 2 isoforms of the IR and 
GAPDH as a control for mRNA quantity and quality. Relevant bands were identified 
and quantified using a Phosphorimager.  
 









Figure 3.1.4.A  Fluorescein tagged ASOs targeting the IR  exon 11. Schematic 
diagram shows a portion of the IR pre-mRNA from exon 10 to exon 12 (not to scale).  
Exon 11 and surrounding intronic sequences are shown. Exons are delineated by the 
grey shading, the rest of the sequence being intronic. ASOs are illustrated above the IR 
pre-mRNA.  ASOs INSR ex1+2 and INSR ex1+2 scram were tagged with fluoroscein. 
Cells were transfected with ASOs at 250 nM. A proportion of the transfection reaction 
was transferred to a 6 well chamber slide for fluorescent microscopy. RT-PCR was 
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Figure 3.1.4.B Fluorescein-tagged 2′-O-methyl ASOs targeting the IR exon 11. 
Polyacrylamide gel showing IR isoforms from cells transfected with ASO INSR  ex1+2flu 
and INSR ex1+2flu scram. ASO INSR ex2 was transfected as a positive control. IR-B 
(exon 11 inclusion) and IR-A (exon 11 exclusion) are shown. GAPDH was run as a control 








Figure 3.1.4.C Fluorescein-tagged 2′-O-methyl ASOs targeting the IR exon 11. 
The graph shows percentage IR-B with respect to total IR (IR-A + IR-B) following 
transfection by ASOs INSR ex1+2flu; INSR ex1+2flu scram and INSR ex2 at a 
concentration of 250nM.  Quantitative data from one experiment. ASO INSR ex1+2flu 
was more effective at causing exon 11 skipping than INSR ex1+2. INSR ex1+2flu 

















































Figure 3.1.4.D Fluorescein-tagged 2′-O-methyl ASOs targeting the IR 
exon 11. Fluorescein was tagged to ASO INSR ex1+2flu and INSR ex1+2flu 
scram. DAPI staining identified cellular nuclei (right column). ASOs localised 
to cytoplasmic inclusions and the nucleus. ASOs and scramble ASOs were 
distributed equally. INSR ex2, a control without a fluorescein tag showed no 
luminescence. 
 
INSR ex1+2 flu 
Figure 3.1.4.D 
INSR ex1+2scram flu 
INSR ex2 
 




Figure 3.1.4.B shows a polyacrylamide gel which confirms the efficacy of the ASO 
INSR ex1+2flu (lane 3) in comparison to the no oligo control (lane 2). The scramble 
ASO INSR ex1+2flu scram (lane 4) appears to have a minimal effect on the splicing 
of the IR exon 11 but in the context of an experiment not repeated in triplicate 
(figure 3.1.4.C). The fluorescein-tagged ASO INSR ex1+2flu was more effective at 
causing IR exon 11 skipping (IR-B <1%) than the untagged ASO INSR ex1+2 (IR-B 
4%) assessed in Chapter 3.1.1. This difference may be ascribed to the fact that the 
fluorescein-tagged ASOs were highly purified whereas the untagged ASOs were 
not. Fluorescein-tagged ASOs may therefore have appeared more potent at a 
given concentration than the non-tagged equivalent. An alternative explanation is 
that some inherent property of the fluorescein tag increases transfection efficiency, 
or that the fluorescein increases the exon-skipping effect of the ASO.   
Figure 3.1.4.D demonstrates that the fluorescein-tagged ASO INSR ex1+2flu was 
localised both in the cytoplasm and more intensely in the nuclei (figure 3.1.4.D - top 
row). Scramble ASO INSR ex1+2flu scram localised in an identical pattern (figure 
3.1.4.D - middle row) despite being ineffective at altering IR exon 11 splicing. 
Difference in efficacy between effective ASOs and ineffective ASOs are therefore 
not related to differences in cellular localisation. 
This set of experiments confirms the prediction that the effective exon-skipping 
ASOs localise in identical patterns, with predominance in nuclei, to those which are 
ineffective in causing exon skipping. ASO localisation is independent of the effects 
these ASOs have on IR exon 11 splicing. 
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 3.1.5  TOES ASOs targeting the IR exon 11. 
 
Background 
Previous experiments from this chapter had shown the ability of ASOs to cause IR 
exon 11 skipping. No ASO tested to this point had demonstrated the ability to 
increase exon 11 inclusion. To achieve this, an adjunct to the current approach was 
the addition of ‘non-complimentary’ tail sequences designed to enhance the 
splicing process by various means. ‘Tailed oligonucleotide enhancement of splicing’ 
or TOES ASOs consist of an ASO complementary to a chosen sequence and a 
non-complementary tail mimicking an ESE sequence, designed with the intention of 
recruiting enhancing SR proteins. This approach has been used successfully both 
in vitro and in vivo (Owen et al. 2011; Skordis et al. 2003). SMN1 defects are 
known to cause the disease spinal muscular atrophy. The paralogous gene, SMN2 
encodes transcripts which do not include exon 7 leading to an unstable SMN 
protein (Khoo et al. 2009). In the above studies TOES ASOs were designed to bind 
to SMN2 pre-mRNA and to recruit enhancing splicing factors (ASF/SF2) to exon 7 
(Owen et al. 2011; Skordis et al. 2003). This approach was able to successfully 
increase exon 7 inclusion, leading to restoration of SMN protein function in cells 
derived from patients with spinal muscular atrophy. It was therefore reasoned that a 
similar approach might be able to increase the inclusion of IR exon 11.   
 
Aim  









TOES ASOs were designed with a 2′-O-methyl RNA ASO base as used in earlier 
experiments (figure 3.1.5.A). Sequences are given in Chapter 6.1 - appendix. The 
ASO was targeted to the 5′ end of the IR exon 11 on the basis of experiments from 
Chapter 3.1.1. This portion of exon 11 appeared to have a neutral effect on the 
splicing of the exon when targeted and would therefore not be expected to inhibit 
exon 11 inclusion. The ESE tail sequence was identical to that used in the rescue 
of exon 7 in SMN2 (Skordis et al. 2003). Tails were added to either to the 3′ or 5′ 
end of the ASO. An ESE tail, unattached to an ASO, was transfected as a control.  
TOES ASOs were reverse-transfected into HepG2 cells using Lipofectamine 2000 
(Gibco/Invitrogen, Paisley, UK) at varying concentration according to the standard 
protocol provided in Chapter 2 - materials and methods. ASO INSR ex1+2 was 
used as a positive control.  HepG2 cells were incubated 48 hours under standard 
conditions.  RNA was subsequently harvested and subjected to RT-PCR to identify 
the 2 IR isoforms and GAPDH as a control for mRNA quality and quantity. Products 
were run on a polyacrylamide gel and the radioactivity from each sample quantified 
using a Phosphorimager. Experiments were repeated in triplicate.  
 
 






Figure 3.1.5.A  TOES ASOs targeting the IR exon 11. Schematic diagram shows a 
portion of the IR pre-mRNA from exon 10 to exon 12 (not to scale).  Exon 11 and 
surrounding intronic sequences are shown. Exons are delineated by the grey shading 
and black characters, the rest of the sequence being intronic. TOES ASOs are 
illustrated above the IR pre-mRNA with grey shadowing and white characters.  TOES 
ASOs, 18 nucleotides long, were designed to block the 5′ half of exon 11. A tail, 23 
nucleotides long, simulating an exonic splicing enhancer sequence (ESE), was 
attached either to the 3′ or the 5′ end of the ASO designated INSR TOES ex1 3′ tail or 
INSR TOES ex1 5′ tail respectively. The ESE tail sequence, unattached to a 2′-O-
methyl RNA sequence, designated INSR TOES tail only, was transfected into cells as 
a control.  Cells were transfected with ASOs at 250 nM concentration. RT-PCR was 













Figure 3.1.5.B TOES ASOs targeting the IR exon 11. Polyacrylamide gel from a 
representative experiment showing IR isoforms from HepG2 cells transfected with 
ASOs at 250 nM concentration. Each column represents a well of transfection with 
ASOs marked above the column. The left side of the figure represents the two IR 
isoforms - IR-B (exon 11 inclusion) and IR-A (exon 11 exclusion). The right side of the 
figure represents GAPDH which was run as a control for mRNA quantity and quality.  
Figure 3.1.5.B 
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Figure 3.1.5.C TOES ASOs targeting the IR exon 11. The graph shows percentage 
IR-B with respect to total IR (IR-A + IR-B) following  transfection by TOES molecules at 
a concentration of 250nM. Quantitative data from three independent replications of the 
experiment (error bars show the S.E.M.). Overall one-way repeated measures ANOVA 
of the dataset showed p<0.0001, indicating statistically significant differences between 
groups. Dunnett’s multiple comparison test was used to compare the no oligo control 
versus TOES transfected cells. The TOES molecules had no effect on splicing in 
contrast to the ASO INSR ex1+2. 
Figure 3.1.5.C 
 




The representative gel in figure 3.1.5.B demonstrates that the TOES ASOs 
designed to target the IR exon 11 do not enhance exon inclusion (compare lane 2 
with lanes 3 and 4).  No effect was noted with increasing concentration of TOES 
ASOs between 250-1000 nM (data not shown). The positive control, ASO INSR 
ex1+2 (lane 6) continued to cause IR exon 11 skipping, confirming transfection had 
occurred (figure 3.1.5.C). The position of the tail, at the 3′ or 5′ end of the ASO, did 
not influence the degree of exon 11 inclusion. The ESE tail transfected alone (lane 
5) did not alter splicing.  A TOES ASO targeting the 3′ end of the IR exon 11 was 
not studied.  
A previous study noted a TOES ASO increased inclusion of exon 7 in the SMN2 
transcript in vivo from 57% inclusion up to 84% inclusion. This affect was initially 
noted at a 100 nM concentration (Skordis et al. 2003). The aim, to increase IR exon 
11 inclusion using a tailed-oligonucleotide localising an additional enhancer 












PNA and PNA-peptide hybrid antisense oligonucleotides 
targeting the insulin receptor exon 11
 




3.2.1  PNA ASO targeting the IR exon 11 
 
Experiments in Chapter 3.1 demonstrated that 2′-O-methyl RNA ASOs targeting 
key intronic and exonic sites around the IR exon 11 were unable to stimulate exon 
11 inclusion. 18mer 2′-O-methyl RNA ASOs may have been too long to target 
silencer regions in isolation within exon 11, which may have facilitated exon 
inclusion. An alternative strategy was employed to target shorter regions within 
exon 11. This required the use of different oligonucleotide chemistry. Peptide 
nucleic acids are synthetic DNA-like compounds which substitute the DNA 
phosphodiester backbone for a pseudopeptide backbone ((N-(2-
aminoethyl)glycine). A methylene carbonyl link binds the nucleotide bases to this. 
PNA ASOs have several advantages over earlier oligonucleotides chemistries. 
These included increased stability due to the non-charged peptide backbone as 
well as resistance to breakdown by nucleases and peptidase. They also 
demonstrate increased binding specificity and affinity for their targets (Egholm et al. 
1993; Jensen et al. 1997). The increased stability that PNA ASOs offered allowed 
smaller targets within exon 11 to be pursued. The chemistry was also chosen as it 
formed the basis of PNA-peptide hybrid molecules which were to be used to 
attempt exon 11 inclusion in subsequent work (Chapter 3.3). 
The prediction was that targeting shorter regions of the IR exon 11 would target 
enhancer or silencer regions more precisely. Shorter (12mer) PNA ASOs targeting 
the 5′, 3′ and central regions of the IR exon 11 would cause either IR exon 11 
inclusion or skipping. 
 
Aim 
To assess the effects of PNA ASOs targeting the IR exon 11. 
 





PNA ASOs, 12 nucleotides in length were designed to target the 36 nucleotides of 
the IR exon 11. The PNA targeting the 12 nucleotides at the 5′  end of exon 11 was 
designated INSR PNA ex4, the PNA ASO targeting the middle 12 nucleotides was 
designated INSR PNA ex5 and the 12 nucleotides at the 3′  end was designated 
INSR PNA ex6. PNA ASOs were produce by Bio-Synthesis Inc (Texas, U.S.A). 
PNA ASOs were reverse-transfected into HepG2 cells for 48 hours as per the 
previously detailed methodology (Chapter 2 - materials and methods). PNA ASOs 
were transfected at a concentration of 250 nM initially. The 2′-O-methyl RNA ASO, 
INSR ex2 was transfected as a positive control. Following RNA harvest, RT-PCR 
was carried out with primers identifying the 2 isoforms of the IR and GAPDH. 
Products were then run on a polyacrylamide gel.  
 








Figure 3.2.1.A  PNA ASOs targeting the IR exon 11. Schematic diagram shows a 
portion of the IR pre-mRNA from exon 10 to exon 12 (not to scale).  Exon 11 and 
surrounding intronic sequences are shown. Exons are delineated by the grey 
shading, the rest of the sequence being intronic. PNA ASOs are illustrated above the 
IR pre-mRNA.  PNA ASOs, 12 nucleotides long, were designed to block a third each 
of exon 11. INSR PNA ex4 covered the 5′ end of exon 11, INSR PNA ex5, the 
middle 12 nucleotides and INSR PNA ex6 covered the 3′ end of exon 11. Cells were 
transfected with ASOs at 250 nM concentration. RT-PCR was carried out on the 
total RNA extracted from these cells after 48 hours. 
 




Figure 3.2.1.B  PNA ASOs targeting the IR exon 11. Polyacrylamide gel 
showing IR isoforms from cells transfected with PNA molecules at 250 nM; INSR 
PNA ex4; INSR PNA ex5 and INSR PNA ex6. INSR ex2 was run as a positive 
control. IR-B (exon 11 inclusion) and IR-A (exon 11 exclusion) are shown on the 
left side of the figure. GAPDH was run as a control for mRNA quantity and quality.  
Figure 3.2.1.B 
 









Figure 3.2.1.C PNA ASOs targeting the IR exon 11. The graph shows percentage 
IR-B with respect to total IR (IR-A + IR-B) following transfection by PNA ASOs at a 
concentration of 250nM. Quantitative data from three independent replications of the 
experiment (error bars show the S.E.M.). Overall one-way repeated measures ANOVA 
of the dataset showed p<0.0001, indicating statistically significant differences between 
groups. Dunnett’s multiple comparison test was used to compare the no-oligo control 
versus PNA molecule transfected cells. The PNA molecules were not effective at 









Figure 3.2.1.B shows a representative gel following transfection of INSR PNA ex4, 
ex5 and ex6 into HepG2 cells at a 250 nM concentration for 48 hours and the graph 
in figure 3.2.1.C represents the results of experiments completed in triplicate. 
These show that PNA ASOs targeting consecutive 12 nucleotide stretches of the IR 
exon 11 have no effect on the splicing (compare no oligo in lane 2 with PNA INSR 
ex4, ex5 and ex6 in lanes 3, 4 and 5 respectively). The positive control INSR ex2 
maintains its effect on IR exon 11 splicing. These results are against the prediction 
that 12mer PNA ASOs would cause either IR exon inclusion or skipping. They do 
not support the prediction that PNA ASOs can more precisely target enhancer or 
silencer regions within the exon. Several explanations may be postulated for these 
findings: firstly, inadequate concentration of PNA ASO; secondly, poor transfection 
efficiency results in failure to bind the appropriate sites; thirdly, failure to block key 
splicing interaction e.g. with the spliceosome and finally, simultaneous blocking of 
competing enhancer and silencer sites in exon 11. 
 




3.2.2  PNA ASOs targeting an equivalent sequence to ASO INSR ex2 in the IR 
exon 11 - Are the effects equivalent? 
 
Background 
Data from Chapter 3.2.1 has shown that PNA ASOs targeting the IR exon 11 do not 
alter its splicing. This was an unexpected finding given that some of the 2′-O-methyl 
RNA ASOs targeting exon 11 did alter splicing. The PNA ASOs tested however 
were not directly comparable to the 2′-O-methyl RNA ASOs with respect to the 
sequences they targeted.  It was therefore necessary to confirm whether PNA 
ASOs and equivalent 2′-O-methyl RNA ASOs have the same effects on splicing.  
The specific prediction was that PNA ASOs and 2′-O-methyl RNA ASOs had 
equivalent effects on splicing and that a PNA ASO targeting the same sequence in 
the IR exon 11 as the 2′-O-methyl ASO INSR ex2 would cause exon 11 skipping. 
 
Aim 
To confirm the similar effects of PNA ASOs and 2′-O-methyl ASO targeting the 
same sequence on IR exon 11 splicing. 
 
Methods 
A PNA ASOs, designated PNA INSR ex2 (18mer) was designed to target the same 
sequence as the 2′-O-methyl ASO INSR ex2 (figure 3.2.2.A and Chapter 6.1 - 
appendix). PNA INSR ex2 (18mer) was specifically designated ‘18mer’ to avoid 
confusion with another PNA ASO designated PNA INSR ex2. PNA INSR ex2 
formed the basis for a PNA-peptide hybrid molecule tested subsequently which 
targeted the same sequence as PNA INSR ex2 (18mer) except the 3 nucleotides at 
the 3′ end of exon 11 and was therefore a 15 mer. A scramble sequence of PNA 
 




INSR ex2 (18mer) was constructed as a further control and designated PNA INSR 
ex2scram (18mer). 
PNA INSR ex2 (18mer) and PNA INSR ex2scram (18mer) were transfected at a 
concentration of 250 nM in HepG2 cells for 48 hours according to the standard 
protocol as detailed in Chapter 2 - materials and methods. The 2′-O-methyl ASO 
INSR ex2 was transfected as a positive control. Following RNA harvest and RT-
PCR using primers to identify the IR isoform and GAPDH, products were run on a 













Figure 3.2.2.A  PNA ASOs targeting an equivalent sequence to ASO INSR ex2 in 
the IR exon 11. Schematic diagram shows a portion of the IR pre-mRNA from exon 10 
to exon 12 (not to scale).  Exon 11 and surrounding intronic sequences are shown. 
Exons are delineated by the grey shading, the rest of the sequence being intronic. PNA 
ASOs are illustrated above the IR pre-mRNA.  PNA ASOs, 18 nucleotides long, were 
designed to block the 3′ half of exon 11, designated INSR PNA ex2 (18mer). A 
scramble control sequence designated INSR PNA ex2scram (18mer) was also 
designed. Cells were transfected with ASOs at 250 nM concentration. RT-PCR was 
carried out on the total RNA extracted from these cells after 48 hours.  
 




Figure 3.2.2.B  PNA ASOs targeting an equivalent sequence to ASO INSR ex2 in 
the IR exon 11. Polyacrylamide gel from a representative experiment showing IR 
isoforms from HepG2 cells transfected with PNA ASOs. Each column represents a 
well of transfection with the ASO marked above the column. The left side of the figure 
represents the two IR isoforms - IR-B (exon 11 inclusion) and IR-A (exon 11 
exclusion). 2′-O-methyl RNA ASO INSR ex2 was run as a positive control. GAPDH 









Figure 3.2.2.C PNA ASOs targeting an equivalent sequence to ASO INSR ex2 in 
the IR exon 11.The graph shows percentage IR-B with respect to total IR (IR-A + IR-
B) following transfection by ASOs in HepG2 cells at a concentration of 250 nM. 
Quantitative data from three independent replications of the experiment (error bars 
show the S.E.M.). Overall one-way repeated measures ANOVA of the dataset 
showed p<0.0001, indicating statistically significant differences between groups. 
Dunnett’s multiple comparison test was used to compare the no-oligo control versus 
ASO transfected cells: statistically significant differences were only found between 
the no oligo control transfected cells and  the positive control ASO INSR ex2.  
Figure 3.2.2.C 
 





Figure 3.2.2.B shows a representative gel from experiments involving the 
transfection of PNA INSR ex2 (18mer) and PNA INSR ex2scram (18mer). Graph 
3.2.2.C shows the cumulative results of 3 replicate experiments. At a concentration 
of 250 nM, neither PNA INSR ex2 (18mer) (figure 3.2.2.B lane 3) or PNA INSR 
ex2scram (18mer) (lane 4) had any significant effect on IR exon 11 splicing in 
comparison to the no oligo transfected cells (lane 1). This is also in comparison to 
the positive control INSR ex2 (lane 2) which caused significant exon 11 skipping. 
Other PNA molecules had been transfected up to a concentration of 1 µM without 
demonstrating an effect on splicing. (Chapter 3.2.3 and 3.2.4).  
These findings contradict the prediction that equivalent PNA ASOs and 2′-O-methyl 
RNA ASOs would have similar effect on splicing of the IR exon 11. Despite 
targeting the same sequences, assumptions can not be made about the effects of 









3.2.3  PNA-peptide hybrid ASOs targeting the 5′  end of the IR exon 11. 
 
Background 
Results from Chapters 3.1 and 3.2 have shown that neither 2′-O-methyl RNA 
ASOs, TOES ASOs or PNA ASOs are able to increase IR exon 11 inclusion. An 
alternative strategy to achieve this was the use of PNA-peptide hybrid ASOs to 
enhance exon 11 splicing.  PNA-peptide hybrids ASOs or ‘ESSENCE’ (exon 
specific splicing enhancement by small chimeric effectors) are ASOs with 
arginine/serine tails simulating the RS domain of splicing enhancers. These 
compounds have been used in various models to correct aberrant splicing including 
the rescue of SMN2 exon 7, BRCA exon and Bcl-2 (Cartegni et al. 2003; Wilusz et 
al. 2005).   Exon inclusion is mediated in two ways. The PNA ASO may bind and 
block a cis-acting inhibitory site resulting in enhanced splicing. Secondly a tail 
consisting of ten arginine serine repeats, mimicking the RS domain of an SR 
protein, tails the antisense portion of the molecule and should recruit relevant 
enhancing splicing factors and the spliceosome to the exon thereby enhancing 
splicing. This approach has been adapted in this study to enhance the splicing of 
the IR exon 11. 
The specific prediction for these experiments was that modified ASOs (PNA-
peptide hybrid ASOs) with the ability to recruit and interact with splicing factors 
and/or the spliceosome would enhance exon 11 splicing.  
 





To assess the ability of PNA-peptide hybrid ASOs to enhance exon 11 inclusion by 
targeting its 5′ end. 
 
Methods 
In the published studies the PNA ASO targets inhibitory sites resulting in the 
enhancement of splicing even in the absence of an RS tail (Cartegni et al. 2003). 
No inhibitory sites had been identified within exon 11 so a neutral region was 
targeted instead. Chapter 3.1 demonstrated that ASO INSR ex1 targeting the 5′ 
half of exon 11 had no effect on splicing. This region was therefore targeted with 
15mer PNA ASO targeting nucleotides 4 - 18 of exon 11. The first 3 nucleotides of 
exon 11 were not targeted on the basis that this may hinder the 3′ splice site 
recognition by the spliceosome and hinder the splicing process. The arginine/serine 
tail (10 repeats) was attached to the PNA ASO via a glycine-glycine linker. Two 
PNA-peptide hybrid ASOs were constructed with the RS domain tail at either the 3′ 
end of the molecule or the 5′ end (figure 3.2.3.A) designated INSR PNA ex1 3′ tail 
and INSR PNA ex1 5′ tail respectively. Additional compounds where constructed to 
serve as controls and these included the PNA ASO alone, designated INSR PNA 
ex1 and the RS domain tail with the glycine-glycine linker alone, designated INSR 
PNA tail only. PNA-peptide hybrids were manufactured by Bio-Synthesis (Texas, 
U.S.A). 
PNA-peptide hybrid ASOs were reverse-transfected into HepG2 cells at various 
concentrations for 48 hours as per the detailed methodology given in Chapter 2 - 
materials and methods. The 2′-O-methyl RNA ASO, INSR ex2 was transfected as a 
positive control along with the other controls. RNA was subsequently harvested and 
subjected to RT-PCR. PCR primers identified the 2 isoforms of the IR and GAPDH 
 




which was run as a control for mRNA quantity and quality. Products were run on a 





Figure 3.2.3.A  PNA-peptide hybrid ASOs targeting the 5′ end of IR exon 11.  
Schematic diagram shows a portion of the IR pre-mRNA from exon 10 to exon 12 (not to 
scale).  Exon 11 and surrounding intronic sequences are shown. Exons are delineated 
by the grey shading and black characters, the rest of the sequence being intronic. PNA-
peptide hybrid ASOs are illustrated above the IR pre-mRNA with black shadowing and 
white characters.  The PNA backbone was 15 nucleotides long binding the 5′ end of 
exon 11 after the 3 nucleotides next to the intron/exon border. A tail with 10 arginine 
serine (RS) repeats connected by a glycine-glycine link was attached either to the 3′ end 
of the PNA, designated INSR PNA ex1 3′ tail or the 5′ end of the PNA designated INSR 
PNA ex1 5′ tail. Both the arginine/serine tail alone (INSR PNA tail only) and the PNA 
alone (INSR PNA ex1) were transfected separately as controls. Cells were transfected 
with ASOs at varying concentrations. RT-PCR was carried out on the total RNA 
extracted from these cells after 48 hours. 
Figure 3.2.3.A 
 







Figure 3.2.3.B PNA-peptide hybrid ASOs (5′ tail) targeting the 5′ end of IR exon 
11. Polyacrylamide gel showing IR isoforms from cells transfected with INSR PNA ex1 
with peptide tails at varying concentrations. ASO INSR ex2 was used as a positive 
control. IR-B (exon 11 inclusion) and IR-A (exon 11 exclusion) are shown. GAPDH 









Figure 3.2.3.C  PNA-peptide hybrid ASOs (5′ tail) targeting the 5′ end of IR exon 
11. The graph shows percentage IR-B with respect to total IR (IR-A + IR-B) following 
transfection at varying concentrations (0-1µM). Quantitative data from three 
independent replications of the experiment (error bars show the S.E.M.). Overall one-
way repeated measures ANOVA of the dataset showed p<0.0001, indicating 
statistically significant differences between groups. Dunnett′s multiple comparison test 
was used to compare the no oligo control versus PNA ASO transfected cells. The 
PNA - peptide hybrid ASO (5′ tail) showed a statistically significant reduction in the 









Figure 3.2.3.D PNA-peptide hybrid ASOs (3′ tail) targeting the 5′ end of IR exon 
11. Polyacrylamide gel showing IR isoforms from cells transfected with INSR PNA ex1 
3′ tails at varying concentrations. ASO INSR ex2 was used as a positive control. IR-B 
(exon 11 inclusion) and IR-A (exon 11 exclusion) are shown. GAPDH was run as a 
control for mRNA quantity and quality.  
Figure 3.2.3.D 
 






Figure 3.2.3.E  PNA-peptide hybrid ASOs (3′ tail) targeting the 5′ end of IR exon 
11. The graph shows percentage IR-B with respect to total IR (IR-A + IR-B) following 
transfection at varying concentrations (0-1µM). Quantitative data from three 
independent replications of the experiment (error bars show the S.E.M.). Overall one-
way repeated measures ANOVA of the dataset showed p<0.0001, indicating 
statistically significant differences between groups. Dunnett’s multiple comparison test 
was used to compare the no-oligo control versus PNA molecule transfected cells. The 
PNA-peptide hybrid ASOs all showed a statistically significant reduction in the 









The data presented in the gel (figure 3.2.3.B) and graphically in figure 3.2.3.C 
represents triplicate experiments using PNA-peptide hybrid ASO targeting the IR 
exon 11. The PNA ASO only, INSR PNA ex1, targeting the 5′ end of exon 11 
(nucleotides 4-18) had no effect on IR exon 11 splicing (compare lane 2 and lane 4) 
at a concentration of 1 µM. The arginine/serine (RS) tail (INSR PNA tail only) 
transfected into HepG2 alone had no effect on exon 11 splicing (lane 5). The 
positive control, INSR ex2, continued to cause exon 11 skipping (lane 3). ASO 
INSR PNA ex1 5′ tail unexpectedly resulted in exon 11 skipping (lane 6) which was 
significantly increased in comparison to the no oligo control (lane 2) at 1 µM 
concentration. Figure 3.2.3.D shows a polyacrylamide gel from transfection with 
increasing concentrations of INSR PNA ex1 3′ tail. Increasing doses of INSR PNA 
ex 1 3′  tail from 250 nM (lane 3) to 1 µM (lane 5) also resulted in increased IR exon 
11 skipping with a dose related reduction in the proportion of IR-B (figure 3.2.3.E) 
from  to 13% to 6.6%. 
Arginine/serine tails placed at either end of INSR PNA ex1 appeared to cause IR 
exon 11 skipping (compare 5′ tail - figure 3.2.3.B lane 7 and 3′ tail - 3.2.3.D lane 5). 
At equivalent concentrations, molecules with 3′ tails appeared to cause more exon 
skipping that those with 5′ tails (unpaired t test p= 0.0142). 
2′-O-methyl RNA ASOs were more potent i.e. more efficacious at a lower 
concentration, compared with the PNA-peptide hybrid ASOs.  For an equivalent 
effect on splicing, the concentration of INSR PNA ex1 3′  tail was 1 µM in 
comparison to 250 nM for the 2′-O-methyl RNA ASOs INSR ex2 (figure 3.2.3.D 
compare lanes 5 and 6). 
Given that the tail sequence should provide a stimulus to enhancer splicing factors 
the PNA-peptide hybrid ASOs would be expected to enhance the IR exon 11 
 




inclusion. On the basis of this evidence here modified ASOs with associated 
enhancer tails do not facilitate exon inclusion in the context of the IR exon 11. 








3.2.4  PNA-peptide hybrid targeting the 3′ end of the IR exon 11. 
 
Background 
The PNA-peptide hybrid ASOs, INSR PNA ex1 3′ or 5′ tail unexpectedly enhanced 
skipping of the IR exon 11 (Chapter 3.2.3). Despite PNA ASO targeting a neutral 
region of exon 11 (5′ end) and the theoretically splicing enhancer characteristics of 
an RS domain tail. To rule out the possibility that these effects were positional a 
further set of PNA-peptide hybrid ASOs were assessed. These targeted the 3′ end 
of exon 11. Though INSR ex2 caused exon 11 skipping and this further PNA-
peptide hybrid ASO was to target a similar region, results from Chapter 3.2.2 
demonstrate that the PNA INSR ex2 (18mer) had no effect on splicing. 
The prediction was that the PNA-peptide hybrid ASO targeting the IR exon 11 with 
an enhancer tail sequence would increase its splicing. PNA-peptide hybrid 
molecules targeted the 3′ end of IR exon 11 with either a 3′ or a 5′ RS domain tails.  
 
Aim 
To assess the ability of PNA-peptide hybrid ASOs to enhance exon 11 inclusion by 
targeting its 3′ end. 
 
Methods 
The PNA-peptide hybrid targeting the 3′ end of exon 11 were manufactured by Bio-
Synthesis (Texas, U.S.A). Essentially the PNA was a 15mer ASO targeting 
nucleotides 19 - 33 of the IR exon 11. The last 3 nucleotides of exon 11 were not 
targeted on the basis that this may hinder the 5′ splice site recognition by the 
spliceosome. The arginine/serine tail (10 repeats) was attached to the PNA ASO 
via a glycine-glycine linker. Two PNA-peptide hybrid ASOs were constructed with 
 




the RS domain tail at either the 3′ end of the molecule or the 5′ end (figure 3.2.4.A) 
designated INSR PNA ex2 3′ tail and INSR PNA ex2 5′ tail respectively. Additional 
compounds where constructed to serve as controls and included the PNA ASO 
alone designated INSR PNA ex2 and the RS domain tail with the glycine-glycine 
linker alone designated PNA tail only. INSR PNA ex2 was a 15mer and is 
differentiated from the 18mer - INSR PNA ex2 (18mer) used in Chapter 3.2.2.  
PNA-peptide hybrid ASOs were then transfected into HepG2 cells at varying 
concentrations for 48 hours as per the previously detailed methodology (Chapter 2 
- materials and methods). The 2′-O-methyl RNA ASO, INSR ex2 was transfected 
as a positive control.  RNA was subsequently harvested and subjected to RT-PCR. 
PCR primers allowed identification of the 2 isoforms of the IR and GAPDH as a 
control for RNA quantity and quality. Products were run on a polyacrylamide gel. 
Each experiment was replicated in triplicate.  
Table 3.2.4.A provides replicate data of transfections involving ASO INSR ex2 from 
multiple experiments in previous chapters.  
 








Figure 3.2.4.A  PNA-peptide hybrid ASOs targeting the 3′ end of the IR exon 11. 
Schematic diagram shows a portion of the IR pre-mRNA from exon 10 to exon 12 (not 
to scale).  Exon 11 and surrounding intronic sequences are shown. Exons are 
delineated by the grey shading and black characters, the rest of the sequence being 
intronic. PNA-peptide hybrid ASOs are illustrated above the IR pre-mRNA with black 
shadowing and white characters.  The PNA backbone was 15 nucleotides long binding 
the 3′ end of exon 11 beyond the 3 nucleotides next to the intron/exon border. A tail 
with 10 arginine/serine (RS) repeats attached by a glycine-glycine link was attached 
either to the 3′ end of the PNA, designated INSR PNA ex2 3′ tail or the 5′ end of the 
PNA designated INSR PNA ex2 5′ tail. Both the arginine/serine tail alone (INSR PNA 
tail only) and the PNA alone (INSR PNA ex2) were transfected separately as controls. 
The ASO PNA ex2 (15mer) used in these hybrid ASOs was different to PNA INSR ex2 
(18mer). Cells were transfected with ASOs at varying concentrations. RT-PCR was 
carried out on the total RNA extracted from these cells after 48 hours. 
Figure 3.2.4.A 
 







Figure 3.2.4.B PNA-peptide hybrid ASOs (3′ and 5′ tails) targeting the 3′ end of 
IR exon 11. Polyacrylamide gel showing IR isoforms from cells transfected with INSR 
PNA ex2 with RS domain tails and associated controls (no oligo, INSR PNA ex2 only, 
PNA tail only). ASO INSR ex2 was used as a positive control. IR-B (exon 11 inclusion) 
and IR-A (exon 11 exclusion) are shown. GAPDH was run as a control for RNA quality 
and quantity.  
Figure 3.2.4.B 
 




Figure 3.2.4.C  PNA-peptide hybrid ASOs (3′ and 5′ tail) targeting the 3′ end of IR 
exon 11. The graph shows percentage IR-B with respect to total IR (IR-A + IR-B) 
following transfection at varying concentrations (0-1µM). Quantitative data from three 
independent replications of the experiment (error bars show the S.E.M.). Overall one-
way repeated measures ANOVA of the dataset showed p<0.0001, indicating 
statistically significant differences between groups. Dunnett’s multiple comparison test 
was used to compare the no-oligo control versus PNA molecule transfected cells. The 









Figure 3.2.4.D  PNA-peptide hybrid ASOs targeting the IR exon 11 - summary. 
The graph shows percentage IR-B with respect to total IR (IR-A + IR-B) following 
transfection at varying concentrations (0-1µM). Summary data for all PNA-peptide 
hybrid ASOs (error bars show the S.E.M.). Overall one-way repeated measures 
ANOVA of the dataset showed p<0.0001, indicating statistically significant differences 
between groups. Dunnett’s multiple comparison test was used to compare the no-
oligo control versus PNA molecule transfected cells. The PNA-peptide molecules all 
showed a statistically significant reduction in the proportion of IR-B as did the positive 








Figure 3.2. 4.D 
 


























Table 3.2.4.A INSR ex2 ASO - Reproducibility.  Data shown represents 
percentage IR-B as a proportion of total IR (IR-A+IR-B) from multiple replicates of 
transfection of ASO INSR ex2 into HepG2 cells. Results are given in two sets of 
columns with no oligo control transfection given in each case. The shaded cells 
represent data from transfection using a separate batch of INSR ex2. The no oligo 
transfection gave an IR-B/(IR-A+IR-B) of 29.8% (SD+5.35). The coefficient of 
variation is 18% for the replicates. IR-B/(IR-A+IR-B) for ASO INSR ex2 is 10.3% 
(SD+3.73) with a coefficient of variation of 36%. This improves to 27% when the 
data from the second batch of ASO INSR ex2 (shaded) is removed. 
 
IR-B/(IR-A+IR-B) % 
No oligo INSR ex2 No oligo INSR ex2 
23 13 33 9 
19 6 34 9 
33 10 34 9 
25 12 30 6.4 
24 10 27 6 
44 11 28 11 
35 13 26 6 
33 6 26 7 
29 10 41 20 
28 11 29 14 
26 6 31 15 
26 7 31 12 
30 9 30 18 
 





Figure 3.2.4.B provides a representative gel from experiments involving the 
transfection of PNA-peptide hybrid ASOs targeting the 3′ end of the IR exon 11. 
Figure 3.2.4.C summarises graphically, the result of experiments carried out in 
triplicate. 
HepG2 cells which were transfected with INSR PNA ex2 only (figure 3.2.4.B lane 
12), at a concentration of 1 µM, revealed no change in the proportion of IR-B.  
Transfection with the INSR PNA tail only (lane 13), did not cause any alteration in 
the proportion of exon 11 splicing. These results are consistent with those noted in 
the previous Chapter  3.2.3.  
PNA-peptide hybrid ASOs targeting the 3′ end of exon 11 including INSR PNA ex2 
3′ tail  (lanes 14 and 16) and INSR PNA ex2 5′ tail (lanes 15 and 17) failed to 
increase exon 11 inclusion and in fact caused exon 11 skipping. This effect 
increased with increasing ASO concentration from 250 nM to 1 µM (figure 3.2.4.C). 
This replicates data from Chapter 3.2.3 relating to the effects of PNA-peptide 
hybrids targeting the 5′ half of exon 11.  
As with the PNA-peptide hybrids targeting the 5′ end of exon 11, the hybrid ASOs 
targeting the 3′ end of the exon appeared to be less potent than the 2′-O-methyl 
RNA ASOs at causing exon skipping. Equivalent effects between the compounds 
were seen when the PNA-peptide hybrids were 4 fold the concentration (1 µM) of 
the 2′-O-methyl RNA ASOs INSR ex2 (250 nM). 
At a 1 µM concentration, INSR PNA ex2 3′ tail appeared to cause a greater 
reduction in the proportion of IR-B (9.3%) compared to INSR PNA ex2 5′  tail 
(12.3%) though this difference was not statistically significant (unpaired t test p= 
0.22). 
 




Figure 3.2.4.D graphically summarises the effects of all PNA-peptide hybrid ASOs 
tested in Chapter 3.2.3 and 3.2.4. This graph emphasises the finding that all PNA-
peptide hybrid ASOs cause paradoxical IR exon 11 skipping.  There also appears 
to be an inherent strength in a 3′ tail causing more exon skipping in comparison to 
a 5′ tail in PNA-peptide hybrids ASOs. This trend was noted in both sets of PNA-
peptide ASOs tested but was significantly different in the INSR PNA ex1 3′ and 5′ 
tail transfected at a 1 µM concentration.  
 
Figure 3.2.4.C shows the fall in the proportion of IR-B to 15% due to the effect of 
the ASO INSR ex2 at a concentration of 250nM. Table 3.2.4.A provides data from 
multiple replicates of INSR ex2 transfection in HepG2 cells taken from previous 
experiments. This demonstrates a mean reduction in IR-B to 10% overall. Two 
separate batches of INSR ex2 ASO were used in these sets of experiments.   The 
latter batch of ASO INSR ex2 appeared to be less effective at causing exon 
skipping (shaded columns including data from this chapter). 
Apparent differences in the effect of two batches of the same ASO (in this case the 
ASO INSR ex2) may be ascribed to either variation in experimental conditions or 
the ASO used. Assuming identical experimental conditions, then the ‘purity’ of the 
ASO in terms of the presence of full length transcript only, sequence fidelity and the 
presence of contaminates (by-products of the synthesis process) may account for 
variable effects seen. Failure sequences (oligo sequences aborted during 
synthesis) or those with an incorrect sequence may not exert the same effects in 
cell culture as the full length correctly sequenced transcript. Contaminants used in 
the synthesis and purification process may be toxic in cell culture.  
The ASOs used were commercially acquired (Dharmacon).  Standard purification 
methods include desalting to remove the by-products of the synthesis process 
 




either using gel infiltration or ethanol precipitation. Short of re-sequencing the ASO 
to check sequence fidelity, MALDI-TOF mass spectrometry is used as a surrogate 
marker to confirm that the full length transcript has been generated. With standard 
production methods wrongly sequenced ASOs are unlikely. An 85% purity level is 
quoted for full length ASO production. Purification via HPLC (high pressure liquid 
chromatography) or PAGE (polyacrylamide gel electrophoresis) can remove failure 














2′-O-methyl RNA antisense oligonucleotides targeting 
multiple exonic silencer sequences within 









3.3   2′-O-methyl RNA ASOs targeting multiple exonic splicing silencer within 
Apolipoprotein B exon 26.  
 
Background 
The average length of an exon has been estimated at 137 nucleotides (Hawkins 
1988). Therefore, at 7,572 nucleotides, the constitutively spliced APOB exon 26 is 
unusually long.  This is in stark contrast to the short, alternatively spliced IR exon 
11 at 36 nucleotides which had been the subject of study in Chapter 3.1 and 3.2. 
There are two predominant splice site sequences to which the majority sites 
conform in canonical splicing. At the 5’ splice site it is the sequence GU and AG at 
the 3’ splice site. However there are exceptions.  A non-consensus sequence at 5’ 
splice site is the dinucleotide GC (Wu et al. 1999) though these splice sites appear 
to match well in other positions. U12 introns have different conserved sequences 
(Tarn et al. 1997). There are also other non-consensus cryptic splice sites which 
are recognised when the native splice site is inactivated without the dinucleotides 
AG or GU (Roca et al. 2003). Consensus sequences defining the 5′ and 3′ splice 
sites of these exons are highly degenerate (Shapiro et al. 1987). As a result, 
matches to these consensus sequences are highly prevalent throughout the 
genome (Fairbrother et al. 2000) and outnumber genuine splice sites by an order of 
magnitude e.g. the human HPRT gene (Sun et al. 2000). These ‘pseudo splice 
sites’ are not normally employed in splicing but it remains unclear how the 
spliceosome is able to differentiate these numerous sites from few genuine splice 
sites present. Due to its length, APOB exon 26 contains multiple pseudo splice 
sites which are not spliced.  
However further study of these pseudo splice sites using the position score matrix 
of Shapiro and Senapathy (Shapiro et al. 1987) raises a paradox. Position score 
 




matrices out of 100 provide an estimate of the likelihood of a sequence being 
identified as an exon boundary and utilised in splicing. The 3′ splice site flanking 
exon 26 scored 83.2 and the 5′ splice site scored 86.5 (combined score 169.7). 
Using the exon 26 flanking scores of 83.2 and 86.5 as thresholds, 32 3′ splice sites 
and two 5′ splice sites within exon 26 were identified as closer matches to the 
consensus with higher scores than the genuine splice sites flanking exon 26. On 
theoretical grounds, therefore, each of these pseudo splice sites could be used in 
preference to the genuine splice sites. Two possible 3′ shortened alternatives 
combining the 5′ pseudo splice sites with the 3′ splice site flanking exon 27, and 32 
possible 5′ shortened alternatives combining the 3′ pseudo splice sites with the 5′ 
splice site flanking exon 25.  
Further to this, a search was also made for plausible pseudoexons within the length 
of exon 26 using this subset of high-scoring pseudo splice sites. These were 
defined as sequences bounded by 3′ and 5′ pseudo splice sites in the right 
orientation, with lengths of 39-374 base pairs, these being the range of lengths for 
the other APOB internal exons. Using these criteria at least 3 alternative 
pseudoexons could be identified that contain pseudo splice sites that are a better fit 
to the consensus than the genuine splice sites, and which on these bioinformatic 
criteria are more plausible exons than exon 26 itself. 
This analysis raises the issue of why certain pseudo splice sites are not spliced in 
preference to the apparently weaker constitutive sites. Miriami E et al. have shown 
that latent 5’ splice site in introns have a higher frequency of associated stop 
codons in their vicinity than introns without these sites suggesting an inbuilt 
mechanism to suppress their use (Miriami et al. 2004). Another hypothesis is that 
exonic splicing silencer (ESS) sites may suppress the use of these potential 
pseudo sites.  Previous work undertaken using the in vitro heterologous splicing 
 




reporter assays DNA ligase III and ß-globin splicing reporter HßΔ6 has attempted 
to address this question. Candidate sequences, initially 400 nucleotides in length 
where derived from exon 26 and cloned into the reporters replacing the native ESS. 
These constructs were transcribed and tested for splicing in vitro. Suppression of 
C-ß or HßΔ6 splicing indicates the presence of ESS activity within the candidate 
sequence. Various sequences of 25 nucleotides, derived from the 400 nucleotide 
sequences demonstrating silencing activity, were then cloned into the splicing 
reporter to investigate these regions more closely. This work identified multiple 
sequences along the length of exon 26 with silencer activity suggesting the 
presence of multiple ESSs (unpublished data). It remains unclear whether these 
multiple sites work independently or in tandem and indeed how physiologically 
relevant they might be in the in vivo cellular environment.   
To investigate the role of ESS elements in in vivo cell culture, we turned to 2′-O-
methyl RNA ASOs targeting some of these regulatory elements identified in 
previous experiments. ASOs provided an opportunity to test the effects of blocking 
specific sites in isolation and in tandem to assess the effects in splicing.  
The prediction was that ESS sites in APOB exon 26 allow the exon to be 
constitutively spliced by suppressing pseudo splice sites within it. Blocking these 
ESS sites in APOB exon 26 using 2′-O-methyl RNA ASOs may alter its splicing 
choices preferentially favouring a stronger pseudo splice site within it. 
 
Aim 
To assess the effect of targeting ESS elements separately and in tandem on the 









We chose to use ASOs in an in vivo model with the native APOB transcript to 
provide proof of principle in the most physiological manner possible. 2′-O-methyl 
RNA ASOs were designed to sites predicted to behave as ESSs in APOB exon 26 
from previous studies. ASOs were designed as 25mers in line with the length of 
sequences assessed in the in vitro assays. ESS elements were targeted from 2 
regions of exon 26. Firstly within the first 200 nucleotides of 3′ splice site of APOB 
exon 26, designated A1 and a region approximately 2300 nucleotides from the 3′ 
splice site in a region designated A6. Regions A1 and A6 were chosen to provide a 
contrasting analysis of two regions with both low and high silencing activity 
respectively. The A1 region has fewer silencing sequences that A6 but within this 
region (A1) there are powerful silencer regions between nucleotides 65-89. The 
specific targeted regions identified as ESS were at nucleotides 66-89, 97-121, 129-
153, 2319-2343 designated APOB ex1, APOB ex2, APOB ex3 and APOB ex4 
(figures 3.3.A; 3.3.B and 3.3.C).  Within regions A1 and A6, 2 neutral sequences 
were targeted with ASOs as negative controls. The ASO APOB ex5 targeted the 
neutral A1 region 193-217 while APOB ex6 targeted the neutral A6 region 2191-
2215.  
These ASOs were transfected into HepG2 cells, which are a well-characterised cell 
line that synthesises and secretes Apolipoprotein B. The transfection agent 
lipofectamine 2000 (Gibco/Invitrogen, Paisley, UK) was used. ASOs were 
transfected individually or in combinations (at 125 nM concentration each). In order 
to equalise the total concentration of ASO per reaction (500 nM) a neutral ASO, in 
this case INSR ex2scram, was used to make up the differences. INSR ex2scram 
was also transfected alone to provide a further negative control ASO which did not 
match any sequences within the APOB pre-mRNA. ASOs were incubated with 
 




HepG2 cells for 48 hours at 37oC/5% CO2. RNA was subsequently harvested and 
subjected to RT-PCR to assess the splicing of APOB exon 26. PCR was 
undertaken with the EXL DNA polymerase (Stratagene, CA, USA) which was 
particularly optimised for replication of longer targets (greater than 20 kb) and with 
higher fidelity than Taq polymerases.  PCR primers were designed to allow the 
identification of the full length exon 26 transcript with forward and reverse primers 
being located in APOB exon 25 and APOB exon 27 respectively (primer sequences 
given in Chapter 6.2 - appendix). Products were run on a 6% polyacrylamide gel. 
The PCR incorporated the radioactive nucleotide [α-32P] dCTP (Perkin-Elmer, 
Wellesley, USA) allowing relevant bands to be identified and quantified using an 
autoradiograph. Each experiment was replicated in triplicate. Bands which 
appeared to be new or increased in the presence of ASOs were identified and 
removed from the gel. The remaining bands were not sequenced.  Bands were 
then purified using a PCR purification kit (Qiagen, Valencia, CA) and a further PCR 
undertaken without radioactive nucleotides in order to send products for 
sequencing.  Products were sent for sequencing via the Genome centre, William 
Harvey Research Institute. An ABI 3700 automated DNA/RNA Sequencer (Applied 
Biosystems) was used, employing the ABI Prism Big Dye sequencing Kit. Data 
Collection software 2.0 was used to collect data and results were analysed with the 
BioEdit sequence analysis software version 7. Expression of novel bands was 
reported as the relative expression of a given band in comparison to its expression 
in the no oligo control lane.  
 
 






Figure 3.3.A  2′-O-methyl RNA ASOs targeting ESSs in APOB exon 26. Schematic 
diagram shows APOB pre-mRNA including exon 25, 26 and 27 (not to scale). 2′-O-
methyl RNA ASOs (25mers) were designed to bind putative exonic splicing silencer 
(ESS) sites in exon 26 as shown.  Four ASOs, designated APOB ex1; APOB ex2; APOB 
ex3 and ApoB ex4 blocked ESS sites (shown as black blocks). APOB ex5 and APOB 
ex6 blocked neutral sites as controls (shown as small grey blocks).   
Figure 3.3.A 
 






Figure 3.3.B  2′-O-methyl RNA ASOs targeting ESSs in region A1 of APOB exon 
26. Schematic diagram shows the 5′ end of the ApoB exon 26 pre-mRNA (figures at 
each end of the nucleotide sequence indicate position from 5′ end of APOB exon 26). 
Sequences identified as ESS are delineated by bold type and neutral sequences by light 
grey type. 2′-O-methyl RNA ASOs, 25 nucleotides long, were targeted to 3 predicted 
ESS sequences at the 5′ end of ApoB exon 26, designated APOB ex1, APOB ex2, 
APOB ex3 (black boxes, white characters). A further 2′-O-methyl RNA ASO, 25 
nucleotides long, was designed to target the neutral sequence, designated APOB ex4 
(grey box, white characters). HepG2 cells were transfected with ASOs in varying 
combinations and at varying concentrations. RT-PCR was carried out on the total RNA 
extracted from these cells after 48 hours. 
Figure 3.3.B 
 





Figure 3.3.C  2′-O-methyl RNA ASOs targeting ESSs in region A6 of APOB 
exon 26. Schematic diagram shows a region in the first third of the ApoB exon 26 
pre-mRNA (figures at each end of the nucleotide sequence indicate position from 5′ 
end of ApoB exon 26).  Sequences identified as ESS are delineated by bold type 
and neutral sequences by light grey type. A 2′-O-methyl RNA ASO, 25 nucleotides 
long, was targeted to an ESS sequences in the A6 region of APOB exon 26, 
designated APOB ex5 (black boxes, white characters). A further 2′-O-methyl RNA 
ASO, 25 nucleotides long, was designed to target a neutral sequence, designated 
APOB ex6 (grey box, white characters). HepG2 cells were transfected with ASOs in 
varying combinations and at varying concentrations. RT-PCR was carried out on 








Figure 3.3.D 2′-O-methyl RNA ASOs targeting ESSs in APOB exon 26. 
Representative gel from HepG2 cells transfected with single and combination ASOs 
targeting ESS in APOB exon 26. Each lane represents a well of transfection. Fragment 
lengths in bp of the markers are indicated on the left side. The -RT control PCR (lane 1) 
was performed without reverse transcriptase. In lane 2 (no oligo) the cells were not 
transfected with ASOs. In lane 3, the cells were transfected with negative control ASO at 
500 nM concentration. Lanes 4-13 were transfected with the indicated ASOs at 125 nM 
each; the total concentration of ASO was adjusted to 500 nM with additional negative 
control ASO. APOB ex1, ex2, ex3 and ex4 targeted putative ESS sequences while 
APOB ex5 was a control ASO targeting a neutral region. Cells were incubated for 48 
hours and RT-PCR was carried out on the total RNA extracted from these cells with 
primers annealing to the adjacent exons 25 and 27. The positions of the bands 
corresponding to the APOB mRNA species with constitutive exon 26 inclusion (top), 
pseudo 3′ splice site activation (middle) and skipping of exon 26 (bottom) are indicated 
on the right side.  
Figure 3.3.D 
 





Figure 3.3.E   2′-O-methyl ASOs targeting ESSs in APOB exon 26. Representative gel 
from HepG2 cells transfected with single ASOs targeting ESS and neutral sequences in 
APOB exon 26. Each lane represents a well of transfection. Fragment lengths in base-pairs of 
the markers are indicated on the left side. The -RT control PCR (lane 1) was performed 
without reverse transcriptase. In lane 2 (no oligo) the cells were not transfected with ASOs. 
Lanes 3-6 were transfected with the indicated ASOs. This figure shows transfections with 2 
ASOs targeting ESS sites and 2 ASOs targeting neutral sequences. APOB ex1 and ex4 
targeted putative ESS sequences while APOB ex5 and APOB ex6 were control ASOs 
targeting neutral regions. This figure was principally included to show the effects of the 
second neutral sequence APOB ex6. Cells were incubated for 48 hours and RT-PCR was 
carried out on the total RNA extracted from these cells with primers annealing to the adjacent 









Figure 3.3.F  
 
Figure 3.3.F 2′-O-methyl ASOs targeting ESSs in APOB exon 26 - 823 base 
alternatively spliced product. Sequence of the 298 base product. Black lettering at 
each end of the sequence signifies primer sequences. Central sequence black lettering 
- exon 26. Light grey sequence - exon 25. Dark grey sequence - exon 27.  Alternative 3’ 
splice site selected (see schematic lower figure).  



























Figure 3.3.G  2′-O-methyl ASOs targeting ESSs in APOB exon 26 - 298 base 
alternatively spliced product. Sequence of the 298 base product. Black lettering 
signifies primer sequences. Light grey sequence - exon 25. Dark grey sequence - 
exon 27.  Exon 26 entirely skipped (see schematic lower figure).  
 
298 base product 
 




Figure 3.3.H  2′-O-methyl RNA ASOs targeting ESSs in APOB exon 26 - alternatively 
spliced products. The graphs show the relative expression of alternatively spliced products 
in proportion to their expression in the no oligo control lane. Each ASO was transfected at a 
concentration of 125nM.  Quantitative data from three independent replications of the 
experiment (error bars show the S.E.M.). A. Relative expression of 823 base product. Overall 
one-way repeated measures ANOVA of the dataset showed p=0.3848 indicating no 
statistical difference between the groups. B. Relative expression of 298 base product. 
Overall one-way repeated measures ANOVA of the dataset showed p=0.0004 indicating 
statistically significant differences between groups. Addition of APOB ex1 + ex2 + ex3 and 
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Figures 3.3.D and 3.3.E were polyacrylamide gels from representative experiments 
in which 2′-O-methyl RNA ASOs targeting ESS sequences in APOB exon 26 were 
transfected in cell culture individually or in combination with other ASOs. There 
were a large number of splice products for each reaction. The constitutive splicing 
of exon 26 at the native splice sites continues to generate the dominant isoform. As 
shown in both figures 3.3.D and 3.3.E, targeting ESSs individually did not cause 
significant alternative splicing (figure 3.3.D compare lanes 2 and 3 with lanes 4-7). 
Targeting the neutral sequence 193-217 with ASO APOB ex5 (figure 3.3.D - 
compare lanes 2 and 3 with lane 8) or the neutral sequence 2191-2215 with ASO 
APOB ex6 did not alter splicing (figure 3.3.E - compare lanes 2 and lane 6). 
Though not identical in terms of base composition, an unrelated scramble 
sequence (INSR ex2scram) was included. The scramble sequence confirms that 
the effects on splicing were not dependent merely on the addition of oligonucleotide 
alone. No specific APOB scram sequences were tested but would have provided a 
more robust control. 
When mixtures of ASOs targeting ESSs were combined, increased alternative 
splicing was seen (figure 3.3.D - compare lanes 2 and 3 with lanes 9-13).  Two 
alternative isoforms were noted. A 823 base pair (figure 3.3.F) and a 298 base pair 
product (figure 3.3.G) appeared to be increased when multiple ESSs were blocked. 
These two products were purified, subjected to a further PCR and then sequenced. 
The 823 base product was found to define an alternative 3′ splice site, 7047 bases 
downstream of the constitutive 3′ splice site (Shapiro and Senapathy score 90.4). 
The 298 base product was found to be as a result of complete exclusion of exon 
26.  
 




The amounts of the alternatively spliced products identified on transfection of 
various combinations of ASOs against APOB exon 26 were represented as a 
proportion of that spliced product when no oligonucleotide was transfected. These 
results are shown graphically in figure 3.3.H. Not all oligonucleotides resulted in 
more alternative splicing i.e. alternative spliced product > 100% (see figure 3.3.H B 
APOB ex3 and APOB ex4).  
The products were not represented as a proportion of APOB for two reasons. 
Firstly, as the bands for total APOB were saturated the gel quantification was 
inaccurate. Secondly differentiating between the effects of combinations of ASOs 
would be difficult given the small amount of alternative product as a proportion of 
the total APOB.  
Most of the truncated forms of APOB would be degraded by mechanisms such as 
nonsense mediated decay. However we do know that some truncated isoforms of 
APOB are stable and avoid degradation. The truncated form APOB48 is stably 
present in the intestine and undertakes a crucial role in chylomicron function. 
Heterozygote patients with hypobetalipoproteinemia produce the truncated APOB 
form APOB89 (Talmud et al. 1989). Transfected ASOs heve been shown to 
generated a truncated APOB transcript, APOB87, which was shown to result in a 
stably expressed protein (Khoo et al. 2007). 
These results confirmed the prediction that in vivo blocking of selected ESS with 
ASOs trigger the selection of a strong 3ʹ′ pseudo splice site within exon 26 i.e. 
cryptic activation of the pseudo splice site. Constitutive splicing of exon 26 at the 
native splice sites continues to generate the dominant isoform and the alternative 
splicing effects are small. This study suggests that ESS elements have a function in 
suppressing pseudo splice site selection in vivo. These experiments also 
 




demonstrated that ESS sites were functionally redundant in that that only by 













4.1 Summary of main biological findings. 
 
 
Both the IR and APOB genes code proteins involved in central metabolic 
processes. The study of the regulation of these genes provides models of splicing 
in a short, alternatively spliced exon (IR exon 11) and a long constitutive exon 
(APOB exon 26). ASO technology provides a strategy to study splicing 
mechanisms in these diverse exons and the opportunity for future therapeutic 
intervention as understanding of the technology expands.  
This current work provides complimentary, conflicting and new data to this area. 
The significant findings of this study add to the current body of knowledge in two 
main areas, namely; splicing in the IR exon 11 and APOB exon 26 and the use of 
ASO technology to alter splicing.  
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4.1.1   2′-O-methyl RNA ASOs targeting the IR exon 11. 
Using 2′-O-methyl RNA ASOs, intronic and exonic sites identified as being 
important to the splicing of the IR exon 11 were targeted. Intronic sites included the 
3′ splice site, the 5′ splice site, the branch point sequence and combinations of 
these. Exonic sites included the 5′ half (INSR ex1), 3′ half (INSR ex2), central 
region (INSR ex3) and the whole of exon11 (INSR ex1+2). This data suggested 
blocking intronic sites individually has little effect on splicing but that blocking 
combinations of intronic sites causes exon 11 skipping.  ASOs blocking the 3′ end 
(INSR ex2) and the whole of the exon (INSR ex1+2) cause exon 11 skipping 
whereas those blocking the 5′ half (INSR ex1) and the central region (INSR ex3) 
have no effect. This technique therefore suggests an enhancer region at the 3′ end 
of exon 11. The remainder of the exon contains either no further modulating 




4.1.2   TOES ASOs targeting the IR exon 11. 
TOES ASOs designed to enhance IR exon 11 inclusion had no effect on the 
splicing of this exon. The lack of effect may have been the result of: 
1. Failure to localise or bind to the IR pre-mRNA transcript as a result of poor 
transfection efficiency. The positive control in the experiments suggested that 
transfection had occurred appropriately. Given the charged components within 
the TOES ASO, transfection across the polar cellular membrane would not be 
expected to be hindered.   
2. Steric interference – TOES ASOs may sterically interfere with interaction 
between the spliceosome and IR exon 11.  
3. Secondary structure effects – TOES ASOs bind IR exon 11 and alter pre-mRNA 
secondary structure in such a way as to inhibit splicing. 
4. Incorrect recruitment of splicing factors by ESE tail.  
 
Studies may be designed to clarify these issues.   
1. Poor transfection efficiency/binding   
    - Assess transfection efficacy using fluorescent - tagged ASOs 
    - Change transfection conditions e.g. transfection agent etc. 
       - Gel shift binding assay comparing TOES compound with a 2’O-methyl 
ASO shown to alter splicing. A gel shift binding assay utilising an in vitro 
splicing reaction including radiolabelled ASOs to compare and a pre-mRNA 
transcript including the IR exon 11 could be undertaken. The bound and 
unbound ASO could then be resolved by separating on a polyacrylamide 




5. Steric interference – co-immunoprecipitation study assessing the interference of 
binding of spliceosomal elements by TOES ASOs 
6. Secondary structure effects – Utilise plasmid which contain mutated IR exon 11 
sequences designed to be resistant to secondary structure formation (chapter 
4.5.1) whilst retaining the ability to bind ASOs. Assess whether TOES ASO 
affect splicing in the absence of secondary structure. 
7. Incorrect recruitment of splicing factors by ESE tail – Redesign TOES ASO with 




4.1.3   PNA and PNA-peptide hybrid ASOs targeting the IR exon 11. 
 
4.1.3.1  Equivalent PNA and 2′-O-methyl RNA ASOs do not have equivalent 
effect on splicing in the IR exon 11 splicing. 
Experiments from Chapter 3.2 demonstrate that PNA ASOs alone, targeting the IR 
exon 11 had no effect on its splicing. PNA ASOs only demonstrated an effect on 
splicing as part of the compound PNA-peptide hybrid ASOs. The 2′-O-methyl RNA 
ASO, INSR ex2 caused IR exon 11 skipping by targeting the same nucleotides as 
the ineffective INSR PNA ex2 (18mer). Further it was also clear that 2′-O-methyl 
RNA ASOs exert their effect on IR exon 11 splicing at significantly lower 
concentrations than PNA-peptide hybrid ASOs. These findings may suggest two 
(not mutually exclusive) possibilities for the PNA only ASOs: 
1. Failure of localisation – either due to poor transfection efficiency or failure to 
bind to the target. 
2. Localisation, but failure to inhibit splicing of IR exon 11 - The PNA only ASOs 
predicted to be effective on the basis of identical targeting to effective 2′-O-
methyl RNA ASOs, bind adequately to the require region but do not cause IR 
exon 11 skipping. This may be the result of failure to alter secondary structure 
or failure to block interaction with spliceosome/splicing factors. 
 
4.1.3.2  PNA-peptide hybrid ASOs cause exon skipping in the context of the 
IR exon 11. 
PNA-peptide hybrid ASOs designed to enhance exon inclusion by recruiting 
enhancing splicing factors paradoxically caused exon skipping in the context of the 
IR exon 11. The results of these experiments were unexpected and provide 
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caveats for the use of this technology but also insights relating to the splicing of the 
IR exon 11. Several explanations for this effect may be considered: 
1. Steric interference - PNA-peptide hybrid ASOs sterically interfere with the 
interaction between the spliceosome and IR exon 11 to cause skipping. 
2. Secondary structure alteration - PNA-peptide hybrid ASOs cause alteration in 
secondary structure which are detrimental to exon 11 splicing.  
3. Inappropriate recruitment - The RS domain tail may incorrectly recruit or 
mislocalise splicing factors for the splicing reaction. 
4. Sequestration - PNA-peptide hybrid ASOs do not localise to IR exon 11 but 
instead sequester enhancing splicing factors away from the IR exon 11, 
resulting in reduced exon 11 inclusion. Against this, RS domain tail transfected 
in isolation do not alter IR exon 11 splicing (Chapter 3.2). 
 
4.1.3.3 PNA-peptide hybrid ASOs associated with 3′ tails cause higher 
degrees of IR exon 11 skipping than ASOs associated with 5′ tails.  
This study noted that PNA-peptide hybrid ASOs with 3′ tails appeared to cause 
more exon skipping than equivalent ASOs with 5′ tails. This trend was observed for  
PNA-peptide hybrid ASOs targeting both halves of IR exon 11 though a statistical 
difference was only noted between INSR PNA ex1 3′  tail and INSR PNA ex1 5′  tail 
(unpaired t test p=0.0142). 
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4.1.4   2′-O-methyl ASO targeting multiple ESS in APOB exon 26.  
APOB exon 26 is a long constitutive exon which is spliced despite multiple stronger 
pseudo splice sites orientated correctly within it (3′ splice site → 5′ splice site). It is 
unclear why the constitutive splice sites are chosen over certain high scoring 
pseudo sites. Presumed enhancer and silencer elements in introns and exons are 
thought to exist which strengthen/weaken given splice sites. Previous work has 
identified multiple exonic splicing silencers in APOB exon 26 in vitro splicing 
assays. How these sites interacted and what effects they had in vivo was unclear.  
This study demonstrated that multiple cis-acting elements in a constitutive exon 
acted in a co-operative fashion to modulate and block aberrant splicing.  Blocking 
multiple selected splice sites had an additive effect in causing either exon 26 
skipping or alternative splicing with an alternative downstream 3′ splice site. The 
effects seen were minor however.  This may be ascribed to poor transfection 
efficiency of ASOs to ESS sites in APOB exon 26. Sub-optimal targeting multiply 
redundant ESS, both in terms of number and combinations may also have played a 
role in the limited effect seen. 
While the splice site strength of this cryptically activated 3′  splice site is higher than 
the native 3′  splice site it is unclear why a group of ESS approximately 7,000 
nucleotides upstream might be involved in repressing a pseudo splice site that 
does not have the highest position score. We may speculate that disruption of 
exonic silencers allows more efficient aggregation of splicing factors around cryptic 
splice sites further downstream, thereby increasing the kinetics of spliceosome 
assembly and allowing minor isoforms to become apparent. The other possibility is 
that interference with ESSs allows silencing protein activity to become more 
influential at the constitutive 3′ splice site. Other methodological explanations 
include the possibility that pseudo splice sites nearer the ESS sites are selected 
 225 
 
which would give significantly larger products which were not amplified efficiently by 
the PCR in comparison to the shorter transcripts, or that could not be distinguished 






4.2 Support of findings from published data.  
 
 
4.2.1.   Identifying sites important in IR exon 11 splicing using 2′-O-methyl 
RNA ASOs. 
The results from the current study may be reviewed in the context of the findings of 
Sen et al. (Sen et al. 2009). The Sen model was derived from earlier IR minigene 
studies undertaken from the same laboratory. Mutations, deletions and insertions 
were introduced into a minigene construct containing the IR exon 11 and adjacent 
exons and truncated introns. The effects on splicing were assessed in an in vivo 
cell culture system. These data are discussed in section 1.4.5. The data on 
regulatory sites within exon 11 formed the basis for work to elucidate the splicing 
factors important in the splicing of the IR exon 11.  Using RNA affinity purification, 
SR proteins derived from Hela nuclear extract, bound to immobilised exon 11 RNA 
were analysed by gel electrophoresis. By identifying which bands were removed in 
the presence of mutated exon 11 sequence and considering their size, splicing 
factor identification was confirmed using splicing factors specific monoclonal 
antibodies. These studies identified SRp40, CUG-BP1 and SF2/ASF as the splicing 
factors that interact with the IR exon 11. 
 
Figure 4.2.1.B shows the overlap between ASOs and splicing factor binding sites in 
the IR exon 11. The 2′-O-methyl RNA ASO INSR ex1 blocked the 5′ end of IR exon 
11 (nucleotides 1-18) but appeared to have no effect on its splicing. Figure 4.2.1.A 
shows that INSR ex1 would completely block the putative binding site for the 
enhancer SRp20 (nucleotide 7-12 in IR exon11) and one nucleotide of the binding 
site of the inhibitory factor CUG-BP1 (nucleotide 18). Given this, it may be expected 
that INSR ex1 would cause exon skipping, which it did not. Only if blocking 
nucleotide 18 were crucial to the CUG-BP1 effect might it be argued that 
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simultaneous blocking of the enhancer and inhibitory effect of SRp20 and CUG-
BP1 respectively, explains the neutral effect of INSR ex1. Against this is the finding 
that CUG-BP1 appears to bind strongly to the ESS in exon 11 even in the context 
of mutations to the ESS and did not elute from the exon template with 1 M salt (Sen 
et al. 2009) hinting that INSR ex1, binding to nucleotide 18, is unlikely to displace 
the binding of CUG-BP1. 
 
INSR ex2 (binding nucleotide 19-36 of IR exon11) would block the binding of both 
the inhibitor, CUG-BP1 (nucleotides 18-26) and the enhancer, SF2/ASF 
(nucleotides 26-30). A neutral effect of INSR ex2 might be expected in view of this 
but INSR ex2 causes IR exon 11 skipping. This may suggest that SF2/ASF plays 
the dominant role over CUG-BP1 in this context. The findings of this study with 
respect to the effect of INSR ex2 are in keeping with the identification of a ESE at 
the 3′ end of IR exon 11 however (Kosaki et al. 1998; Sen et al. 2009).  INSR ex3 
(binding nucleotides 10-28) has a neutral effect on IR exon 11 splicing but would 
putatively interfere with all the splicing factors wholly (CUG-BP1) or in part (SRp20 
and SF2/ASF). INSR ex1+2 would block the effects of all the splicing factors 
completely but in contrast to INSR ex3 causes significant exon 11 skipping. These 
two suppositions are in keeping with the findings of Sen et al. in that the difference 
in the effectiveness of INSR ex3 and INSR ex1+2 most likely relates to the fact that 
INSR ex1+2 completely blocks the enhancer splicing factors (SRp20 and SF2/ASF) 
while INSR ex3 only partly blocks their effects.  
 
The ASO INSR 6/7 which targeted the 43 base nucleotide site identified by Kosaki 
et al. (Kosaki et al. 1998) as an intronic inhibitory region to exon 11 splicing did not 
alter splicing. This suggested either that the ASO bound to the target sequence but 
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not sufficiently to block its inhibitory effects or that the deletion in the minigenes 
inadvertently resulted in the creation of an inhibitory region with the apposed 
intronic regions and did not block a pre-existing inhibitory region. 
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Figure 4.2.1.A  Proposed model for interaction between IR exon 11 and splicing 
factors (modified from Sen et al. {Sen, 2009 #1070}). A. IR pre-mRNA showing exon 11 
(capital letters) and putative binding sites for SRp20, CUG-BP1 and SF2/ASF. B. 
Secondary structure of IR pre-mRNA in the vicinity of exon 11 limits the binding of the 
spliceosome. C. Proposed model for splicing factor influence on IR exon 11 splicing. In 
the presence of SRp20 and SF2/ASF the conformation of pre-mRNA is favourable to 
spliceosome binding. In the presence of CUG-BP1 secondary structure conformation of 





Figure 4.2.1.B   Splicing factors and ASOs - interaction with the IR exon 11. 
Schematic diagram shows a portion of the IR pre-mRNA (not to scale).  IR exon 11 
and surrounding intronic sequences are shown. Exon 11 is given as the lettered 
sequence in the pre-mRNA while the introns are delineated by the grey lines. ASOs 
INSR ex1, INSR ex2 and INSR ex1+2 are illustrated above the IR pre-mRNA. Putative 
splicing factor interactions and their positions are given as grey boxes over exon 11. 
SRp20 binds at nucleotide position 7-12, CUG-BP1 binds at position 18-26 and 
SF2/ASF at nucleotide position 26-30. This figure demonstrates the overlap between 




The minigene approach has the advantage over the ASO approach in studying 
splicing in that smaller and more specific changes can be assessed when 
investigating splicing choices. However the system is a poor physiological model. 
Over-expression of a minigene results in the alteration of the ratio of the 
concentration of splicing factors per transcript. Deletional studies may actually 
create artificial enhancer or silencer elements with the apposed ends of the 
transcript which are brought together instead of merely representing the effects of 
the deleted sequence. In the study by Kosaki et al. the ratio of the splice variants 
IR-B:IR-A was 60/40. This suggests that the splicing environment with the addition 
of the minigene differs from the native context. Our ASO strategy lacks some of the 
precision of the minigene approach but provides a more accurate physiological 
picture of splicing in vivo.  Limits on how small the 2′-O-methyl RNA ASO can be 
made without compromising stability means that smaller regions of exon 11 could 
not be assessed. Regions of the exon may have silencer and enhancer properties 
which are not identified in this study because 18mer 2′-O-methyl RNA ASOs span 
both silencer and enhancer regions and nullify any observable effects. Hence the 
minigene approach provides a greater degree of precision in a less physiological 
model whilst ASOs provided less precision but in a more physiological model.  
Work carried out by Khoo et al. (Khoo et al. 2007) transfecting 2′-O-methyl RNA 
ASOs targeting APOB exon 27, using a similar experimental set-up, may be viewed 
in comparison to work on the IR exon 11. In their experiments, intronic combination 
ASOs cause maximal skipping in the order ASO INSR 3B > ASO INSR 5B > ASO 
INSR 53. In terms of magnitude of effect, this is the opposite order to ASOs 
targeting IR exon 11 (INSR 53 > INSR 5B > INSR 3B). Though there were some 
differences between the studies it is of note that ASO effects were not consistent. 
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There do not appear to be any universal rules which can be applied to predicting 
the effects of ASOs on exon splicing. 
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4.2.2  TOES ASOs targeting the IR exon 11. 
TOES ASOs did not alter IR exon 11 splicing. These compounds have been utilised 
effectively in other splicing systems using the same techniques but difference 
between the studies are noted and include (Skordis et al. 2003):                                      
1. The use of 2′-O-methyl and phosphorothioate modifications for the ASO 
base as opposed to 2′-O-methyl RNA ASOs only. TOES ASOs with a 2′-O-
methyl base were less effective at causing SMN2 exon 7 inclusion 
compared with those with 2′-O-methyl and phosphorothioate ASO base 
(Owen et al. 2011). 
2. The transfection agent was jetPEI (Qbiogene, Nottingham, U.K.) as 
opposed to lipofectamine 2000 in this case.  
3. The exon targeted for inclusion (SMN2 exon 7) was 54 nucleotides in length 
in comparison to the smaller 36 nucleotide exon 11 of the IR.  
4. Both a 5′ and 3′ tail were used with the same ASO base in this study in 
comparison only a 5′ tail in the previous study.  
5. TOES ASOs targeted a range of nucleotides in other studies on and around 
exon 7 of SMN2 whilst the first 18 nucleotides were targeted in this study 
including the nucleotide making the exon/intron border. 
What had not been delineated clearly in the IR exon 11 model at the time when the 
TOES ASO design was undertaken was which splicing factors were important in 
exon 11 splicing and exactly where they bound. In the light of the work by Sen at al. 
(Sen et al. 2009) this now may be retrospectively reviewed. The ESE tail of the 
TOES compound has the repetitive sequence ‘GGA’ which binds the splicing factor 
SF2/ASF shown to bind IR exon 11. It does not carry motifs which might bind 
SRp20 or CUG-BP1.  A recent study assessed different tail sequences in TOES 
ASOs. The tail used here with the ‘GGA’ motif tail conferred the highest efficacy in 
 234 
 
the context of SMN2 exon 7. The data also suggest that matching tail sequences to 
splicing factors is not entirely clear given that alternative tails with sequences which 
should recruit SF2/ASF, did not (Owen et al. 2011).  
The TOES ASO bound to nucleotides 4 - 18 of IR exon 11. The TOES ASO tested 
would have blocked the SRp20 binding site (nucleotides 7-12) (figure 4.2.1.B), 
allowed the majority of CUG-BP1 to bind (except over nucleotide 18) and 
presumably attract SF2/ASF appropriately but in the context of an unhindered 
SF2/ASF binding site (nucleotides 26-30). In addition, SF2/ASF is known to be 
expressed in abundance in HepG2 cells (Sen et al. 2009). The overall effect this 
compound may have added might therefore be negligible.   
Other studies have demonstrated that 5’ splice site utilisation may be altered by 
factors bound 18 to 25 nucleotides upstream of a 5’ splice site (Chabot et al. 1987; 
Cunningham et al. 1991). 
 
4.2.3   PNA and PNA-peptide hybrid ASOs targeting the IR exon 11 . 
 
4.2.3.1  Equivalent PNA and 2′-O-methyl RNA ASOs do not have equivalent 
effect on splicing in the IR exon 11 splicing. 
Comparison of the work using tailed ASOs revealed that the use of a 2′-O-
methyl/phosphothoriate ASO base in a TOES ASO  was  associated with a higher 
efficacy in SMN2 exon 7 inclusion at lower concentrations than a PNA molecule in 
an ESSENCE compound (Cartegni et al. 2003; Skordis et al. 2003). However the 
value of this observation is limited given the differences between the ASOs; tail 
sequences; ASO binding sites and different experimental conditions. A more direct 
comparison, comes from a study comparing the effects of ASOs on the trans-
activating response region (TAR) of the HIV genome which revealed a lower IC50 
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for 2′-O-methyl RNA ASOs (20nM) compared with equivalent PNA ASOs (40nM) 
(Boulme et al. 1998). Failure to localise the PNA only ASOs may relate, in part, to 
their neutral backbone. While making these compounds extremely stable and 
highly avid for binding RNA it may make cell penetration more problematic. Since 
the PNA ASOs alone had no effect on splicing but the tailed PNA-peptide hybrid 
ASOs resulted in exon skipping, one may surmise that the effects of the charged 
tail (positively charged arginine due to the associated guanidinium group whilst 
serine is negatively charged due to the hydroxyl grouping) may facilitate 
transfection of these compounds in comparison to PNA ASOs alone. 
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4.2.3.2  PNA-peptide hybrid ASOs cause exon skipping in the context of the 
IR exon 11. 
Previous uses of this technology have resulted in exon inclusion in the context of 
splicing models BRCA, SMN and BCL (Cartegni et al. 2003; Wilusz et al. 2005). 
In the context of work by Sen et al. (Sen et al. 2009) it is clear the both PNA ASO 
targeting components of the PNA-peptide hybrid ASOs i.e. INSR PNA ex1 and 
INSR PNA ex2 targeted regions which bound both splicing enhancers (SRp20 and 
SF2/ASF) and inhibitors (CUG-BP1). The potential splicing enhancing properties of 
the PNA-peptide hybrid ASOs may have been negated by binding (and so blocking) 
natural splicing enhancer sites.  
SR proteins such as SF2/ASF, which are normally thought of as enhancers of 
splicing, can act as splicing repressors when bound to intronic elements (Graveley 
2000; Dauksaite et al. 2002). Exonic splicing enhancer sequences (ESE) can 
behave as splicing inhibitors when placed in an intron of a β-globin reporter system 
(Ibrahim el et al. 2005). It is not clear however, how SR proteins in these contexts 
cause splicing repression. These examples however involve SR proteins and ESE 
sequences in intronic regions and not RS domains as part of ASOs. 
 
 
4.2.3.3  3′ tails associated with PNA-peptide hybrid ASOs caused higher 
degrees of IR exon 11 skipping than 5′  associated tails.  
Previous studies use tails at both 3′ and 5′ ends of the ASO and all these 
compounds are able to cause exon inclusion however, none of these studies 
compare tails at opposing ends of ASOs. (Cartegni et al. 2003; Skordis et al. 2003; 
Wilusz et al. 2005). Two of these studies assess different tailed strategies (TOES 
and ESSENCE ASOs) and use tails at different ends of the molecules in an in vitro 
SMN2 assay system. Though complete comparison can not be made because of 
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different assay set-ups and ASO chemistries used, it is of note that the TOES 
ASOs with a 5′ tail, at approximately a tenth the concentration, result in double the 
effect on exon 7 inclusion in the SMN2 assay system in comparison to the 
ESSENCE ASO with a 3′ tail. Our data shows the opposite effect, but with respect 
to exon exclusion i.e. 3′ tails were twice as effective at causing exon exclusion 
compared to 5′ tails. This may therefore suggest that 5′ tail have some inherent 
advantage over 3′ tails in enhancing exon inclusion. 
 
4.2.4  Constitutive APOB exon 26 can be skipped by inactivating multiple 
exonic splicing silencers within it. 
In most experimentally characterised cases, ESS have been isolated as single 
elements or sometimes bipartite elements of variable length from 5 nucleotides to 
119 nucleotides, usually in the context of alternative splicing (Caputi et al. 1994; 
Staffa et al. 1997). The current data, using 2′-O-methyl RNA ASOs to block these 
sites provides the first evidence that silencer elements appear to work in tandem to 
block pseudo splice sites in vivo in large constitutive exons such as APOB exon 26.  
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4.3 Experimental limitations. 
The limitations of the current study relate to three principle questions. 
1. Confounding factors - Did potential confounding factors account for some 
of the effects or lack of effects seen and attributed to ASOs? 
2. Specificity - Were the effects of given ASOs specific to their intended 
targets? 
3. Quantification - What was the magnitude of the effect and was it 
physiologically relevant? 
4. Relevance -  Were the ESSs targeted in APOB exon 26 appropriate to 
demonstrate a significant effect on splicing?  
 
4.3.1. Confounding factors 
It may be argued that the efficacy or lack of efficacy of the ASOs tested both in the 
context of splicing of the IR exon 11 and APOB exon 26 may have related to the 
effect of confounding factors. Variable degrees of transfection efficiency may 
account for differences in the apparent effects of the ASOs.  Transfection efficiency 
was partially assessed in experiment section 3.1.4 but this was not quantified and 
all ASOs were not comprehensively assessed.  
 
Cell viability is a consideration when assessing the effects of ASOs. It is possible 
that ASOs may affect cell viability differentially and this may have subtle knock-on 
effects on the isoform ratios seen. No obvious evidence of cell death as a result of 
transfecting different ASOs in different quantities was seen via an assessment of 





Secondary structure consideration may account either for the apparent lack of 
efficacy of some of the ASOs or the mechanism by which other ASOs exert their 
effects.  
 
No TOES ASO or PNA-peptide hybrid ASO caused IR exon 11 inclusion as they 
were designed to do. A positive control included in these experiments was INSR 
ex2 to demonstrate transfection resulting in IR exon 11 skipping was still occurring. 
However the experiment lacked a TOES ASO or PNA-peptide hybrid ASO positive 
control. Demonstrating that a TOES ASO or PNA-peptide hybrid ASO could cause 
exon inclusion, in a different splicing model e.g. SMN2, using the current 
experimental set-up is an important further positive control. In its absence it could 
be argued that there may be a methodological impediment to causing exon 




Control experiments were carried out to confirm the specificity of ASOs to their 
targets. These included transfection of scramble ASOs in the sample cell culture 
model to compare the effects on splicing (section 3.1.2). These control experiments 
did not confirm that ASOs only alter splicing in the target gene and not in other 
alternatively spliced genes. If the ASOs are specific, there should be no effect on 
the splicing of other alternatively spliced genes. These experiments have not done 







Semi-quantitative PCR was used to quantify proportions of the IR isoforms and 
APOB exon 26 splicing products in this study. Semi-quantitative PCR was used 
throughout for consistency, because it had been used in comparable studies in the 
literature beforehand and it provided enough resolution for the purposes of this 
study. Real-time PCR would provide more precise quantitative data. 
The effects of ASOs were expressed in terms of levels of RNA expression in this 
study. One way to clarify whether the ASOs caused a change in splicing which was 
biologically relevant would be confirm these effects at the protein level. Given that 
the effects on splicing were relatively minor in some cases e.g. effects of ASOs on 
APOB exon 26, it would be unlikely that these changes would be discriminated at 
the protein level.  
 
4.3.4. Relevance 
The aim of experiments in chapter 3.3 was to target predicted ESS sequences in 
APOB exon 26 separately and in tandem to see whether they de-repressed any 
alternative splice sites within exon 26. Multiple ESS where predicted along the 
length of APOB exon 26 however it was not clear how many sites interacted in 
tandem, the location of these sites and what was the target pseudo splice site 
might be. The apparent limited affect of the blocking multiple ESSs in APOB exon 
26 may hide the potential importance of the mechanism if non-significant ESS sites 
were blocked.  
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4.4 Final conclusions. 
The IR exon 11 represents a short, alternatively spliced exon which can easily be 
skipped using ASOs but in which exon inclusion can not be enhanced using the 
tested ASO technologies. APOB exon 26, in comparison, is a large, constitutively 
spliced exon, in which splicing can be slightly modified by targeting multiple sites 
with ASOs. Though the principles governing the splicing process and the use of 
antisense technology are consistent, study of these contrasting models emphasises 
that there is no universal strategy to alter splicing in these transcripts. We find that 
previously published data using 2′-O-methyl ASOs, TOES ASOs and PNA-peptide 
hybrid ASOs are not applicable to the endogenous IR exon 11. The actions of 
these trans-acting factors are not predictable from current knowledge. Rather, the 
effective use of this technology in each system requires an appreciation of the 
transcript itself, the unique composition of the splicing environment around it and 
the interaction between the two.  
The use of ASOs is increasingly making the transition from laboratory to bedside. 
Drugs based on this technology have been commercially available for some time 
now with many others in development. ASOs provide the attractive proposition of 
providing designer drugs with a high specificity for their targets however there still 
remain factors limiting their efficacy. As investigative tools, though precise and for 
all their advantages, ASOs are unlikely to be able to spatially resolve short, closely 
apposed modifier sites whilst maintaining specificity to the target as illustrated in 
the case of the enhancer and silence regions identified in IR exon 11 by other 
methodologies.  There remains a constant trade off with ASO targeting between 
precision and specificity.   
The effects demonstrated in the study are relatively limited, however, as 
refinements occur, principally in ASO chemistry and drug delivery but also our 
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ability to appreciate and model the local splicing environment, these compounds 
will become even more powerful in the study and therapeutic manipulation of target 




4.5  Future work.  
 
 
4.5.1.   Confounding factors 
Certain ASOs may have been ineffective as a result of poor transfection efficiency 
or poor binding to the target pre-mRNA. Transfection efficiency could be assessed 
more formally by cell counting using fluorescein-tagged ASOs and confocal 
microscopy (Chapter 3.1.4) or via fluorescence activated cell sorting (FACS). 
 
If transfection efficiency is not found to be a significant issue then variability in 
binding to the pre-mRNA could be assessed by utilising a gel-shift binding assay. 
A pre-mRNA transcript including the IR exon 11 and radiolabelled ASOs would be 
subject to an in vitro splicing reaction. Free and bound ASO would be resolved 
using a polyacrylamide gel, excised and quantified. Binding affinity of the ASO 
would be proportional to the radioactivity count of the bound fraction. Whilst this 
method may provide some information regarding relative binding under assay 
conditions, it is unlikely to provide realistic insights into the binding of the ASO in 
the in vivo nuclear environement. 
 
The lack of effect of some ASOs and the mechanism by which others exert their 
effect may be due to secondary structure considerations. It has been suggested 
that secondary structure variation around exon 11 could affect the binding of ASOs, 
splicing factors and spliceosome components to alter exon 11 splicing.  Plasmids 
are available which contain either a wild type IR exon 11 pre-mRNA transcript or 
ones which contain various mutant sequences. These mutated sequences have 
been designed to be resistant to secondary structure formation whilst retaining the 
ability to bind ASOs. Co-transfecting these plasmids with ASOs in HepG2 cell 
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culture may provide evidence as to whether in the absence of secondary structure 
considerations ASOs become more or less effective. 
 
To assess whether ASO effects result from inhibiting the binding of key trans-acting 
factors a co-immunoprecipitation experiment could be undertaken. ASOs including 
the PNA-peptide hybrid ASOs would be added to in vitro splicing reactions using 
radiolabelled IR pre-mRNA transcripts. Sepharose beads bound to antibodies 
against splicing factors known to interact with the IR (SRp20, SF2/ASF and CUG-
BP1) or against U1 snRNP would be added to the splicing reaction followed by 
phenol extraction and ethanol precipitation. The amount of transcript bound would 
be estimated from the amount of radioactivity detected. If the given ASO inhibited 
the binding of a splicing factor or a U1 SnRNP then less radioactive pre-mRNA 
transcript would be detected. 
 
The lack of efficacy of the TOES ASOs and PNA-peptide hybrids may be related to 
methodological errors which have not been identified. To confirm the experimental 
set-up is correct a further positive control would be crucial. TOES ASOs and PNA-
peptide hybrids have been used to enhance exon 7 inclusion in SMN2 and 
experiment should been run concurrently with the previous experiments to 
demonstrate that exon inclusion is possible in the experimental set-up used. 
 
4.5.2.   Specificity  
 
To further confirm the specificity of the ASOs targeting IR exon 11 other 
alternatively spliced genes e.g. TSC2 exon 25, Caspase 9 exon 3-6, could be 
examined from Hep G2 cells transfected with these ASOs to see whether they 
cause any off-target isoform changes. For greater coverage an exon-specific 
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microarray looking for alternative splicing events induced by ASOs e.g. Affymetrix 
Human Exon 1.0ST assay could be used on RNA harvested from transfected cells 
 
4.5.3.   Quantification 
Real-time PCR will provide a more precise quantatative analysis of the 
effectiveness of a given ASO.  
Western blotting could be employed to confirm that the levels of IR-A and IR-B 
protein are equivalent to the changes demonstrated with RNA. Differences in 
protein concentration are unlikely to be demonstrated in the context of APOB exon 
26 however given the minor effect on splicing demonstrated by blocking ESS sites  
tested in exon 26. 
 
4.5.4.  Relevance 
The results from Chapter 3.3 demonstrate that targeting multiple ESS in APOB 
exon 26 causes aberrant splicing of a constitutive exon to a minor degree. The 
magnitude of this effect may be explained by various factors including transfection 
efficiency and sub-optimal targeting of ESS sites. As an extension to this work it 
would be of value to assess the effects of targeting further combinations of sites 
both in close proximity and at a distance to one another to confirm whether splicing 
may be altered to a greater degree than the initial experiments suggest.   
Were the ESSs targeted in APOB exon 26 appropriate to reveal the real silenced 
pseudoexons? An alternative strategy may be to attempt to switch splicing to favour 
expression of the 3 pseudoexons within APOB exon 26, calculated to have stronger 
combined  splice sites scores (Shapiro & Senapathy) than the constitutive exon 26 
splice sites. Confirming pseudoexon selection by targeting multiple neighbouring 
ESS sites around these combined splice sites would provide persuasive evidence 
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Sequence (5′- 3′) 
  
INSR 3 mCmUmGmUmGmGmAmAmAmCmAmAmAmAmCmCmAmA 
INSR 5 mCmGmCmAmCmAmGmGmUmGmAmGmUmCmAmUmAmC 










INSR ex1 mGmUmGmCmCmUmGmAmAmGmAmGmGmUmUmUmUmU 
INSR ex2 mCmUmAmGmGmGmUmCmCmUmCmGmGmCmAmCmCmA 




INSR ex1+2 flu fl-mCmUmAmGmGmGmUmCmCmUmCmGmGmCmAmCmCmA 
mGmUmGmCmCmUmGmAmAmGmAmGmGmUmUmUmUmU 







INSR ex1scram mGmCmUmUmUmAmUmUmGmGmGmAmGmUmCmUmGmA 




INSR TOES  ex1  
3′  Tail 
mGmUmGmCmCmUmGmAmAmGmAmGmGmUmUmUmUmUAGGAG
GACGGAGGACGGAGGACA 
INSR TOES  ex1 
 5′  Tail 
AGGAGGACGGAGGACGGAGGACAmGmUmGmCmCmUmGmAmAm
GmAmGmGmUmUmUmUmU 
INSR TOES Tail only AGGAGGACGGAGGACGGAGGACA 
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INSR PNA ex1 pGpTpGpCpCpTpGpApApGpApGpGpTpT 
INSR PNA ex2  pGpGpGpTpCpCpTpCpGpGpCpApCpCpA 
INSR PNA ex2  
(18mer) 
pCpTpApGpGpGpTpCpCpTpCpGpGpCpApCpCpA 
INSR PNA ex4 pGpApApGpApGpGpTpTpTpTpT 
INSR PNA ex5 pGpCpApCpCpApGpTpGpCpCpT 
INSR PNA ex4 pCpTpApGpGpGpTpCpCpTpCpG 
  
PNA ex1 3′  TAIL pGpTpGpCpCpTpGpApApGpApGpGpTpT-GlyGly-ArgSerArgSer 
ArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSer 
PNA ex1 5′  TAIL ArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSer-
GlyGly- pGpTpGpCpCpTpGpApApGpApGpGpTpT 
PNA ex2 3′  TAIL pGpGpGpUpCpCpUpCpGpGpCpApCpCpA-GlyGly-ArgSerArgSer 
ArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSer 
PNA ex2 5′  TAIL ArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSer-
GlyGly- pGpGpGpUpCpCpUpCpGpGpCpApCpCpA 
PNA Tail only ArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSerArgSer 
  
APOB ex1  
(65-89)          
mGmAmUmAmUmUmCmGmAmAmUmCmUmAmGmAmAmAmUmUm
UmGmUmGmG 
APOB ex2  
(97-121)        
mUmUmGmUmUmUmCmCmAmAmGmUmUmUmUmUmCmUmAmCm
AmUmGmAmC 
APOB ex3  
(129-153)      
mCmAmUmCmGmAmAmUmAmUmUmAmGmUmAmAmAmCmCmUm
UmUmUmGmA 




APOB ex5  









Key: mACGU = 2′-O-methyl RNA bases; ACGU = RNA bases; pACGU = 
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Exon Cycles Primer Forward 
GAPDH 22 Forward AAGGTGAAGGTCGGAGTCAACGG 
  Reverse CCACTTGATTTTGGAGGGATCTC 
IR exon 11 32 Forward AACCAGAGTGAGTATGAGGATTCG 
  Reverse TTCTCAAAAGGCCTGTGCTCCTCC 
APOB exon 26 30 Forward GCCATCTCGAGAGTTCCAAG 
  Reverse GTCACGGTGTGCAAATGTTC 
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6.3 Web-based tools  
 
See Chapter 2.8 for information regarding the web-based tools ESE Finder, 
RESCUE-ESE,   the PESXs server and the FAS-ESS web server.   
 
1.  Ensembl 
 - http://www.ensembl.org/index.html 
 - For gene sequences. 
 
2.  Primer3Plus  
- http://www.bioinformatics.nl/cgi-bin/primer3plus/primer 3plus.cgi. 
- For primer design. 
 
3.  ESE Finder  
- http://rulai.cshl.edu/tools/ESE2/ 
- For identification of ESE sites. 
 
4.  RESCUE-ESE  
-  http://genes.mit.edu/ burgelab/rescue-ese/index.html 
- For identification of ESE sites. 
 
 
5.  PESXs server  
- http://cubweb.biology .columbia.edu/pesx/ 
- For identification of ESE/ESS sites. 
 
 
5.  FAS-ESS web server  
- http://genes.mit.edu/fas-ess/ 
- For identification of ESS sites. 
 
 
6.  BLAST  
- http://blast.ncbi.nlm.nih.gov /blast/Blast.cgi 
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- For sequence comparison for homology.  
 
7.  Alex Dong Li's splice site finder  
- http://violin.genet.sickkids.on.ca/ ali/splicesitefinder.html  
- For splice site identification 
- Site no longer available. 
 
8.  Reverse complement  
- http://www.bioinformatics.org/sms/rev_comp.html 
- For sequence reversal and/or complementation 
 
 
9.  siRNA Wizard  v3.1 
 - http://www.sirnawizard.com 
 - For scramble sequences. 
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6.4 Insulin receptor Pre-mRNA sequence exon 10- exon 12 
 
Pre-mRNA sequence showing sequence exon 10 - intron 10 - exon 11 - intron 11 - 
exon 12. Grey shaded areas are exonic sequences, the remaining sequence being 
intronic. Numbering gives nucleotide position within the IR gene. 
 
141661 TTTCTTTCTCCAGGGCTGAAGCTGCCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAA 141720 
141721 GATTCTCAGAAGCACAACCAGAGTGAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGT 141780 
141781 CCAAAGACAGACTCTCAGATCCTGAAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTT 141840 
141841 GAGGATTACCTGCACAACGTGGTTTTCGTCCCCAGGTCAGGACTTGGCGCTGGGCTCTCT 141900 
141901 TAGTGGGTGCCAATTGGCTTGGTGTTGGTGGAAGGTCATTACTTAGGGACCGAGAGGTAG 141960 
141961 TGGGACCCAGAGACGGCAGAAGGGTGGGTGGAGTCTGAATGGAGCCCTTTCCTGGGTGGA 142020 
142021 GGAAGAGATCTTGCAGTTTCGAAATTTCGAGGGGAATTTTATCAGGAAGAGCAAATAATC 142080 
142081 GCACAAAAGGGGAAAAATGGACAAAACTCAGCATTTGCCTTTCTTACCTCTCCTGAGCTG 142140 
142141 GTCTCCACGTGAGTTCCAAAACAAACTCCGTTAGACGATTAACATTTTTTTTTTTCTCTC 142200 
142201 TCTCTCTTTTTTTTTTTTTTTTGACAGAGTCTCACTCTATCGTCCAGGCTGGAGTGCGGT 142260 
142261 GGTGCGATTTCAGCTCACCCTTTCCGGGTTCGAGTGATTCTTGTGCCTCAGCCTCCCAAG 142320 
142321 TAGCTGGGACTACAGGTGCGCAGCACCACGCCCAGCTAATTTTTATATTTTTAGTAGAGA 142380 
142381 CGGGGTTTTGCCATGTTGGCTAGGCTGGTCTCTAACCCCTGACCTCAGGTGATCTGCCTG 142440 
142441 CCTCGGCCTCCCAGAGTGCTGGGATTATAGGTGTGAGCCACCGTGCCTGGCCGTGATTAT 142500 
142501 TGAGGCTTTAGCTGAGCGCAGTGGTGTAAGCCTGTGGTCCCAGCTAGTTGGGAAGCCGAG 142560 
142561 GTGGTAGGGTTGCTTGAGGCCAGCCTGGGCAACATAATGAGACCCCATCGCTACCAAAAA 142620 
142621 AAAAAAAAAACAGTTTAAAAATTAGTCAGGCATGGTAATGCATGTCTGAACTCCTAGCCC 142680 
142681 ATGGGGAGGCTGAGAAAGAAGGATCACAAGAGGCCAGGAGATGGAGGCTACGATAAGCGA 142740 
142741 TGATGGCGCCACTGCGCTCCAGCCTGGGTGACAGAGTGAGACCCTGTCTCTAAAAAAAAA 142800 
142801 TTAAAAGTATCTGTTCAGATGTTTACCAATGCTATTCATCCGAGCAGACTTTTCTCCCAG 142860 
142861  A A C C A C C A G TG T G T A A G A A T C C T C T T T T T T T T T T T T C T T T T C T T T T T C T T T T T T T G T T G C  142920 
142921 ATGTTTCCCCTATGACCCTGAGTCCAAAAGAATGTTCAGGGGGACAGCCAAGGCTTCAAA 142980 
142981 GTGGTTACTGTTTCACCTGTTACAAACAAAATGTTGGCTAGGCACAGTGGCTCACTCGTG 143040 
143041 TAATCCCAGCACTTTGGGAGGCCGAAGTGGGAGAATCAGTTGAGGCCAAAGGTGGAGACC 143100 
143101 AGCCTGAGCAACAGAGTGAGACCCTATCTCTACTAAAAAAGGAAAAAAAAAAAAAAAATA 143160 
143161 GCCAGACATGTTGGTGCATGCCTTGTAGTCCCAGCTACTCCGGAGGCTGAGGCGGGAGAA 143220 
143221 TTGCTGGAGCACAGGAGTTGGAGGCTGCTGTGAGCTATGATGGCACCATTGCACTCCAGC 143280 
143281 CTGGGCAACAGAGCAAGACCCTGTCTCAAAAAGGAAGGAAGGGAAAAAAAGAAAGAAAGA 143340 
143341 AAGGAATGGAGGGAGGGAGGGAAAGAGGAAGGAAGGAAGAGAGAAAGAAAAAGAAAGAAA 143400 
143401 GAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAGAAAGAAAGAAAGGAAAGAGAG 143460 
143461 AAAGAAAGGACAGAGAAAGGAAGGGGGCAAGGGAGGGAGAGAGGAGGGAAGGAAGGAAGG 143520 
143521 AAAAAAGGAAAAGAAAGAAAAGAAAGAGAAAGAAAATGAAAAAAAGAAGGAAGGAAAGAG 143580 
143581 AAAGAAAGCAAATGAAGGAAGGAAAGAGGGAAAAAGAGAGAAAGAAAGTAAAAGAGGAAA 143640 
143641 GAAGGAAGGAAGGAGAGAGAGGGAGAGAGAAAAGAGAAAGAGAAAAGAAAAGGAGAAAGA 143700 
143701 GGAAAGAAACCAGAAAGAGAGAGAGAAAGAAGAAAGAAGGGAAAGAAAAGAAAAATTCTG 143760 
143761 CCAGACTTGGAGAAGTGGCTGAGTCAGTTGTGATGTCCACATGTAGTCACGTTTGACATC 143820 
143821 CCAGGGCCACCTCAGCAGGCCGTCTCTGGGGAGAATTTTCTCTGATTTCTTCCCCTTCCC 143880 
143881 TTGCTGGACCCCTGCACCTGCTGGGGAAGATGTAGCTCACTCCGTCTAGCAAGTGATGGG 143940 
143941 AGCGAGTGGTCCAGGGTCAAAGCCAGGGTGCCCTTACTCGGACACATGTGGCCTCCAAGT 144000 
144001 GTCAGAGCCCAGTGGTCTGTCTAATGAAGTTCCCTCTGTCCTCAAAGGCGTTGGTTTTGT 144060 
144061 TTCCACAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGTATGACTCACCTGTG 144120 
144121 CGACCCCTGGTGCCTGCTCCGCGCAGGGCCGGCGGCGTGCCAGGCAGATGCCTCGGAGAA 144180 
144181 CCCAGGGGTTTCTGTGGCTTTTTGCATGCGGCGGGCAGCTGTGCTGGAGAGCAGATGCTT 144240 
144241 CACCAATTCAGAAATCCAATGCCTTCACTCTGAAATGAAATCTGGGCATGAATGTGGGGA 144300 
144301 GAAACCTTCACTAACACACTCTTGCTAAAACATAGAATCATGGGAGTGCTTCCTGGGTAC 144360 
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144361 CCCCTCCCTGCCTTCTGTTTGCAGCCACTGTTTGCTCACTAAACATCTCTGCACCTCCCG 144420 
144421 CGTGCATTTGCAGAGGTGGGTGGGGGTCCCCGGAGTCTGAGCTCCCCGCGGCTGGGTGCC 144480 
144481 CCGACCCAGCAGCTCCTACACCATGAATGGAGGTTGATCTGGAAACAGAATATTTTCATG 144540 
144541 AAAGGGCGACAGGGTATGAACAAAAGAACACCGTGTCGCTCACTGAATTCCACGGAGGAG 144600 
144601 AGTCAGGGATCTCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTC 144660 
1 4 4 6 6 1  C T T C T T T C T T T T T T T C C T T C T T T C T T T C T T T C C T T C T T T C T T T T C T T T T C T T T A T T C C C T  1 4 4 7 2 0 
144721  CCCTCTCTCCCTCCGTCCGTCCCTCCCTCCCTTCCTTCTTTCCTTCTTCTTTTTTTTTTG 144780 
144781 GATGGAATTTCACTCTTGTTGCCCAGGCTAGAGTGCAGTGGTGCGATCTCGGCTCTCCAC 144840 
144841 AACCTCCACCTCCCGGGTTCAAGCAATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATT 144900 
144901 ACAGGCATGCGCCACCACGCCCGGCTAATTTTTGTACTTTTAGTAGAGACAGGGTTTCTC 144960 
144961 CATGTTGGTCAGGCTGGTCTCGATCTCCCGACCTCAGGCGATCCGCCCGCCTCGGCCTCC 145020 
145021 CAAAGTGCTGGAATTACAGGCGTGAGCCACCGCCCCTGGCCAGGGACGTTTCTTTTCAAC 145080 
145081 TTGAGTCTTAAGAGAATGAAGCAGTATGGTCCTGGGAGAGAGAAAAAGCTTGGAGAACTT 145140 
145141 GGGAGAAAGGCAAGGAGATGTTTACCTGTCGTGGCTTTTGGGAGGAACAGGAGGTGAGAC 145200 
145201 TAAAGAGGCAAGTTGGGACCACTTGGAGAGATTTTCTTCCTTTAGCAGAGTGTTTATTTA 145260 
145261 TTTATTTTTTCCCAGGCACCTGTGTGGCCTGATCTGCCCTCTAGTGGCCATTTGCAATAC 145320 
145321 TAACTGTAGCCAAGAAGGGTCTAAAAATGTACGGGCTTGGTCCAAAGCAGATCTCAATCT 145380 
145381 CAGTCCTGCTATTAATAATATTCGGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGG 145440 
145441 CCGAGGCGGGCGGATCATGAGATCAGAAGATCGAGACCATCCTGGCTAACACGGTGAAAC 145500 
145501 CCCGTCACTACTAAAAATACAAGAAATTAGCTGGGCGTGGTGACGCAGCTACCCCAGGCG 145560 
145561 GGGCAATCACTTGAGGCCAGGAGTTCGAGACCAGCCTGACCAAGATGGTGAAACCCCGTT 145620 
145621 ACTACAAGAAACATAAAAATTAGCCGGGCGTGGTGACACACGCCTGTAGTCCCAGCTACT 145680 
145681 CGGGAGGCTGAGGCAGGAGAATGGCGTGAACCTGGGACGCGGAGCTTGCAGTGAGCCAAG 145740 
145741 ATCGTGCCACTGCACTCCAGCCTGGGCCACAGAGCGAGACTCCGTCTCAAAAAAAATAAA 145800 
145801 AATAAAATAATATTTGGGGCCACAGCTGGACTTGGTAGCTCACGCCTGTAATCCCAACAC 145860 
145861 TTTGAGAGGCCCAGGCGGGGCAATCACTTGAGGCCAGGAGTTCGAGACCAGCCTGACCAA 145920 
145921 GATGGTGAAACCCCGTTACTACAAGAAATATAAAAATTAGCCGGGCATGGTGACACACGC 145980 
145981 CTGTAGTCCCAGCTACTTGGGAGGCCGAGGCAGGAGAATCACTTGATTTCTGGAGGCGGA 146040 
146041 GGTTGCGGTGAGCCGAGATCTCGCCACTGCATTCCAGCCTGGGTGACAGAGCGAGACTCT 146100 
146101  GTCTCAAAAAAAAAAAAAAAAAAGAATAAATACATAATACTAATAATAATAATAAATAAT 146160 
146161 ATTTGGGGTCAGATTATTCTAGGGCACTGTCCAACAACACTGAGAAGCATCCCTGGCTTC 146220 
146221 CACTCATCTGATGCCAGTAGTGTGTCTTCCCCCTAAAGTAGTAATAACCAAAAATATCTT 146280 
146281 CAGACATTGCTAAATATCCCCCTGGGTGATGGGGTCAGAAGGACCCTTGGTTGAGATGAC 146340 
146341 CAGGTTAGTGTGGGATTGCTGGATAATAAAATGCTGCCTAGGCCAGGTGCTGTGGCTCAT 146400 
146401 GCCTGATGCCTGTAATCCCAGCACTTTGGGAGGCCCAGGCAGGCAGATCACCTGAGGTCA 146460 
146461 AGAGTTTGAAACCAGCCTGGGCAACATGGCGAAACCCCGTCTCTACTAAAAATACAAAAA 146520 
146521 TTAGCCGGGCATGATGATGCACGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAG 146580 
146581 AATCGCTTGAACCCAGAAATTGGAAGTTACAGTGAGCCAAGATCACACCACTGCACTCCA 146640 
146641 GCCTGGGCAACAGAGCAAGACTCTGTCTCAAAAAAAAAAATCAGTTGATGCTTTGTCTTT 146700 
146701  TGCCACTTCATGGTCTTTTTGGTTATAATCTTTTTGGTATATAAACTCATTTGGCCTGTT 146760 
146761 TGATGAGCCCATTTTACATCTCTGGTTGTTGAGATACCAATTTCTCAGTAGTTACTCATG 146820 
146821 AAGCACCAACGTCTTGGTTATTTTCACGAGACCCATTTGTGCCTGTATAGAAATTATCTG 146880 
146881 AATCTTGCTAATACGGACATATCTTTGGCTTGATAAGTGGTGGAGCTGTTTTCTTTTCCA 146940 
146941  TTCTACAATGTTGTTAGTCTTTTAATACAAAAAGACCATAAAGAGAATCTTAAGAAATGC 147000 
147001 CCCCAAAGTAGGATTTGTTTTCTGACCACACATTTTCTGATGACGCTGCAATAGAAACTA 147060 
147061  AAAGTTAATTTCAAAAGATTAAACAGAAAACTTCACTTCTTGGTGGTTAAAAGTTAAACA 147120 
147121 CTTACAGGCTGGGCGCAGTGACTCACACCTGTAATCGCAGCACTTTGGGAGGCCCAGGCA 147180 
147181 GGCGGATCACCTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAATATGGTGAAACCCCTTC 147240 
147241 TCTACTAAAAATACAAAAATTAGCCAGATGTGGTAACGTGCGCCTGTAGTCCCAGCTACT 147300 
147301 CAGGAGACTGAGGCAGAAGAATCACTTGAACCTGGGAGGTGGAGGTTGCAGTGAGCCGAG 147360 
147361 ATCACGCCACTGCCCTCCAGCCTGGGCAACAGAGCGAGACTCTGTCTAAAAAAAAAAAAA 147420 
147421 GTTAAAAAGTTAAACACTTACATATCTATCGGGCCAAAGCAGAAATGGAAACTTCCATTG 147480 
147481  AAGTCCTTTTGGAAAATAATGAAAATGTGAATATCACATACCTTAACTTGTAGAATATTG 147540 
147541 TCAAAGCTTGGCTTTGATGTTACTTAGCAGACTTAAATGGATTGATAAATTAAGAAATAA 147600 
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147601 ACTTTAAACTATAAAACTATAAATGTGTTAGGAAGGGAAAAGCAATAACAGCTAAGCCTA 147660 
147661 TGGTAAACATAATCAAAGGGAAAACACAAACCAGAAGGAAAGAAGATGACATAAAACTAG 147720 
147721 CGTCTGAAGAAAATTTTAATGTGTTAAGTTCTTTGGACAATGGTGCACTTGCTAAATTTG 147780 
147781 AAAGTTTCAGTAAGGTGGGAAAATTTAACTTGTCTAAATGGATTCAAAAAGAAGCAGAAA 147840 
147841 AATTAAGTGGTTATGAACCTTGGAAAAAGATATGTGTCAAATAATTTCCTCAAAAAAGTC 147900 
147901 CCTTGGCCCAGAGAGTTTTATAGACACGTTCTTTCAAATTGTGAGAGAGCAACTATTTCC 147960 
147961  TATAATAGAAAAACTATTTTAGGGCACAGAAATCTATAAAAGTTATCCCAGTTCATTTTA 148020 
148021 TGAAATGAACATAACACCCTTAAAGAACTTGACAAAGAGGTTGAGCATGGTGGCTCATGC 148080 
148081 CTGTAATCCCAGTACTTTGGGAGGCTGAGGTGGGGGGCGGATCACAAGGTCAAGAGATTG 148140 
148141 AGAACATTCTGGTCAACATGGTGAAACACTGTCTCTACTAACAATACAAAAATTAGCCAG 148200 
148201 ACATGGTGGCACACGCCTGTAATCCCAGCTACTTGGGAGGCTGAGCCAGGAGAATCGCTT 148260 
148261 GAACCTGGGAGGCAGAGGTTGCAGTGAACCGAGGTTGCGCCATTGCACACTCCAGCCTGG 148320 
148321 CAACAGAGCAAAACTCTGTCTCAAAAAAAAAAAAAAAAAAAAAAGAACTTGACAAAGATA 148380 
148381 CTGCACTGAACAAAAGCCACAGGCCAAGCTAATATGTGATGTTAGATTCAAATGTCCCAA 148440 
148441 ATAAAACACTGCACTGGCAATATTGTTTATCTCCAAAATGCAAGGATGGTTTAAGATCAG 148500 
148501 AAGATTTGATAACATCATCTAGTTCATCAAGAGGTGCAATAAGGAAGATCATATCTGTTT 148560 
148561 CAATAACCTTAATTTAAAATTCCTAACTTAGAGAAAGGGGAGGAAAAAAAGAGGCTTCAT 148620 
148621  AAAACTCATAATAGAATATTTCTTCTACAAGATAAATATTACCTAGGTTAAACCAACAGC 148680 
148681 CAAGCTAACATCATTCTTAAAATTATTCTTAGCAGAGTTAGGAACAAAACAAGGAAGCCC 148740 
148741 CATCTCATCATTACTAATTAACATTTCTCTGGGCATCCAGCCAATGTAATAAGACAAGAA 148800 
148801 ACAGAAATCAGAGTTGTAAAGAATGGAATGTGGGAAATAAAGTCATTGCTATTTGCAGAG 148860 
148861 CGTCTAGCTCAAGGGTAGGCAAACTATGGCCCATGGGCTAGCTGCCTGTTTTTGTAAATG 148920 
148921 AACTCTTATTGGAATGCAACCCCACCCACTTGTTTACACATCATGTAGGGCTGCTTTAAG 148980 
148981 CTACAATGACAGAGTAGTTGTGACAGAGGTCATTTGGCTTGCAAAACCCAAAATATTTAT 149040 
149041 TATCTAGCCCTTTACGGGAAAATTTTGTTGACCCCTCTTCTAGTGTGTCATTGAAAACCC 149100 
149101 AGGAAAGCCAATTATGAAACTTTTTAAATGAGTTAGAGTTTGGGAAAGTAGGTACATAGA 149160 
149161 AATAAGCAAAAAGACTGTAGATACACAAGCAATAATTAGAATATAAAATAAGGGAAAAGA 149220 
149221 TCCCTTTCAAAATTGCCGTAAAACCTTAGCACAACTCATAATAACCCCATCTAGAATGAC 149280 
149281  TTATAAAGGAACACGTTTTAAAGTGTTACTGATATATTAAATTGTACAAATAAACATGAA 149340 
149341 AGCCTGTTTCAAATCATTTAAAGAAAGCTTACTGGCAAATGGAAAAGAGTAAGTTGTATA 149400 
149401 GCACGATACATAAAAGGTTAATATCCTTAATGAATAAACAACACAGGAGTAAGGAAAACA 149460 
149461 CAAGAAATTCATGGAAAAACAGACAAAAGACAAGGAGGGGACAATTCTTTGGAGAATCAC 149520 
149521 AGAGAACCAATAAAGGAAAAATGAAGTCACACTCAGTAATATAAAGATCCGCAAATAACG 149580 
149581 TAGTCGAGTGATAGCATATTTTTAATCTCTTGGGTTAAAGATCTAGACAAACAAACATAG 149640 
149641 AAAGAAAAAAAAAAACTATTAAGGCTTAGGGGTTGCTGAGATTGTCCTGGAATGCAGTCT 149700 
149701 CATGGCCTGCTGGTGCAACCACAAGTCAATATAGAGTTTCTGGACAACCATTTAGCTGTA 149760 
149761 GGTATTAAGAAGCTTAAAGAGTTTCTTATCTCCCTGAACCTAGTAATATTTTCCTCTAGG 149820 
149821 AATCTACTTTGGGGAAGTAATAAGACAATCAGACAATGATCAAAGGAATATTTATAACAG 149880 
149881 CAAAAAAAAAAAAAAAGAGCCATGTGCGGTGGCTCATGCCTGTAATCCTGGCACTTTGGG 149940 
149941 AGGCTGAGGTGGGCAGATCACCTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAACATGGC 150000 
150001 GAAACTCCGTCTCTACTAAAAATACAAAAATTAGCTGGGCATGGTGGCGGACTCCTGTAA 150060 
150061 TCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATCGCATGAACTCAGGAGGCGGAGGTTGC 150120 
150121 AGTGAGCCAAGATCACGCCGTCGCACTCCAGCCTGGGCGACAAGAGTGAAACTCTGTCTC 150180 
150181 AAAATAAATAAATAAATAAGGAGGATGGTTAAGTGAGTGACGACTCACGTAGCAAATGGA 150240 
150241  ATATTTTACAGTCATTCATCGTTTTCCAAGTTTTCTGCAGGGAACACATGCTACTTTTGT 150300 
150301 AGATGATGGAGGAAAACCCTAATATTAAAAAGGAAAAGTCCCAAAATTCTCTCCTAAAAT 150360 
150361  GTTATGTTGAAAGGAAAATATTTAGTAAATGCTTCCAATATAATAAGTAGACAAAGTTTA 150420 
150421 CTTATAAAACAGGCTTGATCCTCATCATGTTCACACATAATATTTACAGGGAAAAAATTG 150480 
150481  TCCAAAGGAAGCAGTGGGCTGTGGATTTATGAGTGATTTATATTTTCTTTTCTTTTTTTT 150540 
150541 TTTTTTGAGACAGAGTCTCACTCTGTCGCCCAGGCTGGAGTGCAGTGACACGATCTCAGC 150600 
150601 TCACTGCAACCTCCGCCTCCCGGGTTCAAGCAATTCTCTTGCCTCAGCCTCCTGAGTAGC 150660 
150661 TGGGATTAAAGCTGTGCACCATCAGGCTCGGCTAATTTTTGTATTTTTAGTAGAGACGGG 150720 
150721 GTTTCCCCATGTTGGCCAGACTGGTCTTGAACTCCTAACCTCAGGTTATCTGCCCGCCTT 150780 
150781 GGCCTCCCAAAGTACTGGGATTATAGGCATGAGCCACCTCGCCCAGCCTACATTTTCTTC 150840 
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1 5 0 8 4 1  T T T A T C C T T T T T T C T T T G T A T T T T A A A A T T T G T T A G C T A T C A A C C T T T G T T G T T T A A T A T  1 5 0 9 0 0 
150901 GTCTTCTTAAGGGATGGGGAGAAGTGTGCCAATTGCATAGATGTTTCTTGGAGTTAATCT 150960 
150961 TCCTGACCTGAGTGATGTGATTCCTTTTCTAAGAATTGCAGCTTAATCACTCAAATTATA 151020 
151021 CAGGTGCCCTAAGCAGCAATAAGAAGGAAAAGATGTATTTTTTCCTATTTAAACTGATGA 151080 
151081 TGTCGATCAGTAGCTTGGGCCAATGAGCAAATGCCATTTGGCAGGGCTTCCTGAAAAGCT 151140 
151141 AGACTCTTACGTGCTTTTGGTGTCTTATTTTTGTCACTGACCCTGGCTGGCCTATTTATC 151200 
151201 TGCAAAATGAAAAACCTGAAATCGAGCATGTCGAGGGGAATATCGGTGTGTGTCTACCAT 151260 
151261 TGACGGTCTTAGAAGCACTCATCCCTCACGAGGTGGGCCTGCTCTAATCCTTCAGATGCT 151320 
151321 CACAAGGGTATATTGAAAGCTGCTCTGAGTGGTCATTCCTGGCAGTCTGTATTGTAATCC 151380 
151381 ATGTTCCCCATTGCTGCACCCTCCTGCGCTCTGATCTTTCTTCTTAATCAAGCCTTTTAT 151440 
151441 TCTCCAGTGTCACTTTTTTAAAAAAAATGATGGTGATGGTGTCATCATACATGTCCTACT 151500 
151501 GTCGTTCCAGGCCATCTCGGAAACGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGG  151560 
151561 CCGTGCCCACGGTGGCAGCTTTCCCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGG  151620 
151621 AGGAGCACAGGCCTTTTGAGAAGGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGC  151680 
151681 GACACTTCACGGGCTATCGCATCGAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAAC  151740 
151741 GGTGCAGTGTGGCAGCCTACGTCAGTGCGAGGACCATGCCTGAAGGTAGGGCTGCTGCTC 151800 
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6.5 Apolipoprotein B Pre-mRNA sequence exon 25-exon 27. 
 
Pre-mRNA sequence showing APOB sequence exon 25 - intron 25 - exon 26 -
intron 26 - exon 27. Grey shaded areas are exonic sequences, the remaining 
sequence being intronic. Black shaded area represents 3' end of exon 26 included 
in the 823 base alternatively spliced product (Chapter 3.3) Numbering gives 
nucleotide position within the APOB gene. 
 
 
 31141 CGATGGCCGGGTCAAATATACCTTGAACAAGAACAGTTTGAAAATTGAGATTCCTTTGCC   31200 
 31201 TTTTGGTGGCAAATCCTCCAGAGATCTAAAGATGTTAGAGACTGTTAGGACACCAGCCCT   31260 
 31261 CCACTTCAAGTCTGTGGGATTCCATCTGCCATCTCGAGAGTTCCAAGTCCCTACTTTTAC   31320 
 31321 CATTCCCAAGTTGTATCAACTGCAAGTGCCTCTCCTGGGTGTTCTAGACCTCTCCACGAA   31380 
 31381 TGTCTACAGCAACTTGTACAACTGGTCCGCCTCCTACAGTGGTGGCAACACCAGCACAGA   31440 
 31441 CCATTTCAGCCTTCGGGCTCGTTACCACATGAAGGCTGACTCTGTGGTTGACCTGCTTTC   31500 
 31501 CTACAATGTGCAAGGTGAGCTATGCTCAGGTAAAGGGTGCACCGGGCTAGTTCATGGCAG  31560 
 31561 GCTCTAAGAGGAGAGCCTCCTCCAGGGAGGAAAGGACTTTGGCTTTCTAGCAGATAATCT  31620 
 3 1 6 2 1  T C C T T G C T A C T T G G A A G T C T T T T A T T T T A T T C A A C A A A T A G A A A T A T T T A T T A A A C A T A T   3 1 6 8 0 
 31681 CACGTGTATTAAATATTCTAGTAGGCAGTAACAGAAAGTAGACAGATAAGCCAGCAATTA  31740 
 31741 TAATTCAGTGTGAGAGGTGCTATGATAAAGTGTAGTATATAAGTATAAGGTAGAGTGGAA  31800 
 31801 GCACTCAACAAGGGAACCTAAACAAAGCCTGTGGTGGTCAGGCAAGGCTTCCTGGAGGAA  31860 
 31861  TGCCTTTTGCTATCAGATTTTATCTTTGCATTACAGATGGAGGAGTCTATTGCACAATTG  31920 
 31921 GCCCAGAAAAATGGGGCTTTATTATTGAAAGACTTTCAACATAGAGATTGCTCTGGAAAT  31980 
 31981  GTACTGCTTAATTTAACCAATGTCTTTTCATTTTTATGTTAGGATCTGGAGAAACAACAT   32040 
 32041 ATGACCACAAGAATACGTTCACACTATCATATGATGGGTCTCTACGCCACAAATTTCTAG   32100 
 32101 ATTCGAATATCAAATTCAGTCATGTAGAAAAACTTGGAAACAACCCAGTCTCAAAAGGTT   32160 
 32161 TACTAATATTCGATGCATCTAGTTCCTGGGGACCACAGATGTCTGCTTCAGTTCATTTGG   32220 
 32221 ACTCCAAAAAGAAACAGCATTTGTTTGTCAAAGAAGTCAAGATTGATGGGCAGTTCAGAG   32280 
 32281 TCTCTTCGTTCTATGCTAAAGGCACATATGGCCTGTCTTGTCAGAGGGATCCTAACACTG   32340 
 32341 GCCGGCTCAATGGAGAGTCCAACCTGAGGTTTAACTCCTCCTACCTCCAAGGCACCAACC   32400 
 32401 AGATAACAGGAAGATATGAAGATGGAACCCTCTCCCTCACCTCCACCTCTGATCTGCAAA   32460 
 32461 GTGGCATCATTAAAAATACTGCTTCCCTAAAGTATGAGAACTACGAGCTGACTTTAAAAT   32520 
 32521 CTGACACCAATGGGAAGTATAAGAACTTTGCCACTTCTAACAAGATGGATATGACCTTCT   32580 
 32581 CTAAGCAAAATGCACTGCTGCGTTCTGAATATCAGGCTGATTACGAGTCATTGAGGTTCT   32640 
 32641 TCAGCCTGCTTTCTGGATCACTAAATTCCCATGGTCTTGAGTTAAATGCTGACATCTTAG   32700 
 32701 GCACTGACAAAATTAATAGTGGTGCTCACAAGGCGACACTAAGGATTGGCCAAGATGGAA   32760 
 32761 TATCTACCAGTGCAACGACCAACTTGAAGTGTAGTCTCCTGGTGCTGGAGAATGAGCTGA   32820 
 32821 ATGCAGAGCTTGGCCTCTCTGGGGCATCTATGAAATTAACAACAAATGGCCGCTTCAGGG   32880 
 32881 AACACAATGCAAAATTCAGTCTGGATGGGAAAGCCGCCCTCACAGAGCTATCACTGGGAA   32940 
 32941 GTGCTTATCAGGCCATGATTCTGGGTGTCGACAGCAAAAACATTTTCAACTTCAAGGTCA   33000 
 33001 GTCAAGAAGGACTTAAGCTCTCAAATGACATGATGGGCTCATATGCTGAAATGAAATTTG   33060 
 33061 ACCACACAAACAGTCTGAACATTGCAGGCTTATCACTGGACTTCTCTTCAAAACTTGACA   33120 
 33121 ACATTTACAGCTCTGACAAGTTTTATAAGCAAACTGTTAATTTACAGCTACAGCCCTATT   33180 
 33181 CTCTGGTAACTACTTTAAACAGTGACCTGAAATACAATGCTCTGGATCTCACCAACAATG   33240 
 33241 GGAAACTACGGCTAGAACCCCTGAAGCTGCATGTGGCTGGTAACCTAAAAGGAGCCTACC   33300 
 33301 AAAATAATGAAATAAAACACATCTATGCCATCTCTTCTGCTGCCTTATCAGCAAGCTATA   33360 
 33361 AAGCAGACACTGTTGCTAAGGTTCAGGGTGTGGAGTTTAGCCATCGGCTCAACACAGACA   33420 
 33421 TCGCTGGGCTGGCTTCAGCCATTGACATGAGCACAAACTATAATTCAGACTCACTGCATT   33480 
 33481 TCAGCAATGTCTTCCGTTCTGTAATGGCCCCGTTTACCATGACCATCGATGCACATACAA   33540 
 33541 ATGGCAATGGGAAACTCGCTCTCTGGGGAGAACATACTGGGCAGCTGTATAGCAAATTCC   33600 
 33601 TGTTGAAAGCAGAACCTCTGGCATTTACTTTCTCTCATGATTACAAAGGCTCCACAAGTC   33660 
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 33661 ATCATCTCGTGTCTAGGAAAAGCATCAGTGCAGCTCTTGAACACAAAGTCAGTGCCCTGC   33720 
 33721 TTACTCCAGCTGAGCAGACAGGCACCTGGAAACTCAAGACCCAATTTAACAACAATGAAT   33780 
 33781 ACAGCCAGGACTTGGATGCTTACAACACTAAAGATAAAATTGGCGTGGAGCTTACTGGAC   33840 
 33841 GAACTCTGGCTGACCTAACTCTACTAGACTCCCCAATTAAAGTGCCACTTTTACTCAGTG   33900 
 33901 AGCCCATCAATATCATTGATGCTTTAGAGATGAGAGATGCCGTTGAGAAGCCCCAAGAAT   33960 
 33961 TTACAATTGTTGCTTTTGTAAAGTATGATAAAAACCAAGATGTTCACTCCATTAACCTCC   34020 
 34021 CATTTTTTGAGACCTTGCAAGAATATTTTGAGAGGAATCGACAAACCATTATAGTTGTAC   34080 
 34081 TGGAAAACGTACAGAGAAACCTGAAGCACATCAATATTGATCAATTTGTAAGAAAATACA   34140 
 34141 GAGCAGCCCTGGGAAAACTCCCACAGCAAGCTAATGATTATCTGAATTCATTCAATTGGG   34200 
 34201 AGAGACAAGTTTCACATGCCAAGGAGAAACTGACTGCTCTCACAAAAAAGTATAGAATTA   34260 
 34261 CAGAAAATGATATACAAATTGCATTAGATGATGCCAAAATCAACTTTAATGAAAAACTAT   34320 
 34321 CTCAACTGCAGACATATATGATACAATTTGATCAGTATATTAAAGATAGTTATGATTTAC   34380 
 34381 ATGATTTGAAAATAGCTATTGCTAATATTATTGATGAAATCATTGAAAAATTAAAAAGTC   34440 
 34441 TTGATGAGCACTATCATATCCGTGTAAATTTAGTAAAAACAATCCATGATCTACATTTGT   34500 
 34501 TTATTGAAAATATTGATTTTAACAAAAGTGGAAGTAGTACTGCATCCTGGATTCAAAATG   34560 
 34561 TGGATACTAAGTACCAAATCAGAATCCAGATACAAGAAAAACTGCAGCAGCTTAAGAGAC   34620 
 34621 ACATACAGAATATAGACATCCAGCACCTAGCTGGAAAGTTAAAACAACACATTGAGGCTA   34680 
 34681 TTGATGTTAGAGTGCTTTTAGATCAATTGGGAACTACAATTTCATTTGAAAGAATAAATG   34740 
 34741 ACATTCTTGAGCATGTCAAACACTTTGTTATAAATCTTATTGGGGATTTTGAAGTAGCTG   34800 
 34801 AGAAAATCAATGCCTTCAGAGCCAAAGTCCATGAGTTAATCGAGAGGTATGAAGTAGACC   34860 
 34861 AACAAATCCAGGTTTTAATGGATAAATTAGTAGAGTTGGCCCACCAATACAAGTTGAAGG   34920 
 34921 AGACTATTCAGAAGCTAAGCAATGTCCTACAACAAGTTAAGATAAAAGATTACTTTGAGA   34980 
 34981 AATTGGTTGGATTTATTGATGATGCTGTCAAGAAGCTTAATGAATTATCTTTTAAAACAT   35040 
 35041 TCATTGAAGATGTTAACAAATTCCTTGACATGTTGATAAAGAAATTAAAGTCATTTGATT   35100 
 35101 ACCACCAGTTTGTAGATGAAACCAATGACAAAATCCGTGAGGTGACTCAGAGACTCAATG   35160 
 35161 GTGAAATTCAGGCTCTGGAACTACCACAAAAAGCTGAAGCATTAAAACTGTTTTTAGAGG   35220 
 35221 AAACCAAGGCCACAGTTGCAGTGTATCTGGAAAGCCTACAGGACACCAAAATAACCTTAA   35280 
 35281 TCATCAATTGGTTACAGGAGGCTTTAAGTTCAGCATCTTTGGCTCACATGAAGGCCAAAT   35340 
 35341 TCCGAGAGACCCTAGAAGATACACGAGACCGAATGTATCAAATGGACATTCAGCAGGAAC   35400 
 35401 TTCAACGATACCTGTCTCTGGTAGGCCAGGTTTATAGCACACTTGTCACCTACATTTCTG   35460 
 35461 ATTGGTGGACTCTTGCTGCTAAGAACCTTACTGACTTTGCAGAGCAATATTCTATCCAAG   35520 
 35521 ATTGGGCTAAACGTATGAAAGCATTGGTAGAGCAAGGGTTCACTGTTCCTGAAATCAAGA   35580 
 35581 CCATCCTTGGGACCATGCCTGCCTTTGAAGTCAGTCTTCAGGCTCTTCAGAAAGCTACCT   35640 
 35641 TCCAGACACCTGATTTTATAGTCCCCCTAACAGATTTGAGGATTCCATCAGTTCAGATAA   35700 
 35701 ACTTCAAAGACTTAAAAAATATAAAAATCCCATCCAGGTTTTCCACACCAGAATTTACCA   35760 
 35761 TCCTTAACACCTTCCACATTCCTTCCTTTACAATTGACTTTGTAGAAATGAAAGTAAAGA   35820 
 35821 TCATCAGAACCATTGACCAGATGCTGAACAGTGAGCTGCAGTGGCCCGTTCCAGATATAT   35880 
 35881 ATCTCAGGGATCTGAAGGTGGAGGACATTCCTCTAGCGAGAATCACCCTGCCAGACTTCC   35940 
 35941 GTTTACCAGAAATCGCAATTCCAGAATTCATAATCCCAACTCTCAACCTTAATGATTTTC   36000 
 36001 AAGTTCCTGACCTTCACATACCAGAATTCCAGCTTCCCCACATCTCACACACAATTGAAG   36060 
 36061 TACCTACTTTTGGCAAGCTATACAGTATTCTGAAAATCCAATCTCCTCTTTTCACATTAG   36120 
 36121 ATGCAAATGCTGACATAGGGAATGGAACCACCTCAGCAAACGAAGCAGGTATCGCAGCTT   36180 
 36181 CCATCACTGCCAAAGGAGAGTCCAAATTAGAAGTTCTCAATTTTGATTTTCAAGCAAATG   36240 
 36241 CACAACTCTCAAACCCTAAGATTAATCCGCTGGCTCTGAAGGAGTCAGTGAAGTTCTCCA   36300 
 36301 GCAAGTACCTGAGAACGGAGCATGGGAGTGAAATGCTGTTTTTTGGAAATGCTATTGAGG   36360 
 36361 GAAAATCAAACACAGTGGCAAGTTTACACACAGAAAAAAATACACTGGAGCTTAGTAATG   36420 
 36421 GAGTGATTGTCAAGATAAACAATCAGCTTACCCTGGATAGCAACACTAAATACTTCCACA   36480 
 36481 AATTGAACATCCCCAAACTGGACTTCTCTAGTCAGGCTGACCTGCGCAACGAGATCAAGA   36540 
 36541 CACTGTTGAAAGCTGGCCACATAGCATGGACTTCTTCTGGAAAAGGGTCATGGAAATGGG   36600 
 36601 CCTGCCCCAGATTCTCAGATGAGGGAACACATGAATCACAAATTAGTTTCACCATAGAAG   36660 
 36661 GACCCCTCACTTCCTTTGGACTGTCCAATAAGATCAATAGCAAACACCTAAGAGTAAACC   36720 
 36721 AAAACTTGGTTTATGAATCTGGCTCCCTCAACTTTTCTAAACTTGAAATTCAATCACAAG   36780 
 36781 TCGATTCCCAGCATGTGGGCCACAGTGTTCTAACTGCTAAAGGCATGGCACTGTTTGGAG   36840 
 36841 AAGGGAAGGCAGAGTTTACTGGGAGGCATGATGCTCATTTAAATGGAAAGGTTATTGGAA   36900 
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 36901 CTTTGAAAAATTCTCTTTTCTTTTCAGCCCAGCCATTTGAGATCACGGCATCCACAAACA   36960 
 36961 ATGAAGGGAATTTGAAAGTTCGTTTTCCATTAAGGTTAACAGGGAAGATAGACTTCCTGA   37020 
 37021 ATAACTATGCACTGTTTCTGAGTCCCAGTGCCCAGCAAGCAAGTTGGCAAGTAAGTGCTA   37080 
 37081 GGTTCAATCAGTATAAGTACAACCAAAATTTCTCTGCTGGAAACAACGAGAACATTATGG   37140 
 37141 AGGCCCATGTAGGAATAAATGGAGAAGCAAATCTGGATTTCTTAAACATTCCTTTAACAA   37200 
 37201 TTCCTGAAATGCGTCTACCTTACACAATAATCACAACTCCTCCACTGAAAGATTTCTCTC   37260 
 37261 TATGGGAAAAAACAGGCTTGAAGGAATTCTTGAAAACGACAAAGCAATCATTTGATTTAA   37320 
 37321 GTGTAAAAGCTCAGTATAAGAAAAACAAACACAGGCATTCCATCACAAATCCTTTGGCTG   37380 
 37381 TGCTTTGTGAGTTTATCAGTCAGAGCATCAAATCCTTTGACAGGCATTTTGAAAAAAACA   37440 
 37441 GAAACAATGCATTAGATTTTGTCACCAAATCCTATAATGAAACAAAAATTAAGTTTGATA   37500 
 37501 AGTACAAAGCTGAAAAATCTCACGACGAGCTCCCCAGGACCTTTCAAATTCCTGGATACA   37560 
 37561 CTGTTCCAGTTGTCAATGTTGAAGTGTCTCCATTCACCATAGAGATGTCGGCATTCGGCT   37620 
 37621 ATGTGTTCCCAAAAGCAGTCAGCATGCCTAGTTTCTCCATCCTAGGTTCTGACGTCCGTG   37680 
 37681 TGCCTTCATACACATTAATCCTGCCATCATTAGAGCTGCCAGTCCTTCATGTCCCTAGAA   37740 
 37741 ATCTCAAGCTTTCTCTTCCAGATTTCAAGGAATTGTGTACCATAAGCCATATTTTTATTC   37800 
 37801 CTGCCATGGGCAATATTACCTATGATTTCTCCTTTAAATCAAGTGTCATCACACTGAATA   37860 
 37861 CCAATGCTGAACTTTTTAACCAGTCAGATATTGTTGCTCATCTCCTTTCTTCATCTTCAT   37920 
 37921 CTGTCATTGATGCACTGCAGTACAAATTAGAGGGCACCACAAGATTGACAAGAAAAAGGG   37980 
 37981 GATTGAAGTTAGCCACAGCTCTGTCTCTGAGCAACAAATTTGTGGAGGGTAGTCATAACA   38040 
 38041 GTACTGTGAGCTTAACCACGAAAAATATGGAAGTGTCAGTGGCAACAACCACAAAAGCCC   38100 
 38101 AAATTCCAATTTTGAGAATGAATTTCAAGCAAGAACTTAATGGAAATACCAAGTCAAAAC   38160 
 38161 CTACTGTCTCTTCCTCCATGGAATTTAAGTATGATTTCAATTCTTCAATGCTGTACTCTA   38220 
 38221 CCGCTAAAGGAGCAGTTGACCACAAGCTTAGCTTGGAAAGCCTCACCTCTTACTTTTCCA   38280 
 38281 TTGAGTCATCTACCAAAGGAGATGTCAAGGGTTCGGTTCTTTCTCGGGAATATTCAGGAA   38340 
 38341 CTATTGCTAGTGAGGCCAACACTTACTTGAATTCCAAGAGCACACGGTCTTCAGTGAAGC   38400 
 38401 TGCAGGGCACTTCCAAAATTGATGATATCTGGAACCTTGAAGTAAAAGAAAATTTTGCTG   38460 
 38461 GAGAAGCCACACTCCAACGCATATATTCCCTCTGGGAGCACAGTACGAAAAACCACTTAC   38520 
 38521 AGCTAGAGGGCCTCTTTTTCACCAACGGAGAACATACAAGCAAAGCCACCCTGGAACTCT   38580 
 38581 CTCCATGGCAAATGTCAGCTCTTGTTCAGGTCCATGCAAGTCAGCCCAGTTCCTTCCATG   38640 
 38641 ATTTCCCTGACCTTGGCCAGGAAGTGGCCCTGAATGCTAACACTAAGAACCAGAAGATCA   38700 
 38701 GATGGAAAAATGAAGTCCGGATTCATTCTGGGTCTTTCCAGAGCCAGGTCGAGCTTTCCA   38760 
 38761 ATGACCAAGAAAAGGCACACCTTGACATTGCAGGATCCTTAGAAGGACACCTAAGGTTCC   38820 
 38821 TCAAAAATATCATCCTACCAGTCTATGACAAGAGCTTATGGGATTTCCTAAAGCTGGATG   38880 
 38881 TAACCACCAGCATTGGTAGGAGACAGCATCTTCGTGTTTCAACTGCCTTTGTGTACACCA   38940 
 38941 AAAACCCCAATGGCTATTCATTCTCCATCCCTGTAAAAGTTTTGGCTGATAAATTCATTA   39000 
 39001 TTCCTGGGCTGAAACTAAATGATCTAAATTCAGTTCTTGTCATGCCTACGTTCCATGTCC   39060 
 39061 CATTTACAGATCTTCAGGTTCCATCGTGCAAACTTGACTTCAGAGAAATACAAATCTATA   39120 
 39121 AGAAGCTGAGAACTTCATCATTTGCCCTCAACCTACCAACACTCCCCGAGGTAAAATTCC   39180 
 39181 CTGAAGTTGATGTGTTAACAAAATATTCTCAACCAGAAGACTCCTTGATTCCCTTTTTTG   39240 
 39241 AGATAACCGTGCCTGAATCTCAGTTAACTGTGTCCCAGTTCACGCTTCCAAAAAGTGTTT   39300 
 39301 CAGATGGCATTGCTGCTTTGGATCTAAATGCAGTAGCCAACAAGATCGCAGACTTTGAGT   39360 
 39361 TGCCCACCATCATCGTGCCTGAGCAGACCATTGAGATTCCCTCCATTAAGTTCTCTGTAC   39420 
 39421 CTGCTGGAATTGTCATTCCTTCCTTTCAAGCACTGACTGCACGCTTTGAGGTAGACTCTC   39480 
 39481 CCGTGTATAATGCCACTTGGAGTGCCAGTTTGAAAAACAAAGCAGATTATGTTGAAACAG   39540 
 39541 TCCTGGATTCCACATGCAGCTCAACCGTACAGTTCCTAGAATATGAACTAAATGGTAAGA  39600 
 39601  AATATCCTGCCTCCTCTCCTAGATACTGTATATTTTCAATGAGAGTTATGAGTAAATAAT  39660 
 39661  TATGTATTTAGTTGTGAGTAGATGTACAATTACTCAATGTCACAAAATTTTAAGTAAGAA  39720 
 39721  AAGAGATACATGTATACCCTACACGTAAAAACCAAACTGTAGAAAATCTAGTGTCATTCA  39780 
 39781  AGACAAACAGCTTTAAAGAAAATGGATTTTTCTGTAATTATTTTAGGACTAACAATGTCT  39840 
 39841  TTTAACTATTTA TTTTAAAATAAGTGTGAGCTGTACATTGCATATTTTAAACACAAGTGA  39900 
 39901  AATATCTGGTTAGGATAGAATTCTCCCAGTTTTCACAATGAAAACATCAACGTCCTACTG  39960 
 39961 TTATGAATCTAATAAAATACAAAATCTCTCCTATACAGTTTTGGGAACACACAAAATCGA   40020 
 40021 AGATGGTACGTTAGCCTCTAAGACTAAAGGAACATTTGCACACCGTGACTTCAGTGCAGA   40080 
 40081 ATATGAAGAAGATGGCAAATATGAAGGACTTCAGTATGGAGCTTTTATTGAATTGAAACC  40140 
